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Abstract 
Age‐related	macular	degeneration	(AMD)	is	the	leading	cause	of	blindness	in	the	
developing	world	 in	 people	 aged	 over	 60	 years,	manifested	 as	 a	 loss	 of	 central	
vision	 in	 one	 or	 both	 eyes,	with	 significant	morbidity	 including	 loss	 of	mobility	
and	 depression.	 This	 condition	 involves	 the	 degeneration	 of	 the	 macula,	 and	
although	the	exact	aetiology	of	 this	disease	 is	unknown,	various	epidemiological	
studies	have	shown	it	to	be	multifactorial.		
Current	 research	 points	 towards	 the	 involvement	 of	 a	 dysregulated	 immune	
system	in	the	pathogenesis	and	progression	of	the	disease:	as	the	body	ages,	the	
immune	 system	 increasingly	 adopts	 a	more	 inflammatory	 basal	 state.	However,	
not	 all	 of	 the	 aged	 population	 develops	 AMD	 and	 it	 is	 highly	 likely	 that	 an	
additional	stimulus	or	stimuli	is/are	needed	to	exploit	this	dysregulated	immune	
environment	to	initiate	this	disease.	Given	the	range	of	pathogens	that	can	infect	
the	 retina,	we	 hypothesize	 that	 this	 breaking	 point	 could	manifest	 as	 a	 chronic	
inflammation	 as	 a	 result	 of	 a	 low‐level	 infection.	 West	 Nile	 Virus	 (WNV)	 is	 a	
flavivirus	that	has	come	into	international	prominence	ever	since	its	spread	into	
previously	WNV‐free	regions	 following	 the	1999	New	York	outbreak.	As	 several	
case	reports	have	shown	that	WNV	is	capable	of	infecting	the	retina,	and	given	its	
immunopathogenic	properties,	we	believe	the	virus	is	a	useful	tool	to	model	key	
immune	pathways	and	 responses	 that	may	be	 involved	 in	 the	development	 and	
progression	of	AMD.	
  viii
Of	 significant	 interest	are	 the	processes	 involved	 in	 the	breakdown	of	 the	outer	
blood‐retinal	barrier	(BRB),	which	is	an	important	step	in	the	progression	of	AMD	
from	 an	 early	 stage	 to	 a	 more	 severe	 one.	 Additionally,	 deciphering	 and	
understanding	the	profile	and	populations	of	leukocytes	that	are	recruited	during	
an	immunopathic	infection	in	an	organ	regarded	as	being	immunoprivileged	is	of	
great	 appeal.	 	 With	 this	 in	 mind,	 we	 set	 out	 to	 investigate	 the	 effects	 of	 WNV	
infection	 on	 the	 retinal	 pigment	 epithelium	 (RPE),	 which	 comprises	 the	 outer	
BRB.	
Previously,	 our	 laboratory	 established	 the	 WNV	 BRB	 model	 by	 quantitating	
various	parameters,	such	as	level	of	infectivity,	viral	output	by	WNV‐infected	RPE	
and	effects	of	WNV	 infection	on	RPE	proliferation/migration.	The	effect	of	WNV	
on	 the	 extracellular	matrix	 (ECM)	production	by	RPE	was	 also	 investigated	 and	
increases	 in	 collagen	 I,	 IV	 and	 fibronectin	 were	 noted.	 Global	 ECM	 production	
induced	a	lowered	rate	of	proliferation	of	RPE	seeded	on	WNV‐infected	RPE	ECM	
as	opposed	to	mock‐infected	ECM.	A	full	genome	microarray	was	also	undertaken	
on	WNV‐infected	RPE	to	analyse	differentially	regulated	gene	mRNA	production,	
and	 increases	 in	 several	 immune	genes,	 as	well	 as	 genes	 involved	 in	 the	 stress‐
response	pathway	and	the	TGFβ	pathway	were	found.	
  ix
	This	 current	 investigation	 expanded	 upon	 these	 results,	 and	 found	 that	 WNV	
infection	produces	a	predominantly	CCL5	chemokine	response	rather	than	a	CCL2	
response.	Additionally,	a	lack	of	TNF	production	was	noted,	despite	a	high	initial	
upregulation	of	the	TNF	gene	in	WNV‐infected	cells.	WNV	attenuation	was	found	
to	 be	 predominantly	 IFNβ‐1‐driven,	 while	 induction	 of	 indoleamine	 2,3	
dioxygenase	 activity	 was	 induced	 in	 part	 by	 IFNλ‐1	 and	 ‐2.	
The	 effects	 of	WNV	 infection	 on	 RPE	 barrier	 integrity	was	 investigated,	 and	 an	
initial	 increase	 in	 infected	 cells	 of	 barrier	 integrity	 was	 observed.	 Several	
investigations	 resulted	 in	 a	 conclusion	 of	 a	 soluble‐mediator	 as	 the	 likely	
mechanism	behind	this	initial	increase,	and	while	none	of	the	chemokines	tested	
appeared	 to	 contribute	 to	 this	 change,	 the	 results	 suggest	 that	 it	 may	 be	
TLR3/RIG‐I	independent.	
Finally,	establishment	of	a	murine	WNV	intravitreal	model	was	also	undertaken,	
and	 several	 key	 parameters	 were	 determined,	 including	 confirmation	 of	 WNV‐
infection	of	 the	murine	 retina,	 effect	 of	WNV	 titre	 on	mortality,	 and	histological	
analysis	 of	 the	 effects	 of	 WNV	 infection	 on	 the	 murine	 retina.	
Quantification	 of	 the	 leukocyte	 profile	 recruited	 into	 the	 WNV‐infected	 murine	
retina	 and	 choroid	 revealed	 significant	 increases	 in	 inflammatory	 Ly6Chi	
monocytes,	 as	 well	 as	 significant	 differences	 between	 immune	 mice	 and	 naïve	
mice	intravitreally	infected	with	WNV,	and	differences	between	2	month	old	and	5	
month	old	mice.		
  x
Collectively,	 these	results	highlight	 the	 importance	of	 the	 interferon	response	 in	
both	direct	and	indirect	anti‐WNV	activities	and	immunomodulation,	the	changes	
in	 outer	 BRB	 integrity	 and	 possible	 contributors	 to	 its	 degradation,	 and	 the	
establishment	of	the	murine	 intravitreal	WNV	model	along	with	 identification	of	
several	 key	 leukocytes	 that	 are	 recruited	 at	 the	 peak	 of	 infection.	 These	 results	
will	 help	 guide	 further	 research	 and	 highlight	 possible	 immune	 pathways	 that	
may	 contribute	 to	 dysregulated	 inflammatory	 processes	 that	 may	 occur	 during	
the	pathogenesis	of	AMD.	
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Chapter 1: General Introduction 
 
 
	
Of	all	the	senses,	sight	must	be	the	most	delightful	
‐Quote	attributed	to	Helen	Keller	
Over	 30%	 of	 sensory	 input	 to	 the	 brain	 is	 visual	 (1),	 which	 exemplifies	 the	
importance	of	sight	and	consequently	the	eye	as	a	sensory	organ.	Degradation	of	
visual	 acuity	 presents	 a	 significant	 economic	 and	 societal	 burden,	 due	 to	
depression,	increased	risk	of	injury	and	restriction	of	day‐to‐day	activities	(2).	
	
1.1.	Ocular	anatomy	
 
1.1.1.	Gross	ocular	anatomy	
 
The	eye	is	a	complex	multi‐structured	organ,	with	the	outermost	 layer	being	the	
corneosclera.	 This	 is	 composed	 of	 the	 sclera,	 a	 tough,	white,	 fibrous	 outer	 coat	
that	 encases	most	 of	 the	 eye,	 and	 the	 cornea,	 a	 clear,	 curved	 structure	 located	
centrally	 in	 the	 anterior	portion	of	 the	 eye	 (3).	 Encased	within	 that	 layer	 is	 the	
uvea,	which	supplies	the	nutrients	to	the	inner	eye.	The	uveal	tract	is	composed	of	
the	iris,	the	ciliary	body	and	the	choroid.	The	iris	and	the	ciliary	body	are	located	
within	 the	anterior	 segment	of	 the	 eye,	while	 the	 choroid	 and	neural	 retina	 are	
located	in	the	posterior	segment	(4),	(Figure	1.1).	
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Figure	 1.1.	 Simplified	 diagram	 of	 the	 eye,	 showing	 the	 anterior	 and	 posterior	
segments	of	the	eye	and	the	various	structures	located	in	each	one.	
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Anterior segment of the eye 
 
The	structures	that	comprise	the	anterior	segment	of	the	eye	affect	the	entrance	
of	 light	 into	 the	 eye.	 The	 iris	 is	 responsible	 for	 controlling	 the	 amount	 of	 light	
entering	the	eye;	in	bright	scenarios,	it	contracts	to	reduce	the	number	of	photons	
that	 enter	 the	 eye,	 while	 in	 low‐light	 environments,	 it	 dilates	 to	 maximize	 the	
amount	of	light	collected	by	the	eye	(3).	
In	 order	 to	 focus	 the	 light,	 the	 eye	 contains	 a	 lens	 composed	 of	 specialised	
transparent	 epithelial	 cells	 and	 lens	 fibres;	 accommodation	 (changing	 focus)	 is	
achieved	by	changes	in	lens	shape	associated	with	lens	zonule	(Zonule	of	Zinn)	as	
a	result	of	relaxation	and	contraction	of	the	ciliary	muscles	(located	in	the	ciliary	
body).	The	ciliary	body	is	also	responsible	for	the	production	of	aqueous	humour,	
which	fills	the	anterior	cavity	(5).	An	extensive	review	of	this	segment	is	beyond	
the	scope	of	this	thesis.	
	
Posterior	segment	of	the	eye	
Within	 the	 eye,	 the	 anterior	 and	 posterior	 segments	 are	 separated	 by	 the	 ora	
serrata.	 The	 large	 chamber	 of	 the	 posterior	 segment	 is	 filled	 with	 the	 vitreous	
humour,	a	colloidal	gel	that	gives	the	eye	its	turgid	structure	(3).		
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Anatomical	features	of	the	posterior	segment	
The	retina	lines	the	inside	of	the	posterior	segment	and	is	crucial	in	the	first	step	
in	detecting	and	processing	light	for	vision.	
	
Optic	disc	
This	is	the	region	in	the	eye	where	the	nerve	fibres	from	the	ganglion	cells	form	
the	 optic	 nerve,	 and	 electrical	 signals	 from	 the	 eye	 are	 relayed	 to	 the	 visual	
processing	 centres	 of	 the	 brain.	 This	 region	 is	 devoid	 of	 any	 light	 processing	
structures	and	forms	the	physiological	blind	spot	(4).		
 
Neural	retina	
An	extension	of	 the	brain,	 the	 retina	 is	derived	embryologically	 from	the	neural	
tube,	with	various	components	homologous	to	the	brain,	such	as	microvasculature	
(6),	blood	barriers	(7)	and	glutamate	receptors	(8).	
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The	retina	is	a	multilayered	structure	(Figure	1.3).	The	outermost	layer,	which	lies	
on	 the	 RPE,	 is	 composed	 of	 the	 outer	 (OS)	 and	 the	 inner	 (IS)	 segments	 of	 the	
photoreceptors,	with	 the	 following	 layer	 composed	of	 their	nuclei	being	 termed	
the	outer	nuclear	 layer	(ONL).	There	are	two	types	of	photoreceptors,	 the	cones	
(responsible	for	high	acuity	vision	and	colour	vision)	and	the	monochromatic	low‐
light	 rod	 cells	 (9).	 Photoreceptors	 form	 synapses,	 in	 the	 OPL	 (outer	 plexiform	
layer)	 to	 the	 cells	 in	 the	 inner	 nuclear	 layer	 (INL).	Within	 this	 layer,	 there	 are	
several	 classes	 of	 cells.	 Horizontal,	 amacrine	 and	 bipolar	 cells	 have	 specific	
functions	 related	 to	 signal	 processing	 of	 the	 photonic	 information,	 relating	 to	
processing	of	contrast	information,	directional	motion,	and	signal	mediation	(10).	
Also	 within	 this	 layer	 are	 the	 cell	 bodies	 of	 the	 Müller	 cells,	 which	 perform	 a	
variety	of	supportive	roles	to	surrounding	retinal	cells	and	are	the	only	cells	that	
span	 throughout	 the	 whole	 of	 the	 retina	 (9).	 From	 there	 the	 photonic	 signal	
passes	 through	 the	 inner	plexiform	 layer	 (IPL)	 to	 the	ganglion	 cells	 in	 the	 aptly	
named	ganglion	cell	layer	(GCL).	This	is	the	final	layer	of	the	retina,	and	the	GCL	
axons	exit	via	the	optic	nerve	to	synapse	at	the	lateral	geniculate	nucleus	and	then	
relay	to	the	area	of	the	brain	where	visual	processing	occurs	(9)	(Figure	1.3).		
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Figure	 1.3	 Differential	 interference	 contrast	 image	 of	 a	 macaque	 retina,	
annotated	to	show	the	various	structures,	which	 include	the	outer	segment	(OS)	
and	 inner	segments	 (IS)	of	 the	photoreceptors,	outer	nuclear	 layer	 (ONL),	outer	
plexiform	layer	(OPL),	 inner	nuclear	 layer	(INL),	 inner	plexiform	layer	(IPL)	and	
ganglion	 cell	 layer	 (GCL).	 The	 feature	 marked	 with	 a	 ‘*’	 is	 a	 capillary	 of	 the	
superficial	capillary	plexus	(discussed	in	the	section	‘Inner	blood	retinal	barrier’.	
The	nerve	fibre	layer	above	the	GCL	is	composed	of	ganglion	cell	axons	leading	to	
the	optic	nerve.	Adapted	from	(8).		
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Macula and fovea 
The	 macula	 is	 a	 retinal	 region	 in	 the	 posterior	 segment	 that	 is	 histologically	
defined	 as	 having	 more	 than	 one	 layer	 of	 ganglion	 cells	 and	 containing	 the	
pigment	 xanthophyll	 (11).	 The	 ratio	 of	 cones	 to	 rod	 cells	 increases	 from	 the	
periphery	of	 the	macular	 towards	the	centre.	Within	 this	centre	 lies	 the	 fovea,	a	
depression	 that	 can	be	seen	 in	 retinal	 images	acquired	by	 fundoscopy	as	a	dark	
region	(Figure	1.2).	An	avascular	region,	the	fovea	is	responsible	for	central	vision	
in	primates.	 It	 has	 the	highest	 concentrations	of	 cones;	 in	particular	 the	 central	
foveola	 is	 devoid	 of	 any	 other	 cell	 type	 within	 the	 neural	 retina	 (9).	 These	
differences	 in	 the	 fovea	 enable	 the	 highest	 level	 of	 acuity	 in	 the	 central	 visual	
region.	
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Figure	 1.2.	 Fundoscopy	 of	 the	macular	 region	 in	 a	 human	 eye.	 The	 image	 has	
been	 annotated	 to	 show	 the	 various	 regions	 within	 the	 macula.	 Adapted	 from	
(12).	
 
  
  12
Choroid 
The	 choroid	 forms	 the	 major	 part	 of	 the	 uveal	 tract	 in	 the	 posterior	 eye,	
comprising	 a	 vascular	 layer,	 the	 choriocapillaris,	 that	 together	 with	 the	 retinal	
vasculature,	supplies	nutrients	and	enables	gas	exchange	to	the	neural	retina	and	
retinal	pigment	epithelium	(RPE).		
The	 basement	membrane	 of	 the	 choriocapillaris	 abuts	 onto	 Bruch’s	membrane,	
which	 is	 composed	of	 collagen	and	elastin	 layers	 separating	 the	 choriocapillaris	
from	the	basement	membrane	of	the	RPE,	the	innermost	layer	of	the	choroid	(13)	
(Figure	1.4).	
 
1.1.2.	Blood	Retinal	Barriers	
 
Due	 to	 the	 high	 metabolic	 demands	 of	 the	 processes	 involved	 in	 retinal	 visual	
processing	(photoreceptors	are	one	of	the	most	metabolically	demanding	cells	in	
the	body	(14)),	the	retina	is	supplied	by	the	retinal	vasculature	(located	within	the	
inner	two‐thirds	of	the	retina)	and	the	choriocapillaris	(outer	retina).	The	retinal	
vasculature	 intertwines	within	 the	 retina	 in	 two	 layers,	 the	 superficial	 capillary	
plexus	 located	 in	 the	GCL	 and	 the	deep	 capillary	plexus	 in	 the	 INL	 (Figure	1.4).	
The	 choriocapillaris	 on	 the	 other	 hand	 exists	 as	 a	 single	 plane	 adjacent	 to	 the	
Bruch’s	membrane	and	these	vessels	have	 fenestrations	on	 the	vessel	walls	 that	
face	towards	the	membrane.		
 
 
 
 
Inner blood retinal barrier  
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The	 inner	 blood	 retinal	 barrier	 is	 composed	 of	 non‐fenestrated	 retinal	 vascular	
endothelial	 cells	 with	 tight	 junctions	 (15)	 and	 the	 glial	 limitans	 of	 the	 retinal	
vasculature	 (composed	 of	 cellular	 projections	 from	 astrocytes,	 microglia,	
amacrine	cells	and	Müller	cells	(16)).	These	structures	provide	a	barrier	that	can	
exclude	molecules	larger	than	376	Da	(17).	
	
Outer blood retinal barrier 
 
The	 outer	 blood	 retinal	 barrier	 is	 composed	 of	 the	 tight	 junctions	 between	 the	
retinal	pigment	epithelium	(RPE)	cells.		
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Figure	1.4.	Illustrated	diagram	of	the	two	sources	of	blood	supply	to	the	primate	
retina	in	relation	to	major	topographical	features.	Adapted	from	(18).	
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1.1.3.	Retinal	pigment	epithelium	
 
The	retinal	pigment	epithelium	(RPE)	is	a	monolayer	of	pigmented	hexagonal	cells	
situated	between	Bruch’s	membrane	and	the	neural	retina.	Within	the	fovea,	RPE	
cells	 are	 narrower	 and	 taller	 compared	 with	 those	 in	 the	 surrounding	 regions	
(19).	 Towards	 the	 periphery,	 RPE	 cells	 are	 flatter	 with	 a	 higher	 incidence	 of	
binucleation	(19).			
The	 inner	 apical	 surface	 is	 populated	 by	 numerous	microvilli	 that	 interdigitate	
with	the	overlying	outer	segments	of	the	photoreceptors	in	a	region	known	as	the	
subretinal	space.	This	region	is	occupied	by	a	composite	mix	of	proteoglycans	and	
extracellular	matrix	proteins	 (called	 the	 interphotoreceptor	matrix,	or	 IPM)	that	
envelops	the	outer	segments	of	photoreceptors.	Ligands	from	this	matrix	bind	to	
various	receptors	such	as	αVβ5	integrin	(20),	that	are	located	on	the	microvilli	of	
RPE.	The	 interdigitation,	microvilli	 receptor/IPM	connections	and	apical	RPE	N‐
CAM	 (neural	 cell	 adhesion	molecule)	 interactions	 are	 responsible	 for	 the	 weak	
adhesion	 of	 the	 retina	 to	 the	 RPE	 (21).	 Integrins	 also	 secure	 the	 RPE	 basal	
membrane	to	the	underlying	Bruch’s	membrane	(22).	
RPE	cells	are	specialized	to	fulfil	a	variety	of	roles	involved	in	the	maintenance	of	
eye	homeostasis.	These	include	the	phagocytosis	of	shed	rod	outer	segment	discs	
(23),	 reduction	 of	 light	 scattering	 (through	 light	 absorption	 by	 the	 melanin	
granules)	and	immune	modulation	(24).	Immune	modulation	by	the	RPE	involves	
production	 of	 the	 immunosuppressive	 molecule	 TGFβ,	 phagocytosis	 of	 T‐cells	
(25),	 production	 of	 FasL	 and	 production	 of	 macrophage	 maturation/growth	
factors	(M‐CSF,	GM‐CSF).	
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1.2.	Tight	junctions	and	adherens	junctions	–	overview	of	epithelial	interactions.	
 
Connections	 between	 epithelial	 cells	 are	 achieved	 though	 linkages	 of	 various	
proteins	that	are	coupled	to	cellular	cytoskeletal	structures	and	to	corresponding	
proteins	in	neighbouring	cells.	While	there	are	several,	two	of	the	most	important	
classes	of	junctions	in	RPE	are	the	Tight	junctions	(TJ)	and	the	Adherens	junctions	
(AJ).	
TJ	 are	 located	 at	 the	most	 apical	 location	between	 adjoining	 epithelial	 cells	 and	
control	 the	 passage	 of	 molecules	 and	 water	 through	 the	 lateral	 intracellular	
spaces	(26).	This	is	proposed	to	occur	through	structures	that	act	as	a	fence	or	a	
gate	depending	on	the	molecule	or	solute	(27).	Contact	between	the	extracellular	
domains	of	TJ	proteins	is	achieved	via	a	zippering	of	two	extracellular	loops	with	
another	 pair	 of	 extracellular	 loops	 from	 an	 adjacent	 cell	 (27).	 The	 electrical	
resistance,	which	is	a	measure	of	permeability	of	the	junctions,	is	not	solely	based	
on	the	number	of	TJ	strands	but	also	the	type	of	proteins	 forming	the	 junctions.	
For	 example,	 claudin‐2	 can	 form	 paracellular	 cation	 channels,	 which	 reduce	
paracellular	electrical	resistance	as	a	result	of	increased	ion	permeability	(28).		
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The	composition	of	these	tight	junctions	includes	the	proteins	ZO‐1,	occludin,	and	
various	claudins	(Figure	1.5).	Encoded	by	the	TJP1	protein,	ZO‐1	is	believed	to	be	
a	 scaffolding	 protein,	 due	 to	 the	 presence	 of	 both	 adherens	 and	 tight	 junction	
binding	domains	with	 the	protein	structure,	 including	 the	 tight	 junction	protein,	
occludin	 (29)	 and	 the	 adherens	 junction	 protein,	 E‐cadherin,	 and	 the	 ability	 to	
bind	to	the	cytoskeletal	structural	protein	F‐actin	(30)	(Figure	1.5).	It	can	also	be	
localised	 with	 the	 cytoplasm	 and	 nucleus	 where	 it	 interacts	 with	 the	 ZO‐1	
regulating	protein,	ZONAB.	Binding	of	ZONAB	to	ZO‐1	can	result	in	a	reduction	of	
proliferation	in	epithelial	cells	(31,	32).		 	
Occludin,	 a	 tetraspan	 protein,	 is	 localised	 in	 basolateral‐based	 cytoplasmic	
vesicles,	but	when	phosphorylated	can	then	localise	to	the	tight	 junctions.	While	
murine	occludin	knockout	mice	experiments	have	shown	that	this	protein	 is	not	
critical	 in	 TJ	 formation	 (33),	 it	 has	 an	 important	 role	 in	 the	 regulation	 of	
paracellular	permeability	between	cells	(34).	
TJs	 and	 their	 functions	 are	 involved	 in	 several	 pathologies.	 Various	 pathogens	
such	as	Helicobacter	pylori	and	HCV	have	been	demonstrated	to	interfere	with	TJ	
proteins,	as	these	pathogens	may	make	use	of	TJ	proteins	as	an	infection	co‐factor	
or	as	a	anchoring	point	on	the	epithelium	(26).	Additionally,	several	inflammatory	
conditions	are	associated	with	disrupted	TJ	function,	such	as	colitis	(35),	asthma	
(36),	and	diabetic	retinopathy	(37).	
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AJ	 are	 the	most	 ancient	 adhesion	 structure	 in	metazoans	 (38)	 and	have	 several	
roles	 in	 cells	 including	 initiating	 and	 maintaining	 cell‐cell	 adhesion.	 Compared	
with	 tight	 junctions,	 they	 differ	 structurally	 and	 compositionally,	 with	 classical	
cadherins	(e.g.	E‐and	N‐cadherin)	being	the	main	transmembrane	protein	of	this	
structure	(27),	(Figure	1.5).	Together	with	p120‐catenin,	β‐catenin	binds	directly	
to	cadherins	and	regulates	their	adhesiveness	by	modifying	F‐actin	structure	and	
stabilizing	 the	 cadherins	 within	 the	 membrane	 (27).	 Like	 ZO‐1	 and	 ZONAB,	 β‐
catenin	also	has	roles	in	differentiation	and	cell	motility,	especially	in	regard	to	its	
involvement	in	the	Wnt	pathway	(39).	Within	RPE	cells,	N	(neural)‐cadherin	is	the	
major	cadherin	instead	of	the	usual	E	(epithelial)‐cadherin	seen	in	other	epithelial	
cells	 (39).	 As	 a	 result	 RPE	 zonular	 junctions	 take	 longer	 to	 form	 than	 those	 of	
other	epithelial	cells	(40).	
The	integrity	of	AJs	is	also	affected	by	inflammatory	conditions,	although	research	
on	 AJ	 during	 inflammatory	 events	 has	 not	 been	 described	 as	 extensively	 as	 TJs	
(41).These	 junctional	disruptions,	 in	 addition	 to	 facilitating	pathogen	entry	past	
an	epithelial	barrier,	result	in	a	dysregulation	of	normal	homeostatic	conditions	of	
the	local	environment.	
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Figure	1.5.	Simplified	diagram	of	tight	and	adherens	junctions	in	epithelial	cells.	
Shown	 in	 this	 diagram	 are	 the	 various	 tight	 junction	 proteins	 and	 associated	
cellular	 structures.	 On	 the	 right	 hand	 side,	 ZO‐1	 is	 shown	 in	 a	 scaffolding	 role,	
linking	the	intracellular	loops	of	occludin	to	the	cytoskeletal	protein,	actin.	On	the	
left	hand	side,	ZO‐1	is	shown	bound	to	ZONAB/CDSA,	which	can	result	in	changes	
in	cell	proliferation.	
 
 	
  22
1.3	Immune	system	
1.3.1.	Overview	
 
Protection	of	the	body	from	disease	is	a	role	fulfilled	by	the	immune	system.	The	
functions	 of	 a	 competent	 immune	 system	 include	 the	 following:	 Recognition	 of	
disease	causing	agents,	such	as	pathogens	or	cancerous	cells,	destruction	of	these	
threats,	recognising	and	sparing	healthy	tissue	(self‐recognition/tolerance)	(42).	
The	immune	system	is	generally	categorised	by	the	type	of	specificity	and	relative	
speed	of	responses	with	much	interplay	between	the	two.	Thus	innate	immunity	
is	fast	and	broad	while	and	adaptive	immunity	slow	but	specific.	
	
1.3.2.	Innate	
 
The	 innate	 immune	 system	 is	 the	 older	 out	 of	 the	 two	 forms	 of	 vertebrate	
immunity	 in	 evolutionary	 terms,	 and	 the	 most	 universal	 among	 eukaryotes.	 In	
humans,	it	comprises	a	humoral	and	cell‐based	system,	and	both	of	these	systems	
have	afferent	and	efferent	components	(42).	Physical	barriers	are	also	sometimes	
considered	part	of	this	system.	
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1.3.2.1.	Cell	based	
	
Pathogen	Recognition	Receptors	(PRRs)	
The	 level	 of	 specificity	 of	 the	 cell‐based	 innate	 immune	 system	 enables	 the	
discrimination	of	 self	 from	non‐self	by	 the	recognition	of	molecules	 that	are	not	
generally	 displayed	 in	 the	 vertebrate,	 i.e.	 likely	 or	 potential	 pathogens.	 The	
afferent	cell‐based	receptor	systems	involved	in	this	discrimination	are	known	as	
PRRs.		
PRRs	 comprise	 families	 of	 receptors	 that	 recognize	 specific	 molecules	 (42),	
usually	 referred	 to	 as	 	 PAMPs	 (pathogen	 associated	 molecular	 patterns)	 and	
expressed	 on	most	 cell	 types.	 Binding	 of	 PAMPs	 to	 PRRs	 leads	 to	 activation	 of	
innate	 immune	 responses	 and	 often	 adaptive	 immune	 responses.	 Some	 of	 the	
many	PRR	families	include	toll‐like	receptors	(TLR),	nod‐like	receptors	(NLR)	and	
C‐type	lectin	receptors	(CLR).	
TLRs	can	be	extracellular	(such	as	TLR	1,2	and	4),	intracellular	(TLR	7	and	9)	(43),	
or	both	(e.g.,	TLR3)	(44,	45).	Each	TLR	class	is	specific	to	a	particular	pathogenic	
ligand/molecule	 such	 as	 the	 lipopolysaccharide	 of	 gram‐negative	 bacteria	 for	
TLR4,	double	stranded	RNA	(dsRNA)	for	TLR3	and	single	stranded	RNA	(ssRNA)	
for	TLR7,	both	the	latter	detecting	likely	virus‐derived	nucleic	acid.	NLRs	(located	
mostly	 in	 the	 cystol)	 recognize	 certain	 microbial	 components	 and	 result	 in	
activation	of	nuclear	factor‐κB	(NFκB)	and	caspases	(46)	while	CLR	activation	can	
modulate	 immune	responses	by	affecting	TLR	signalling	 	directly	or	by	affecting	
the	gene	expression	profile	(47).	
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Leukocytes	
	
Leukocytes	are	generated	in	the	bone	marrow	and	circulate	via	the	bloodstream,	
as	well	 as	migrating	 to	 and	 populating	 tissues	 throughout	 the	 body.	 They	 have	
both	afferent	and	efferent	roles	in	the	innate	immune	system,	both	by	the	antigen‐
presenting	 role	 of	 certain	 subsets,	 production	 of	 chemokines	 to	 facilitate	 the	
recruitment	 of	 other	 leukocytes	 subsets	 and	 the	 destruction	 of	 pathogens	 via	
phagocytosis	 or	 reactive	 molecules.	 Leukocytes	 of	 the	 innate	 immune	 system	
mostly	comprise	myeloid‐lineage	cells	(42).	
	
Granulocytes	–	neutrophils,	eosinophils,	basophils	and	mast	cells.	
Neutrophils	arise	from	the	myeloid	lineage	and	comprise	the	largest	proportion	of	
the	white	blood	cells	in	the	blood		(typical	concentration	in	humans	is	5x106/mL)	
(48)	and	are	crucial	 in	 the	 initial	 response	 to	various	 invading	pathogens.	Their	
numbers	can	increase	by	10‐fold	during	infectious	events,	supplied	from	the	bone	
marrow	(49),	and	they	have	a	relatively	short	half	 life	(6.6	±	1.4	hours	(50)).	As	
granulocytes,	 their	role	has	 traditionally	been	seen	as	microbicidal,	achieved	via	
phagocytosis	 and	 the	 release	 of	 cytotoxic	 proteins	 during	 degranulation.	 In	
addition	to	these	direct	anti‐microbial	properties,	research	in	the	last	decade	or	so	
has	 revealed	 that	 neutrophils	 have	 the	 ability	 to	 affect	 the	 immune	 response	
profile	(51).	These	functions	include	chemoattraction	of	monocytes	and	dendritic	
cells	 (DC),	 secretion	 of	 certain	 cytokines	 such	 as	 TNF	 and	 influencing	 whether	
macrophages	are	generally	pro‐	or	anti‐apoptotic	(51).	
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Mast	 cells,	 basophils	 and	 eosinophils	 also	 have	 various	 roles	 in	 anti‐pathogen	
activity,	fibrosis,	wound	healing	and	shaping/responding	to	the	immune	response	
from	both	innate	and	adaptive	elements	of	the	immune	system.	Most	research	to	
date	 however	 has	 focused	 on	 their	 roles	 in	 allergy	 and	 inflammation	 and	 to	 a	
lesser	extent,	anti‐parasitic	activity	(52).		
	
Antigen‐presenting	cells	
Antigen‐presenting	 cells	 (APC)	are	one	of	 the	major	bridges	between	 the	 innate	
and	 adaptive	 immune	 responses.	 Presentation	 of	 antigens	 to	 adaptive	 immune	
cells	requires	a	complex	of	antigen	with	either	MHC‐I	or	MHC‐II	molecules.	
There	 are	 two	 kinds	 of	 APCs,	 professional	 and	 non‐professional.	 They	 differ	 in	
their	 effect	 on	 unprimed	 T‐cells,	 as	 a	 result	 of	 the	 higher	 expression	 of	 co‐
stimulatory	 molecule	 expression	 (such	 as	 CD80	 and	 CD86)	 on	 professional	 vs.	
non‐professional	 APCs.	 Via	 these	 co‐stimulatory	 molecules,	 APCs	 interact	 with	
CD28	 and	 CTLA‐4	 on	 T‐cells	 (53)	 as	 well	 as	 with	 the	 T‐cell	 receptor	 (TcR)	 via	
MHC/antigen	 complexes	 to	 activate	 unprimed	 T‐cells.	 This	 leads	 to	 the	
proliferation	 of	 T‐cells,	 production	 of	 cytokines	 and	 expression	 of	 relevant	
cytokine	 receptors.	 Non‐professional	 activation	 on	 the	 other	 hand	 appears	 to	
result	 only	 in	 the	 expression	 of	 the	 cytokine	 receptors,	 but	 no	 proliferation	 or	
cytokine	 production,	 at	 least	 in	 CD8	 T‐cells	 (53).	 Non‐professional	 APCs	 also	
require	cytokine	stimulation	in	order	to	express	MHCII.	
Non‐professional	 APCs	 include	 fibroblasts	 (54),	 RPE	 (55,	 56)	 and	 keratinocytes	
(57)	 for	 example,	 while	 professional	 APCs	 include	 monocytes,	 macrophages,	
dendritic	cells	(DCs),	and	B‐cells	(58).	
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Monocytes	
Monocytes	are	produced	in	the	bone	marrow	as	part	of	the	myeloid	lineage,	but	in	
inflammatory	 situations	 they	 can	 also	 be	 released	 from	 reservoirs	 such	 as	 the	
spleen	 (59)	 and	 are	 generated	 from	 both	 macrophage	 and	 DC	 precursor	 cells	
(MDP)	and	common	monocyte	progenitor	cells	(cMoP)	in	mice	(60).	One	manner	
in	which	murine	monocytes	have	been	classified	in	the	literature	is	by	the	level	of	
expression	 of	 a	 marker	 called	 Ly6C.	 Ly6Clow	 monocytes	 are	 cells	 involved	 in	
homeostatic	roles,	recruiting	neutrophils	to	aid	in	the	maintenance	of	endothelial	
integrity	 (61),	 while	 Ly6Chi	 monocytes	 are	 considered	 ‘classical’	 inflammatory	
monocytes,	 and	 migrate	 rapidly	 to	 an	 infection/injury	 site	 (in	 response	 to	 the	
chemokine	 CCL2),	 have	 high	 phagocytic	 activity	 and	 contribute	 to	 cytokine	
production	and	inflammation	at	the	site	of	recruitment	(62).		
Once	they	have	infiltrated	into	tissues,	monocytes	can	differentiate	into	microglia	
(63),	macrophages	or	dendritic	cells	(61),	supplementing	local	populations.	
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Macrophages	
The	 long‐established	 model	 of	 macrophages	 is	 that	 of	 terminally	 differentiated	
tissue‐based	cells	that	are	quiescent,	generally	non‐proliferative	and	play	a	role	in	
pathogen	 elimination.	 However,	 research	 has	 since	 shown	 that	 they	 have	 the	
ability	to	replicate,	albeit	at	a	 low	levels	(64).	They	are	classified	into	two	types,	
inflammatory	M1	macrophages	 (classically	activated)	and	anti‐inflammatory	M2	
(alternately	activated)	macrophages	(64),	although	rigidity	of	this	classification	is	
contentious,	 with	 studies	 showing	 hybrid	 phenotypes	 or	 that	 the	 same	 type	 of	
macrophage	 responds	 to	 the	 same	 stimuli	 differently	 between	 studies.	 These	
differences	 are	 now	 thought	 to	 be	 related	 to	 their	 origins	 (whether	 they	 result	
from	 proliferating	 resident	 tissue	 macrophages	 or	 from	 infiltrating	 monocyte‐
derived	macrophages)	(64).	
Despite	 the	 recruitment	 of	monocyte‐derived	macrophages	 during	 both	 normal	
physiological	 and	 inflammatory	 states,	 most	 resident	 tissue	 macrophages	 are	
believed	to	derived	from	fetal	tissue	macrophages	that	replicate	and	maintain	the	
local	 population	 well	 into	 adulthood,	 with	 microglial	 cells	 being	 one	 exception	
(61).	
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There	are	many	types	of	macrophages	and	macrophage‐derived	cells,	with	some	
types	of	tissues	having	specific	subsets.	Osteoclasts,	which	aid	in	bone	resorption,	
Kupffer	cells	 located	in	 liver	and	alveolar	macrophages	are	among	these	(65).	 In	
neural	tissues	and	in	the	retina,	the	primary	residential	 leukocytes	are	microglia	
(66)	which	have	been	shown	to	be	derived	from	the	yolk‐sac	(67).	The	origins	of	
microglia	 in	 the	 retina	 under	 normal	 physiological	 conditions	 is	 somewhat	
unclear,	with	some	researchers	believing	they	originate	from	mesodermal	cells,	or	
are	 of	 neuro‐ectodermal	 origins.	 Several	 other	 studies	 however,	 point	 to	
circulating	haematopoietic	cells	such	as	monocytes	that	migrate	and	differentiate	
into	microglia	once	in	the	retina,	as	reviewed	by	Li	L	et	al	(68).		
	
Dendritic	cells	(DC)	
Dendritic	cells	are	considered	to	be	one	of	the	most	effective	APCs	in	the	immune	
system.	 They	 are	 mostly	 derived	 from	 the	 aforementioned	 MDP	 cells	 although	
there	 are	 also	 lymphoid	 derived	 DCs	 (69).	 DCs	 are	 divided	 into	 two	 broad	
categories;	 conventional	 (cDC)	 and	 plasmacytoid	 (PDC).	 Immature	 cDCs	 have	
strong	phagocytic	activity	while	mature	cells	have	a	high	cytokine	output	ability	
(70).	 They	 are	 highly	 migratory,	 readily	 journeying	 from	 tissues	 to	 lymphatic	
organs	 and	 are	 specialised	 in	 APC	 activity.	 Over	 time,	 they	 are	 replenished	 by	
blood‐derived	precursors.	
PDCs,	have	longer	lifespans	and	are	specialized	in	direct	anti‐viral	activity,	but	still	
have	APC	activity	and	the	ability	to	shape	T‐cell	responses	(71).	
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DC	distribution	in	the	posterior	eye	is	mainly	restricted	to	the	choroid,	with	few	if	
any	 in	 the	 retina	 (72),	 although	 Lehmann	 et	 al	 (73)	 raised	 the	 possibility	 that	
certain	 cells	 in	 the	 retina	 which	 have	 been	 labelled	 as	 microglia	 by	 other	
researchers	are	in	fact	DCs.	
	
Natural	Killer	cells	
Unlike	 the	other	 innate	 immune	 leukocytes	discussed	so	 far,	Natural	Killer	 (NK)	
cells	 are	 primarily	 of	 lymphoid	 origin.	 As	 their	 name	 suggests,	 NK	 cells	 have	
cytotoxic	 properties	 and	 were	 originally	 named	 because	 of	 their	 anti‐tumour	
activity	 (74).	 They	 are	 large	 granular	 leukocytes,	 located	 in	 both	 lymphoid	 and	
non‐lymphoid	 tissues,	 and	 have	 a	 turnover	 time	 in	 humans	 of	 approximately	 2	
weeks	(75).	Cells	that	have	lost	MHC‐I	are	especially	susceptible	to	NK‐mediated	
cell	death.	Upon	activation	of	the	NK	cells,	cell	death	is	achieved	by	the	release	of	
cytotoxic	granules	into	the	space	between	it	and	the	target	cell	(76).	
NK	cells	also	use	their	lytic	properties	to	act	as	regulatory	cells.	Immature	DCs	and	
activated	T‐cells	may	be	destroyed	by	NK	cells	in	order	to	shape	DC	homeostasis	
(77)	and	regulate	adaptive	T‐cell	responses	(78),	respectively.	
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1.3.2.2.	Humoral	system	
 
Innate	 humoral‐based	 detection	 systems	 rely	 on	 the	 binding	 of	 specialized	
proteins	 to	 specific	 pathogen‐associated	 molecules.	 These	 proteins	 include	 the	
mannose‐binding	 protein	 (MBLP2),	 which	 binds	 to	 mannosyl	 components	 of	
microbial	 cell	 walls	 and	 initiates	 the	 complement	 cascades	 (79),	 while	
lipopolysaccharide	 (LPS)‐binding	 protein	 (LBP)	 in	 conjunction	 with	 CD14	 can	
present	LPS	to	and	activate	TLR2	and	4	signaling	(80).	
 
Complement system 
 
The	complement	system	is	composed	of	a	variety	of	proteins,	some	which	are	part	
of	an	internal	signal	amplification	cascade,	some	have	regulatory	functions,	while	
some	have	direct	and	indirect	anti‐pathogen	activity.	
There	are	three	pathways	for	the	complement	system;	the	classical	pathway,	the	
lectin	pathway	and	the	alternative	pathway	(81).	While	each	of	the	pathways	are	
activated	by	different	mechanisms,	 they	all	end	up	activating	the	C3	component.	
Activation	 of	 the	 classical	 pathway	 requires	 the	 formation	 of	 antibody‐antigen	
complexes,	 the	 alternate	 pathway	 is	 constitutively	 expressed	 as	 it	 involves	 the	
spontaneous	activation	of	C3	 (82),	 and	 the	 lectin	pathway	via	pathogen‐derived	
carbohydrate	interactions	with	plasma‐based	mannose	binding	protein.	
Activation	 of	 the	 complement	 cascade	 leads	 to	 the	 production	 of	 several	
complement	 components	 with	 anti‐microbial	 activities.	 C5a	 has	 the	 ability	 to	
recruit	neutrophils	 (83)	and	C3b	and	C4b	molecules	 can	bind	 to	 the	microbe	 to	
enhance	the	phagocytosis	of	a	pathogen	in	a	process	called	opsonisation	(84).		
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Another	 form	 of	 direct	 anti‐microbial	 activity	 from	 complement	 components	 is	
the	membrane	attack	complex	(MAC)	consisting	of	the	complement	units	C5b,	C6,	
C7,	C8,	and	C9.	The	MAC	embeds	 itself	 into	the	cell	wall	of	a	 target	microbe	and	
results	in	its	destruction	via	lysis	(84),	however	this	process	can	also	mediate	lysis	
of	self‐cells.	
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Figure	1.6.	Diagram	of	 the	 complement	 system,	 showing	 the	 classical,	 alternate	
and	 lectin	 pathways,	 in	 addition	 to	 the	 subsequent	 complement	 cascade	 that	 is	
common	to	all	the	pathways.	Modified	from	(81).	
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Caspases 
 
Caspases	are	involved	primarily	with	the	amplification	of	a	signal	cascade	which	
results	 in	 the	 destruction	 of	 the	 cells	 in	 which	 they	 are	 activated	 (apoptosis).	
There	are	two	types	of	caspases,	initiator	(caspases	2,	8,	9,	and	10)	and	executor	
(3,	6	and	7).	Activated	initiator	caspases	can	go	on	to	cleave	pro‐forms	of	executor	
caspases,	and	thereby	activate	them.	These	executor	caspases	(especially	caspase	
3)	 are	 then	 responsible	 for	 the	 pro‐apoptotic	 cleavage	 of	 cellular	 substrates,	 as	
well	as	cleavage	of	viral	proteins	(85).	
 
1.3.3.	Adaptive/Acquired	
 
Like	 innate	 immunity,	 adaptive	 immunity	 has	 both	 humoral	 and	 cell	 based	
components.	In	adaptive	immunity,	cell‐based	immunity	is	provided	primarily	by	
T‐cells	and	humoral	immunity	is	primarily	by	B‐cells.	While	they	both	originate	in	
the	bone	marrow	post‐foetally,	 they	were	named	 from	the	organs	 in	which	 they	
develop,	 for	 T‐cells	 this	 is	 the	 thymus,	 and	 for	 B‐cells,	 the	 bursa	 of	 fabricius	 in	
chickens,	 where	 they	 were	 first	 discovered	 (in	 the	 case	 of	 mammals,	 B‐cells	
develop	in	the	bone	marrow).	
	
	
T‐cells	
T‐cells	are	divided	into	two	main	groups;	CD4	and	CD8	cells.	Other	types	of	T‐cells	
that	do	not	 fall	under	 these	classifications	 include	double	negative	T‐cells	 (CD3+	
CD4‐	CD8‐),	γδ	T‐cells,	NKT	cells	and	mucosal‐associated	invariant	T‐cells	(86).	
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CD4+	and	CD8+	T‐cells	express	a	cell	surface	T‐cell	receptor	(TCR/CD3)	designed	
to	recognize	cognate	MHC‐antigen	complexes.	They	derive	from	the	bone	marrow,	
but	migrate	 to	 the	 thymus	where	 they	 undergo	 positive	 and	 negative	 selection	
pressures	 in	 response	 to	 self‐MHC	 antigen	 complexes	 (clonal	 selection).	 These	
selection	procedures	ensure	 that	 self‐tolerance	 is	maintained	and	autoimmunity	
is	 avoided.	 It	 is	 also	within	 the	 thymus	 that	 expression	 of	 either	 CD4	 or	 CD8	 is	
determined.	This	in	turn	determines	whether	the	developing	cell	will	interact	with	
class	I	or	class	II	MHC	antigens.	
Additional	 methods	 of	 reducing	 pathological	 T	 cell	 interaction	 with	 self‐MHC	
antigen	 complexes	 include	 the	 down‐regulation	 of	 the	 TCR	 and	 extrinsic	
suppression	of	the	T	cell	(87).		
Once	 these	 T‐cells	 have	migrated	 into	 secondary	 lymphoid	 organs,	 such	 as	 the	
spleen	 and	 lymph	 nodes,	 and	 encounter	 their	 specific	 antigen,	 as	 presented	 to	
them	 via	 APCs	 (along	 with	 co‐stimulatory	 signals),	 they	 become	 activated,	
undergo	 clonal	 expansion,	 and	 migrate	 to	 sites	 where	 the	 target	 antigen	 is	
present.	These	effector	cells	mostly	disappear	after	the	antigen‐producing	source	
is	eliminated,	although	some	remain	behind	and	become	memory	T‐cells.	Unlike	
effector	 T‐cells,	 these	 memory	 cells	 can	 last	 for	 years	 in	 both	 lymphoid	 and	
peripheral	 tissues.	 Should	 the	 same	 antigen	 reappear,	 these	 memory	 cells	 can	
mount	 a	 secondary	 immune	 response	 in	 a	 much	 shorter	 timeframe	 and	 with	
greater	intensity	than	the	initial	primary	response	(88).	
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CD4	T‐cells	
Broadly	speaking,	CD4	T‐cells	are	considered	to	be	immuno‐modulatory	or	helper	
T‐cells.	 Within	 this	 group,	 there	 are	 currently	 6	 recognised	 subsets:	 Th1,	 Th2,	
Th17,	 Regulatory,	 T‐follicular	 helper	 cells	 (TFH),	 Th22	 and	 the	 most	 recently	
identified	Th9	 subset.	 These	 subsets	 are	defined	by	 the	 soluble	 factor	 spectrum	
they	 produce,	which	 is	 tuned	 to	 the	 kind	 of	 pathogen	 encountered	 and	 thereby	
influences	the	outcome	of	the	adaptive	immune	response.	
Th1	cells	are	involved	in	cell‐mediated	immunity	(89),	and	generally	interact	with	
macrophages	and	produce	the	cytokines	TNF	and	IFN‐γ.	Th2	cells	are	involved	in	
humoral	 immunity,	 and	 produce	 cytokines	 such	 as	 IL4,	 which	 serves	 to	
differentiate	naïve	T	cells	into	Th2	cells	(89).	Th17	cells,	primarily	produce	IL‐17A	
and	are	noted	for	their	roles	in	immunity	towards	extracellular	bacteria,	fungi	and	
autoimmunity	(90).	A	small	subset	of	CD4	cells,	which	are	CD25+	and	FoxP3+,	are	
called	T‐cell	 regulatory	cells,	or	Tregs.	These	cells	serve	 to	regulate	 the	 immune	
response,	 dampening	 it	 and	 helping	 to	 prevent	 the	 formation	 of	 autoimmune	
diseases	(91).	
TFH	 cells	 are	 critically	 important	 in	 the	 generation	 of	 B‐cell	mediated	 humoral	
immunity,	 facilitating	 the	 processes	 that	 generate	 affinity	 maturation	 of	
antibodies	(92).	
Th22	cells	produce	IL‐22	but	not	IFN‐γ	(93),	while	Th9	cells	are	characterised	by	
their	ability	to	produce	IL9	and	IL21.	Th22	cells	are	known	to	have	various	roles,	
which	 include	 those	 in	 autoimmune	 responses,	 allergic	 responses	 and	 innate	
immunity	(94).	Most	research	to	date	has	looked	at	the	role	of	Th9	in	allergy	and	
the	anti‐parasitic	response,	however,	newer	reports	have	investigated	a	possible	
role	within	the	anti‐cancer	strategy	of	the	immune	system	(95).	
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CD8	T‐cells	
Within	the	T‐cell	subsets,	if	CD4	cells	are	the	field	commanders,	then	CD8	cells	are	
the	 infantry,	 mediating	 the	 destruction	 of	 targets	 cells.	 Reflecting	 this	 function,	
effector	 CD8	 T‐cells	 are	 referred	 in	 many	 papers	 as	 CTLs	 –	 cytotoxic	 T‐
lymphocytes.	
CD8‐mediated	 cell	 death	 occurs	 via	 two	 pathways:	 perforin‐granzyme	 pathway	
and	the	Fas/Fas‐Ligand	pathway	(96).	 In	the	former,	binding	of	the	CD8	effector	
cell	to	the	target	cell	activates	the	release	of	perforin	proteins,	which	form	pores	
in	the	target	cell,	and	serine	proteinases	(granzymes).	The	latter	pathway	involves	
the	 initiation	 of	 apoptosis	 via	 the	 binding	 of	 Fas‐L	 from	 the	 CD8	 cell	 to	 their	
respective	Fas	receptor	on	the	target	cell.		
Primary	 expansion	 of	 effector	 CD8	 T	 cells	 is	 achieved	 via	 the	 interaction	 of	
antigen‐specific	CD8	T‐cells	with	antigen‐expressing	APC	cells,	but	maintenance	of	
CD8	memory	cells	and	functions	requires	CD4	T‐cells	(97).	
	
  38
B‐cells	
B	 cells	 are	 the	 major	 cells	 of	 humoral	 immunity.	 B‐cells	 also	 mature	 through	
selection	 affinity	 in	 a	 similar	 manner	 to	 T‐cells,	 although	 they	 have	 a	 B‐cell	
receptor	(BCR)	 instead	of	a	TCR,	and	 is	essentially	a	membrane	bound	antibody	
(98).	 Unlike	 T‐cell	 clonal	 selection,	 where	 T‐cells	 that	 demonstrate	 too	 high	 an	
affinity	 for	 self	 are	 deleted,	 B‐cells	 are	 given	 another	 opportunity	 to	 re‐arrange	
their	BCR	conformation	to	one	that	does	not	have	too	high	an	affinity	for	self	(98).	
Thus,	in	addition	to	the	other	anti	auto‐immunity	measures	mentioned	for	T	cells,	
BCRs	also	have	the	ability	to	be	modified	so	that	they	are	no	longer	highly	specific	
for	self‐antigen	(98).	
As	with	T‐cells,	there	are	a	variety	of	different	B‐cell	subsets,	the	main	two	being	
plasma	 B‐cells	 and	memory	 B‐cells,	 but	 there	 are	 also	 follicular,	 marginal	 zone	
and	 regulatory	B‐cells.	 A	more	primitive	 class	 of	B‐cells,	 B1	 cells	 are	 capable	 of	
producing	T‐independent	antibody	in	response	to	the	crosslinking	of	the	BCR	by	
repetitive	moieties	of	bacterial	coat	antigens.	
When	 activated,	 B‐cells	 undergo	 clonal	 expansion	 and	 like	 T‐cells,	 both	 effector	
and	memory	 cells	 are	 created.	 The	 plasma	 B‐cells	 (effector	 cells)	 produce	 vast	
quantities	 of	 antibodies,	 which	 are	 secreted	 into	 the	 plasma	 with	 antibodies	
against	 proteins	 generally	 produced	with	 the	 assistance	 of	 CD4+	T‐cells	 (T‐cell‐
dependent	antibodies)	(99).	
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1.3.4.	Cytokines	
 
Cytokines	 are	 a	 specific	 type	 of	 peptide‐based	 signaling	 molecules.	 They	 are	
commonly	known	for	 their	 immune‐modulating	 functions.	These	 include	driving	
cells	towards	a	pro	or	anti‐inflammatory	profile,	attracting	leukocytes	to	the	site	
of	 release	 via	 concentration	 gradients	 (termed	 chemokines,	which	 include	CCL2	
and	 CCL5)	 (100)	 	 and	 inducing	 other	 cells	 or	 even	 the	 cytokine	 producing	 cell	
(paracrine	 signaling)	 to	 produce	 other	 cytokines	 (101).	 Establishing	 precise	
definitions	 that	 distinctly	 characterise	 the	 difference	 between	 cytokines	 and	
hormones	is	difficult	(102),	and	sometimes	the	same	molecule	can	be	classified	as	
one	or	the	other,	depending	on	the	 location	and	context	 in	which	 it	 is	produced.	
Cytokines	 are	 also	grouped	 into	 two	broad	 categories,	 as	defined	by	 their	 three	
dimensional	 structure	 (103):	 type	 I	 cytokines	 (four	α‐helical	 subunit	 structure),	
encompassing	 many	 types	 of	 interleukins	 and	 certain	 hematopoietic	 growth	
factors.	 Type	 II	 cytokines	 (diverse	 structure)	 include	 interferons,	 the	 TNF	
superfamily	and	Ig	superfamilies.	Cytokines	can	also	exert	a	multitude	of	effects,	
sometimes	 contrasting	 effects,	 although	 this	 usually	 involves	 the	 presence	 of	
other	molecules	 or	 is	 specific	 to	 a	 certain	 condition.	 An	 example	 of	 this	 is	 TNF,	
which	is	well	known	to	have	inflammatory	properties,	but	has	also	been	shown	to	
exhibit	 anti‐inflammatory	 properties	 in	 certain	 conditions,	 such	 as	 TGFβ	 ‐
mediated	APC	immunoregulation	(104).	
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Interferons (IFN)s 
	
The	 IFN	 class	 of	 cytokines	 are	 involved	 in	 the	 innate	 immune	 and	 adaptive	
immune	responses	in	response	to	pathogen	infection	and	tumour	control.	Binding	
of	 IFNs	with	 their	 respective	 receptors	 results	 in	 the	 upregulation	 of	 interferon	
simulated	 genes	 (ISGs)	 such	 as	 MX1	 (myxovirus	 influenza	 virus	 resistance	 1),	
OAS1	(2'‐5'‐oligoadenylate	synthetase	1)	and	various	IRFs	(interferon	regulatory	
factors),	among	other	class‐specific	effects.	
Currently,	there	are	three	classes	of	interferons:		
A.	Type	I.	These	include	the	IFNs	α,	β,	ω,	κ,	ε,	τ,	ζ,	δ	and	ν.	This	class	of	interferons	
is	 mainly	 known	 for	 their	 antiviral	 and	 immunomodulatory	 properties	 that	
contribute	to	antiviral	immune	responses.	Signalling	of	type	I	IFNs	occurs	through	
the	IFNAR	receptors,	(105).	
B.	 IFN‐γ	 is	 the	 sole	member	of	 the	 type	 II	 interferon	 clade,	 is	 only	produced	by	
lymphocytes,	 usually	T‐cells	 and	uses	 a	 receptor	 and	 signaling	 pathway	distinct	
from	the	type	I	 interferons.	Its	effects	on	cells	include	the	upregulation	of	class	I	
and	 II	 antigen	 presenting	 pathways,	 promoting	 a	 Th1‐mediated	 CD4	 T‐cell	
response	and	priming	macrophages	 to	elicit	 a	 stronger	and	quicker	 response	 to	
microbial	products	such	as	LPS	(106).	
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C.	The	type	III	interferons	include	IFNλ1,	IFNλ2,	IFNλ3,	and	the	rare	IFNλ4,	which	
appears	 to	only	be	expressed	by	a	subset	of	 the	human	population	(107).	While	
the	 signal	 transduction	 and	 biological	 activities	 of	 type	 III	 interferons	 are	
essentially	the	same	as	type	I	IFNs,	they	are	genetically	distinct	and	use	a	distinct	
signalling	receptor	composed	of	two	chains:	the	IFNLR1	and	the	IL10R2	(which	is	
also	a	component	of	the	receptors	for	IL‐10,	IL‐22	and	IL‐26)	(108).	While	type	III	
interferons	 are	 produced	 by	 several	 cell	 types,	 expression	 of	 the	 corresponding	
receptor	appears	to	be	exclusively	on	epithelial	cells(108),	with	the	exception	of	
the	soluble	decoy	form	of	IFNRL1	(produced	by	leukocytes)	(109).	This	epithelial	
exclusive	 expression	 results	 in	 a	 targeted	 effect	 of	 the	 type	 III	 interferons.	 As	 a	
result,	type	III	IFN	responses	appear	to	be	more	important	than	type	I	responses	
in	 mice	 infected	 by	 viruses	 that	 preferentially	 infect	 respiratory	 or	 intestinal	
epithelia	 (110).	 Unlike	 type	 I	 interferons	 however,	 there	 appears	 to	 be	 a	
possibility	that	type	III	interferons	also	have	a	role	to	play	in	the	adaptive	immune	
system,	 given	 that	 IFNLR1	 knockout	 mice	 had	 increased	 T‐cell	 responses	 and	
proliferation	 during	 a	 LCMV	 rechallenge	 compared	 with	 wildtype	 mice	 (111),	
perhaps	by	inducing	target	epithelial	cells	to	produce	mitogenic	factors.		
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1.3.5	Ocular	Immunity	in	the	posterior	eye	
	
Immune privilege  
 
Because	of	the	highly	significant	contribution	of	sight	to	the	evolutionary	fitness	of	
many	 organisms,	 it	may	 be	 argued	 that	 there	 is	 selection	 pressure	 to	minimize	
immune‐mediated	tissue	damage	to	the	eye.	As	a	result,	the	eye	is	one	of	the	few	
organs	in	the	body	that	has	what	is	termed	‘immune	privilege’	(the	others	being	
the	brain,	the	testes,	ovaries	and	placenta/foetus)	(112).	The	concept	of	immune	
privilege	was	originally	applied	to	sites	 in	the	body	where	grafts	placed	in	these	
areas	would	survive	for	an	extended	period	whereas	they	would	immediately	be	
rejected	 in	 other	 parts	 of	 the	 body	 (113).	 It	 was	 believed	 up	 until	 relatively	
recently	 that	 this	 immune	 privilege	was	 achieved	 by	 complete	 exclusion	 of	 the	
relevant	 organs/sites	 from	 leukocytes,	 via	 anatomical	 barriers.	 However,	
significant	 research	 has	 shown	 that	 even	 in	 non‐inflammatory	 conditions,	
leukocytes	 do	 traverse	 these	 sites	 (and	 especially	 so	 during	 inflammatory	
conditions	(114)).	
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Thus,	 immune	 privilege	 has	 been	 redefined	 as	 an	 organ	 or	 site	 in	 which	
immunological	 responses	 under	 non‐inflammatory	 conditions	 discourages	 the	
entry	 of	 leukocytes	 and	 skews	 the	 immune	 environment	 towards	 an	 anti‐
inflammatory	profile	(112).	In	addition	to	physical	barriers,	this	is	achieved	by	the	
expression	 of	 soluble	 factors,	 membrane‐bound	 and	 free	 ligands	 that	modulate	
leukocyte	 phenotypes	 towards	 regulatory	 subtypes,	 downregulates	 the	
production	of	inflammatory	cytokines	while	upregulating	their	anti‐inflammatory	
counterparts,	 as	 well	 as	 inducing	 of	 immune	 tolerance/ignorance	 of	 antigens	
(114).	 The	 outer	 BRB	 was	 also	 initially	 considered	 to	 be	 impenetrable	 by	
leukocytes	 under	 homeostatic	 conditions	 (115),	 however,	 given	 that	 low‐level	
leukocyte	 trafficking	 has	 been	 observed	 in	 the	 CNS	 in	 non‐inflammatory	
conditions	 (116),	 and	 that	 there	 is	 evidence	 of	 the	 choroid	 serving	 as	 a	 local	
lymph	 drainage	 site	 (117),	 complete	 leukocyte	 exclusion	 in	 homeostatic	
conditions	by	the	outer	BRB	is	an	unlikely	scenario.	Indeed,	retinal	antigens	have	
been	found	in	the	thymus,	and	are	used	in	negative	selection	of	T‐cells	(118)	albeit	
an	 incomplete	 process	with	 several	 retinal	 antigen‐specific	 T‐cells	 escaping	 this	
process	(17).	
In	 the	 retina,	 humoral‐based	methods	 that	 skew	 the	 immune	 profile	 towards	 a	
non‐inflammatory	 one	 include	 constitutive	 expression	 of	 regulatory	 immune	
complement	 proteins	 such	 as	 CD46,	 CD55,	 CD59	 (119,	 120)	 CD200	 (121),	 high	
basal	levels	of	TGFβ	(122)	and	local	production	of	TGFβ	(123).	
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Leukocyte	modulation	 in	 the	 retina	 includes	 the	 expression	 of	 Fas‐L	 (114,	 124)	
and	 PD‐L1	 (125,	 126)	 (which,	 when	 bound	 to	 a	 cell	 expressing	 Fas	 or	 CD274,	
respectively,	induces	apoptosis	in	this	cell)	by	RPE	cells,	as	well	as	inhibition	of	T‐
cell	 activation	 by	 MHCIIlow‐	 expressing	 RPE	 cells	 (56).	 Concurrently,	 retinal	
microglia	may	 also	 be	 an	 integral	 part	 of	 retinal	 immune	 privilege	 due	 to	 their	
ability	 to	 produce	 anti‐inflammatory	 IL‐10	 in	 response	 to	 IFN‐γ	 and	 LPS	
stimulation	(127).		
An	 opinion	 article	 published	 in	 Nature	 Reviews	 (128)	 further	 proposes	 that	
immune	 privileged	 sites	 can	 employ	 two	 types	 of	 barriers:	 ‘true’	 barriers	
(endothelial	 barriers	 in	 which	 parenchymal	 leukocyte	 entry	 is	 detrimental	 to	
surrounding	 tissue)	 and	 educational	 epithelial	 gates	 (which	 use	
immunomodulatory	 mechanisms	 to	 skew	 the	 leukocyte	 profile	 to	 an	 anti‐
inflammatory	 one).	Within	 the	 retina,	 they	 propose	 that	 the	 inner	 blood	 retinal	
barrier	 is	 the	 former	 while	 the	 outer	 blood	 retinal	 barrier	 is	 the	 latter.		
Within	this	model,	it	is	likely	that	autoimmune	disorders	in	these	organs	may	be	a	
result	of	the	failure	of	one	or	multiple	immune‐skewing	mechanisms,	rather	than	
a	simple	escape	of	barrier	sequestered	antigen,	as	suggested	by	previous	models.	
	
 	
  45
1.4.	Aging‐	Its	effects	on	immunity	and	the	retina		
	
In	addition	to	the	chronological	aspect	of	aging,	several	fields	of	research	strongly	
support	 the	notion	 that	 the	quantity	and	milieu	of	 immunogenic	 challenges	 that	
an	individual	faces	in	their	lifetime,	and	how	effectively	the	body	can	respond	to	
these	challenges,	 is	a	 large	contributor	to	the	ageing	process.	This	 idea	has	been	
designated	 as	 ‘inflamm‐ageing’	 (129),	 however	 the	 term	 has	 been	 expanded	 to	
include	 the	 mechanisms	 behind	 the	 age‐related	 skewing	 of	 the	 basal	 immune	
environment	 towards	 a	 more	 inflammatory	 profile	 (130).	 This	 can	 be	 seen	
thorough	the	various	studies	that	have	shown	higher	 levels	of	pro‐inflammatory	
cytokines	in	the	sera	of	older	people	than	younger	ones,	 including	IL‐6,	TNF	and	
CRP	 (131),	 while	 other	 studies	 (both	 human	 and	 murine	 studies)	 looking	 at		
various	 leukocytes	 have	 noted	 diminished	 phagocytic	 activity,	 reduction	 of	 TLR	
signalling	in	monocytes,	higher	levels	of	reactive	oxygen	species	in	macrophages	
and	 impaired	 IL‐2	 production	 (necessary	 for	 antigen‐activated	 memory	 T‐cell	
proliferation)	 (132).	 The	 humoral	 and	 cell‐based	 age‐related	 immune	 changes	
result	in	not	only	the	aforementioned	higher	basal	inflammation	state,	but	also	a	
decrease	in	the	effectiveness	of	pathogen	clearance	by	the	immune	system.	
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Another	immune	feature	that	is	noted	to	occur	with	increasing	frequency	in	aged	
populations	 is	 what	 is	 termed	 ‘parainflammation’.	 Parainflammation	 has	 been	
described	as	an	 immune	response	midway	between	the	basal	 immune	state	and	
inflammation	 induced	 by	 the	 body	 in	 order	 to	 bring	 the	 body	 back	 to	 a	
homeostatic	 level	after	 the	exposure	to	stressors	(133),	especially	evolutionarily	
novel	ones	(134).	These	stressors	include	chemicals,	altered	dark/light	cycles	and	
excessive	calorific	intake.	Constant	exposure	to	these	stressors	can	create	chronic	
parainflammation,	 which	 in	 turn	 is	 believed	 to	 contribute	 to	 diseases	 such	 as	
diabetes	(134)	and	age‐related	retinal	diseases	such	as	glaucoma	and	age‐related	
macular	degeneration	(AMD,	discussed	in	section	1.6)	(135).	
Within	 the	 retina,	 the	 most	 notable	 physiological	 change	 due	 to	 age	 is	 the	
reduction	of	rods	(almost	half	are	lost	between	the	second	and	fourth	decades	of	
life	 (136)),	 which	 explains	 why	 scotopic	 (low‐light)	 vision	 is	 affected	 by	 age	
significantly	more	than	photopic	vision	(bright	 light).	Other	age‐related	changes,	
such	 as	 decreased	 pigmentation	 and	 retina	 thinning	 (137),	 are	 usually	 not	 as	
detrimental.	 Lipofuscin,	 a	 cellular	 waste	 material	 composed	 of	 cross‐linked	
proteins	 is	considered	to	be	toxic	(138)	and	 inflammatory	(139)	to	cells.	 In	RPE	
cells,	 lipofuscin	is	a	waste	material	formed	from	long‐term	phagocytosis	of	outer	
rod	 segments,	 and	 in	 RPE‐produced	 lipofuscin,	 the	 autofluorescent	 component	
A2E	is	considered	to	be	phototoxic	(140)	due	to	the	high	concentration	of	oxygen	
and	constant	light	exposure	of	retina	enhancing	the	production	of	reactive	oxygen	
species	 by	 lipofuscin.	 Augmenting	 these	 findings,	 activated	 retinal	 microglia	 in	
aged	mice	migrate	into	the	subretinal	space	and	accumulate	lipofuscin	(141),	and	
thus	expose	the	neural	retina	to	the	toxic	effects	of	this	waste	material.		
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An	extracellular	deposit	found	in	higher	levels	in	aged	retinas	is	drusen,	which	is	
composed	of	 lipid	 and	protein‐rich	particles	 (142).	Drusen	 accumulate	 between	
the	 basal	 lamina	 of	 the	 RPE	 and	 the	 underlying	 Bruch’s	 membrane.	 This	
membrane	 itself	 undergoes	 significant	 age‐related	 changes	 that	 can	 lead	 to	 a	
pathological	outcome.	Its	thickness	increases	from	2µm	in	the	first	decade	of	life	
to	4.7µm	by	the	10th	decade	(143).	This	thickening,	along	with	the	lipofuscin	and	
drusen	 deposition	 can	 result	 in	 reduction	 of	 fluid,	 nutrient	 and	 gas	 exchange,	
leading	to	retinal	damage	via	nutrient	starvation	and	toxic	metabolite	retention.	
 
1.5.	Retinal	inflammation	and	outer	BRB	breakdown	
  
However,	 like	 all	 privilege,	 immune	 privilege	 is	 conditional	 and	 despite	 the	
immune‐dampening	 mechanisms	 in	 the	 eye	 (and	 in	 certain	 cases	 because	 of	 it	
(144)),	 inflammation	can	and	does	occur	 in	 the	eye,	 in	 the	 form	of	 autoimmune	
conditions	and	due	to	pathogen	infection.	
One	 key	 example	 of	 this	 is	 posterior	 uveitis,	 which	 can	 be	 mediated	 by	
autoimmune,	 microbial	 or	 idiopathic	 events	 (145).	 All	 involve	 a	 degree	 of	
inflammation	 of	 the	 choroid	 and	 can	 also	 include	 retinitis,	 depending	 on	 the	
severity.	In	posterior	uveitis,	breakdown	of	the	blood	retinal	barrier	as	a	result	of	
leukocyte	infiltration	can	result	in	oedema	and	ensuing	visual	loss	(146).	
Of	particular	concern,	several	retinal	pathologies	and	the	breakdown	of	the	outer	
blood‐retinal	 barrier	 are	 hallmarks	 of	 the	most	 prevalent	 cause	 of	 blindness	 in	
developed	countries	in	people	aged	over	60	(147,	148),	namely	AMD.	
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1.6.	Age‐related	Macular	Degeneration	(AMD)	
	
As	the	name	describes,	AMD	is	an	age‐related	maculopathy.	In	its	late	stages,	AMD	
results	 in	the	 loss	of	central	vision	in	the	afflicted	eye.	Currently,	 treatments	are	
mostly	 limited	 to	 vitamin	 supplement	 regiments	 from	 selected	 from	
epidemiological	research	(149)	and	anti‐VEGF	drugs	to	treat	late	stage	symptoms,	
although	 ongoing	 research	 is	 looking	 at	 the	 efficacy	 of	 corticosteroids,	 anti‐
complement	drugs	and	mTOR	inhibitors	(150).	Diagnosis	occurs	via	observation	
of	 the	 macular	 region	 and	 surrounding	 retina	 by	 fundoscopy,	 after	 noticing	
abnormalities	when	performing	an	Amsler	grid	test.	 	
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1.6.1.	Clinical	presentation	
 
AMD	 is	 clinically	 subdivided	 into	 progression‐centred	 categories	 (early,	
intermediate	or	 late)	and	pathological	presentation	categories	(‘dry’	or	 ‘wet’).	 In	
early	and	intermediate	stages,	a	fundoscopy	can	reveal	the	appearance	of	drusen	
and	pigment	disturbance,	and	vision	can	be	affected	somewhat.	In	contrast,	in	late	
AMD,	 vision	 is	 severely	 compromised	 as	 a	 result	 of	 either	 wet	 or	 dry	 AMD	
processes	 (151). In	 dry	AMD,	 these	processes	 include	 the	degeneration	 of	RPE	
cells	and	overlying	photoreceptor	cells	in	the	macular	region,	leading	to	a	gradual	
loss	 of	 vision	 over	 the	 course	 of	 years.	 In	 contrast,	 damage	 in	wet	AMD	 results	
from	 the	 growth	 of	 new	 vasculature	 from	 the	 underlying	 choroid	 into	 the	
subretinal	space	(termed	choroidal	neovascularization	or	CNV),	which	can	further	
lead	to	disciform	scaring	as	a	result	of	retinal	separation	and	haemorrhaging	into	
the	macula.	Visual	loss	in	this	form	of	AMD	can	occur	in	the	space	of	months	and	is	
of	significant	concern.	Dry	AMD	can	progress	to	wet	AMD	in	certain	cases	(152).	
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1.6.2.	Histopathology	
 
As	previously	stated,	 the	presence	of	drusen	 is	 feature	of	 the	aged	retina.	These	
drusen	 tend	 to	 be	 small,	 compact	 and	 scattered	 throughout	 the	 eye,	 and	 are	
termed	 ‘hard’	 drusen	 (<63um).	 	 The	presence	of	 ‘soft’	 drusen,	which	 are	 larger,	
diffuse	and	tend	to	be	clustered	together	is	indicative	of	retinas	that	are	at	risk	of	
developing	 AMD	 (153)	 especially	 in	 conjunction	 with	 pigment	 abnormalities	
(154),	as	is	a	higher	total	count	of	both	types	of	drusen	(153).	Classifying	drusen	
on	 size	 alone	 however,	 is	 problematic,	 as	 there	 exist	 small	 soft	 drusen	 and	
cuticular	 drusen,	 which	 would	 be	 classified	 as	 ‘hard’	 drusen	 if	 going	 by	
fundoscopy	 alone	 (155).	 The	use	of	 other	 techniques,	 such	 as	 optical	 coherence	
tomography,	is	used	for	a	more	thorough	diagnosis	(155).	A	cracked	and	calcified	
Bruch’s	membrane	 is	 also	 found	at	higher	 frequencies	 in	wet	AMD	(156)	and	 is	
theorised	 to	be	one	of	 the	mechanisms	behind	the	 transition	of	dry	 to	wet	AMD	
(157).		
On	a	microscopic	level,	the	presence	of	monocytes	and	fibroblasts	in	the	Bruch’s	
membrane	 in	people	with	AMD	has	been	noted	 for	 a	 long	 time	 (158)	 and	 these	
finding	are	believed	to	contribute	to	inflammatory	and	fibrotic	changes	in	the	eye.	
Furthermore,	 post‐mortem	 histological	 analysis	 demonstrated	 the	 presence	 of	
leukocytes	in	BRB	breakdown	(16),	and	this	finding	was	most	pronounced	in	AMD	
eyes.	As	certain	macrophages	have	angiogenic	properties	(159),	and	macrophage	
depletion	in	a	CNV	mouse	model	reduces	CNV	lesion	size	and	severity	(160),	it	is	
likely	 that	 the	presence	of	macrophages	 in	AMD	afflicted	eyes	 contributes	 to	 an	
environment	permissive	to	CNV	formation.	
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1.6.3.	Risk	Factors/Pathogenesis	
 
AMD	is	multi‐factorial	disease,	and	ongoing	research	continues	to	uncover	various	
possible	contributors.	The	most	consistent	modifiable	risk	factor	for	this	disease	
is	cigarette	smoking,	with	heavy	smokers	having	almost	3	times	the	likelihood	of	
developing	AMD,	compared	to	non‐smokers	(161).	Strengthening	this	finding	is	a	
murine	smoking	model	that	showed	features	seen	in	dry	AMD,	such	as	RPE	loss,	
thickened	Bruch’s	membrane	and	sub‐retinal	debris	after	only	4.5	months	(162).	
Other	 modifiable	 factors	 believed	 to	 have	 an	 effect	 on	 AMD	 risk	 include	 diet,	
sunlight	exposure	and	alcohol	consumption	(163).	
Various	 genes	 and	 their	 alleles	 have	 also	 been	 investigated	 for	 their	 possible	
contributions	 and/or	 roles	 in	 AMD	 initiation	 and	 progression.	 Some	 of	 these	
genes	are	involved	or	are	a	part	of	the	various	components	of	the	immune	system.	
Polymorphisms	 of	 complement	 factor	 H,	 a	 regulatory	 protein	 involved	 in	 the	
complement	 cascade,	were	one	of	 the	 first	 to	be	 correlated	with	AMD	and	have	
since	been	investigated	in	various	epidemiological	studies	(164,	165).	M280	and	
V249I	variants	of	the	CX3CR1	gene	(which	codes	for	a	receptor	of	the	chemokine	
CX3C)	 have	 also	 been	 linked	with	 AMD	 (166,	 167).	 Other	 immune‐related	 gene	
polymorphisms	 that	 have	 been	 found	 to	 correlate	with	 AMD	 by	 certain	 studies	
(but	 contested	 by	 others)	 include	 complement	 components	 C2,	 C3,	 CFB,	
complement	factor	I,	and	TLRs	3	and	4	(166).	
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Given	the	various	 immune	associations	of	AMD,	 it	 is	perhaps	not	surprising	that	
some	researchers	have	investigated	the	potential	contribution	of	microbes	in	the	
pathogenesis	 of	 AMD,	 such	 as	 cytomegalovirus	 (CMV)	 (168).	 While	 Chlamydia	
pneumoniae	 is	 the	 most	 studied	 microbe	 in	 relation	 to	 AMD	 risk,	 correlations	
between	the	two	differ	amongst	studies	(164,	168,	169).	This	may	be	in	part	to	the	
different	methodologies	used	by	different	researchers.	For	example	a	 study	 that	
found	an	association	between	AMD	and	chlamydia	examined	the	presence	of	the	
pathogen	in	the	CNV	membranes	of	AMD	patients	(170),	while	another	that	found	
no	 link	 looked	 at	 the	 presence	 of	 chlamydia‐reactive	 antibodies	 in	 patient	 sera	
(171).		
	
1.7.	Viral	infection	of	the	retina	and	choroid	
 
Viruses	 that	 are	known	 to	 infect	 the	posterior	 eye	 include	CMV,	varicella	 zoster	
virus	 (VZV)	 and	 Epstein‐Barr	 virus	 (EBV).	 Ocular	 pathologies	 caused	 by	 these	
viruses	can	 include	retinitis,	retinal	atrophy	(172‐174),	retinal	 lesions	and	 leaky	
blood	 vessels	 (175).	 These	 complications	 however,	 mostly	 occur	 in	
immunocompromised	patients	(such	as	untreated‐HIV	patients)	as	a	result	of	the	
low	replicative	potential	of	these	viruses	in	an	immunocompetent	host.	
HSV	 retinitis	 and	 necrosis	 has	 been	 noted	 in	 children	 (176)	 and	 in	 the	 elderly	
(177),	 and	more	 recently	 ocular	manifestations	 have	 been	 observed	 in	 patients	
during	 the	 latest	 outbreak	 of	 Ebola	 haemorrhagic	 fever,	 with	 certain	 patients	
displaying	anterior,	posterior	or	pan	uveitis	(178).	
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1.8.	West	Nile	Virus.	
	
West	Nile	Virus	(WNV),	a	zoonotic	virus	of	the	flaviviridae	family,	is	an	arthropod‐
borne	pathogen	originally	isolated	in	1937	from	a	woman	in	the	West	Nile	district	
in	Uganda,	(hence	the	name)	(179).	 	Collectively,	WNV	subtypes	are	classified	in	
lineages,	 with	 the	 infamous	 NY99	 and	 its	 successor	 WN02	 falling	 under	 the	
lineage	1	group,	as	is	the	Kunjin	subtype,	which	is	endemic	to	Australia	(180).		
	
1.8.1.	Epidemiology		
 
WNV	can	infect	a	variety	of	different	animals,	including	bats,	dogs,	horses,	alpacas	
(181)	 and	 even	 orcas	 (182).	 Despite	 this,	 the	 majority	 of	 animals	 (including	
humans)	are	dead‐end	hosts,	unable	to	produce	viral	titres	high	enough	to	infect	
its	usual	vectors	(mosquitos)	(183).	Human‐to‐human	transmission	can	occur	 in	
rare	 circumstances,	 via	 blood	 transfusions	 (184),	 transplants	 (185)	 and	 breast	
milk	(186).	
Prior	 to	 the	 1999	 New	 York	 outbreak	 in	 Central	 Park,	 WNV	 infection	 was	
generally	restricted	to	Northern	Africa,	the	Middle	East,	and	parts	of	Europe.	Since	
then,	 due	 to	 the	 migratory	 nature	 of	 its	 ornithic	 hosts,	 WNV	 has	 spread	 out	
throughout	 the	 Americas	 and	 become	 endemic	 to	 all	 the	 continents	 with	 the	
exception	 of	 Antarctica	 (187).	 The	 virus	 has	 now	 established	 itself	 within	 the	
North	American	region,	 resulting	 in	an	epizootic	 cycle	with	outbreaks	every	3‐4	
years	(188).		
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1.8.2.	Clinical	presentation	of	WNV	infection	
 
WNV	infection	in	humans	typically	presents	as	one	of	three	manifestations:	
A.	Afebrile/Asymptomatic:	
The	most	common	outcome	(occurring	in	70‐80%	of	people	infected	with	WNV),	
this	manifestation	presents	with	few	or	no	symptoms	(189).	
B.	West	Nile	fever:		
A	 self‐limiting	 febrile	 state	 characterized	 by	 flu‐like	 symptoms,	 such	 as	 fever,	
headache,	malaise,	 fatigue	 and	weakness.	 Other	 symptoms	 include	muscle	 pain,	
nausea,	 vomiting,	 diarrhea	 and	 rash.	 Approximately	 20%‐30%	 of	 infected	
individuals	experience	West	Nile	fever	(189).	
C.	West	Nile	neuro‐invasive	disease:		
West	Nile	neuro‐invasive	disease	(WNND)	is	the	least	common	(<	1%)	(190),	but	
most	 serious	 form	 of	WNV	 infection,	 which	 can	 lead	 to	 brain	 damage,	mobility	
impairment	or	death.	The	clinical	presentations	of	WNND	may	include	meningitis,	
encephalitis,	and	acute	flaccid	paralysis	(190).	WNV‐meningitis	is	more	commonly	
seen	in	younger	age‐groups	while	WNV‐encephalitis	is	associated	more	with	older	
and	 immune‐compromised	 individuals	 (191).	 Within	 the	 U.S.,	 a	 rate	 of	 >1000	
WNV	 cases/year	 occurred	 between	 2002	 and	 2007,	with	 the	 highest	 cases	 and	
deaths	due	to	WNND	occurring	in	2012	(2873	cases),	highlighting	the	seriousness	
of	this	disease	(192).	Additionally,	some	survivors	of	WNND	suffer	from	long‐term	
neurological	deficits	as	a	result	of	the	infection	(193).	
Standard	 diagnosis	 of	 WNV	 infections	 involves	 the	 detection	 of	 anti	 WNV‐IgM	
antibodies	in	blood	serum	or	cerebral	spinal	fluid,	while	treatment	is	restricted	to	
palliative	care	in	the	cases	of	severe	symptoms	(such	as	those	found	in	WNND).	
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1.8.3.	Immune	aspects	of	WNV	
 
Based	on	 in	vivo	mouse	work,	 the	 initial	route	of	WNV	infection	into	the	body	is	
postulated	 to	 occur	 via	 localised	 infection	 at	 the	mosquito	 bite	 site	 of	 a	 dermal	
dendritic	cell	subtype	called	Langerhans	cells.	These	infected	cells	are	thought	to	
travel	 to	 the	 draining	 lymph	 nodes,	 and	 from	 there	 the	 virus	 enters	 the	 blood	
stream	(194).	
WNV	is	an	immunopathogenic	virus,	i.e.	the	immune	response	to	the	virus	causes	
substantial	 pathology	 in	 addition	 to	 whatever	 direct	 viral‐mediated	 damage	 to	
cells/tissues	 may	 occur.	 Several	 viruses,	 such	 as	 HSV,	 HIV	 and	 HCV	 are	 also	
immunopathogenic	viruses	(195).	
Successful	infection	of	an	immuno‐competent	host	by	a	virus	requires	it	to	survive	
against	 the	 immune	 system,	 either	 via	 immune	 evasion	 or	 interference	 of	 anti‐
viral	processes,	for	long	enough	to	be	transmitted	into	a	new	host.	An	example	of	
this	is	hepatitis	C	virus	(HCV)	interference	with	RIG‐I	(196).	Activation	of	this	PPR	
leads	to	production	of	anti‐viral	IFNα	and	IFNβ	cytokines.		
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With	 WNV,	 beneficial	 immune‐modulation	 for	 the	 virus	 is	 achieved	 through	 a	
variety	of	methods.	Partial	inhibition	of	IFN’s	α,	β	and	γ	is	result	of	interference	of	
phosphorylation	 of	 STAT	 1	 and	 2	 by	 WNV	 non‐structural	 proteins	 (197).	 This	
partial	 inhibition	 is	 enough	 to	 create	 an	 environment	 permissive	 to	 WNV	
replication	(196).	Furthermore,	WNV	non‐structural	protein‐1	(NS‐1)	is	believed	
to	interfere	with	TLR3‐dependent	production	of	IL6	(198).	While	TLR3	has	been	
shown	to	restrict	WNV	replication	and	increase	survivability	of	New	York	strain	of	
WNV	 during	 sub‐lethal	 infection	 (199),	 TLR3	 knockout	 mice	 in	 another	 study	
using	WNV	isolate	2741	faired	better	than	their	wild	type	controls	(200).	Finally,	
WNV	 lethality	 was	 significantly	 reduced	 in	 mice	 by	 reducing	 infiltration	 of	
inflammatory	 monocytes	 into	 the	 brain	 by	 either	 CCL2	 neutralization	 (201)	 or	
monocyte	abrogation	via	immunomodulatory	particle	administration	(202).	
Mice	with	impaired	production	of	IgM	or	IgG	did	not	survive	infection	with	WNV	
(203,	 204),	 highlighting	 the	 importance	 of	 B‐cell	 responses	 to	 WNV	 infection,	
while	 elimination	 of	 CD4	 T‐cells	 and	 CD8	 T‐cells	 results	 in	 an	 increased	
susceptibility	to	WNV	infection	(205).	However,	survival	of	WNV	infection	in	mice	
is	not	only	dependent	on	 the	effector	and	cytotoxic	 lymphocytes	of	 the	 immune	
system,	but	also	the	regulator	cells	as	well.	Mice	without	CD4	T‐regs	had	a	lower	
survival	 than	wild‐type	mice	 (206)	while	 blocking	 a	 cytokine	 that	 is	 a	 negative	
regulator	of	T‐reg	responses	(IL‐10)	resulted	 in	an	 increased	survivability	(207)	
during	WNV	 infection.	This	 emphasizes	 the	 immunopathological	 nature	of	WNV	
infection.	
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1.8.4.	WNV/	flaviviral	cases	in	the	eye	
 
Although	 not	 present	 in	 every	 case	 of	 febrile	 WNV	 infection	 and	 WNND,	
ophthalmological	 manifestations	 of	 WNV	 have	 been	 seen	 birds	 (208,	 209)	 and	
humans.	 These	 include	 blurred	 vision,	 vision	 loss,	 chorioretinal	 streaks,	
chorioretinitis	 and	 occlusive	 retinal	 vasculitis	 (210‐212),	 occurring	 in	 greater	
frequency	in	patients	with	pre‐existing	ocular	conditions	(212).	
Ocular	complications	have	also	been	seen	in	dengue‐infected	humans,	with	ocular	
pain	being	the	most	reported	symptom	(213,	214),	and	in	certain	cases	macular	
haemorrhage/oedema	(215).	Several	cross‐observational	studies	have	not	 found	
any	 ocular	 manifestations	 in	 dengue	 virus	 (DENV)‐infection	 cases,	 which	 is	
surprising	 given	 that	 this	 virus	 is	 also	 in	 the	 flavivirus	 genus	 (216),	 	 and	 it	 is	
believed	that	these	case	reports	showing	ocular	manifestations	may	be	serotype‐
specific	(217).	
The	first	research	article	that	postulated	an	infection	route	of	WNV	in	the	eye	in	
patients	with	WNV‐ophthalmological	pathology	described	linear	patterns	of	WNV‐
associated	chorioretinitis	originating	from	the	optic	nerve	and	hence	deduced	that	
WNV	originated	from	the	cerebral	infection	(218).	In	contrast,	a	multimodal	study	
performed	 on	 various	 WNV‐infected	 patients	 hypothesised	 that	 because	 of	
chorioretinal	 involvement,	 along	 with	 outer	 retinal	 and	 RPE	 changes,	 WNV	
infection	 accesses	 the	 retina	 via	 the	 choroid	 and	 not	 via	 neural	 cells	 (219).	
Presently,	 the	majority	of	current	 literature	concerning	flaviviral	 infection	in	the	
eye	is	limited	to	case	reports	by	ophthalmologists,	and	cell	culture	models	of	WNV	
infection	in	RPE	cells	(220,	221).	
	
  58
1.9.	Hypothesis/Aims	
 
Given	the	large	involvement	of	the	dysregulated	aspects	of	the	immune	system	in	
AMD,	 it	 is	 entirely	 plausible	 a	 low‐level	 chronic	 infection	 of	 the	 retina	 by	 a	
pathogen,	 especially	 in	 an	 immune	 environment	 that	 has	 defective	 regulatory	
elements,	may	be	 a	 cause.	 In	 conjunction	with	 this,	 the	 breakdown	of	 the	BRBs	
that	precede	the	pathogenesis	of	AMD	is	almost	certain	to	involve	elements	of	the	
immune	 system,	 whether	 it	 be	 the	 release	 of	 barrier	 modulatory	 cytokines	 or	
MMPs	by	either	the	RPE	cells	themselves	or	 infiltrating	leukocytes.	 Investigating	
the	effect	of	a	pathogen	 infection	on	a	dysregulated	 immune	system,	 in	 terms	of	
the	 production	 of	 antiviral/immunomodulatory	 cytokines,	 barrier	 integrity	 and	
viability	 on	 the	 sole	 cellular	 component	 of	 the	 outer	BRB,	 the	RPE,	would	 yield	
insights	into	possible	mechanisms	(such	as	an	infection),	that	might	increase	the	
risk	 of	 AMD.	 With	 its	 immunopathogenic	 properties	 and	 relatively	 low	
cytopathogenicity,	 WNV	 would	 seem	 to	 be	 an	 ideal	 model	 pathogen.	 This	
approach	 however,	 does	 not	 argue	 for	WNV	 as	 a	 specific	 causal	 agent	 of	 AMD	
pathogenesis.	
	
The	establishment	of	a	retinal	WNV	murine	model	would	also	contribute	greatly	
to	 understanding	 the	 breakdown	 of	 the	 outer	 BRB	 in	 the	 face	 of	 a	 pathogen	
infection,	 given	 the	 limitations	of	a	 cell	 culture	model.	Discerning	 the	 leukocytic	
profile	 that	 is	 recruited	 to	 the	 site	 of	 an	 infection	 would	 greatly	 aid	 in	
understanding	which	 subsets	are	 responsible	 for	 creating	or	 limiting	damage	 to	
the	neural	retina	during	and	after	infection.	
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As	such,	this	project	aimed	to	investigate	the	effects	of	WNV	infection	in	primary	
human	 RPE	 cells,	 in	 terms	 of	 viability,	 cytokine	 production	 and	 effects	 on	 the	
integrity	 between	 the	 cells	 during	 WNV	 infection.	 Additionally,	 it	 aimed	 to	
establish	 a	 direct	 intravitreal	 WNV	 model	 to	 quantify	 the	 levels	 of	 different	
leukocyte	subsets.	
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Chapter 2: Materials and Methods 
	
2.1.	West	Nile	Virus	production/propagation	
West	Nile	virus	(WNV,	Sarafend	strain,	lineage	II),	was	initially	obtained	from	the	
John	Curtin	School	of	Medical	Research	(Canberra,	A.C.T.,	Australia).	The	virus	was	
passaged	alternately	in	vivo	 in	neonatal	C57B57/6	mice	and	in	vitro	 in	Vero	cells	
(American	 Type	 Culture	 Collection,	 CCL‐18,	 African	 Green	 Monkey	 Kidney)	 in	
order	 to	preserve	 the	neurotrophic	activity	of	 the	virus.	For	viral	passage	 in	 the	
mice,	 mice	 pups	 (1‐2	 days	 old)	 were	 intracranially	 inoculated	 with	 virus.	 The	
brains	 were	 harvested	 after	 initial	 symptoms	 of	 illness	 were	 observed,	 which	
occurred	 approximately	 3	 days	 after	 inoculation.	The	brains	were	homogenized	
with	a	Tissue	Tearor	(BioSpec,	Bartlesville,	OK,	USA)	in	Dulbecco’s	Modified	Eagle	
medium	(DMEM,	Sigma	Aldrich,	St.	Louis,	MO,	USA)	containing	10%	FCS	 (Sigma	
Aldrich),	 sodium	 bicarbonate	 (0.044M,	 Sigma	 Aldrich),	 and	 HEPES	 (0.02M,	
Amresco,	 Solon,	 OH,	 USA)	 (referred	 to	 as	 DMEM	 cell	 culture	 media),	 then	
centrifuged	 for	 20	minutes	 at	 600xg	 and	 4°C.	 The	 viral	 titre	 of	 the	 supernatant	
was	assessed	by	plaque	assay	(section	2.2),	and	then	added	to	175cm2	cell	culture	
flasks	 (Corning,	 Corning,	 NY,	 USA)	 containing	 semi‐confluent	 Vero	 cells	 at	 10	
plaque	forming	units	(PFU)	per	cell.		
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The	cells	were	incubated	with	the	brain	extract	supernatant	for	an	hour,	rocked	at	
15	minute	intervals	at	37°C	in	a	humidified	HeraCell	 incubator	(Hereaus,	Hanau,	
Germany)	 supplemented	 with	 5%	 CO2.	 After	 incubation,	 the	 supernatant	 was	
aspirated,	 and	 fresh	 DMEM	 cell	 culture	media	was	 added,	 before	 the	 flask	was	
incubated	 for	 approximately	 40	 hours,	 when	 cytopathic	 effects	 were	 observed.	
The	 flasks	 were	 then	 frozen	 at	 ‐80qC	 and	 thawed	 before	 the	 supernatant	 was	
collected	 and	 centrifuged	 at	 400	 xg.	 The	 supernatant	 was	 then	 collected	 and	
aliquoted	 into	 2ml	microtubes	 (Sarstedt,	 Nümbrecht,	 Germany),	 and	 stored	 at	 ‐
80qC.	The	viral	titre	was	quantified	as	1.2x109	PFU/ml	by	plaque	assay.	All	thawed	
viral	aliquots	were	used	once,	as	freeze/thaw	cycles	degraded	the	PFU	of	the	viral	
stock	by	approximately	10‐fold. 
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2.2.	Plaque	assay	
 
Plaque	 assays	 were	 used	 to	 determine	 WNV	 titre	 of	 viral	 stock	 and	 selected	
supernatants.	 Transformed	 BHK‐26	 (American	 Type	 Culture	 Collection,	 CCL‐10;	
Baby	 Syrian	 Golden	 Hamster	 Kidney	 cell	 line),	 a	 kind	 gift	 from	 A/Prof	 Guna	
Karupiah,	John	Curtin	School	of	Medical	Research,	were	cultured	to	subconfluence	
in	175cm2	tissue	culture	flasks	(Corning)	in	MEM	(Minimal	Essential	Media,	Sigma	
Aldrich)	supplemented	with	5%	FCS.	The	cells	were	then	seeded	into	6	well	plates	
(Corning)	 at	 1x106	 cells/well	 and	 left	 to	 adhere	 overnight.	 The	 following	 day,	
plates	were	confluent,	and	samples	for	PFU	quantification	were	serially	diluted	in	
MEM	with	5%	FCS.	The	cells	were	pulsed	with	150µl	of	the	viral	dilutions	for	an	
hour,	 rocked	 at	 15	minute	 intervals,	 and	 then	washed	with	 Phosphate‐Buffered	
Saline	 (PBS,	 Sigma	 Aldrich).	 The	 cells	 were	 then	 coated	 with	 a	 1x	 MEM,	 1.5%	
(w/v)	 low	 temperature	 agarose	 (Amresco,	 Solon,	 OH,	 USA)	 solution	 containing	
5%	FCS	and	incubated	over	the	course	of	3	days	at	37ºC	and	with	5%	CO2.	After	
this	 incubation	 the	 cells	 were	 then	 fixed	 with	 1ml	 of	 10%	 neutral	 buffered	
formalin	 (Fronine,	Riverstone,	NSW,	Australia)	 for	2	hours	 and	 the	 agarose	was	
removed.	Wells	were	 then	 stained	briefly	with	1ml	of	 crystal	 violet	 (3%	w/v	 in	
20%	v/v	methanol,	Sigma	Aldrich),	excess	crystal	violet	was	washed	off	and	the	
plaques	were	counted.	Viral	titre	was	calculated	to	PFU/ml	after	the	plaques	that	
formed	were	counted	visually,	and	dilutions	of	the	samples	were	accounted	for.	
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2.3.	Human	Retinal	Pigment	Epithelium	Isolation	
 
Cadaveric	 human	 eyes	 were	 obtained	 from	 the	 Lions	 NSW	 Eye	 Bank	 (Sydney,	
NSW,	Australia)	with	consent	and	ethical	approval	from	the	University	of	Sydney	
Human	 Research	 Ethics	 Committee,	 no	 later	 than	 24	 hours	 post	 mortem.	 Eyes	
were	sourced	from	donors	between	12‐	89	years	of	age.	Donors	with	diseases	or	
causes	of	death	that	affected	the	condition	of	the	eye	were	rejected.	As	donor	eyes	
were	 received	 with	 the	 corneas	 removed,	 the	 iris,	 lens,	 surrounding	 structures	
and	the	vitreous	were	then	removed,	and	the	neural	retina	gently	detached	from	
the	ora	serrata	and	separated	from	the	RPE,	and	removed	at	the	optic	nerve	head.	
The	eyecup	was	 then	washed	with	PBS	warmed	 to	37°C,	 then	 filled	with	0.25%	
trypsin/0.1M	 EDTA	 (Gibco,	 Invitrogen	 Carlsbad,	 CA,	 USA)	 and	 placed	 in	 a	 37°C	
incubator	for	30‐45	minutes.	The	trypsin/EDTA	was	then	gently	pipetted	up	and	
down	to	loosen	the	hRPE	cells,	and	the	supernatant	removed,	mixed	with	DMEM	
cell	 culture	media	and	centrifuged	 for	5	minutes	at	480xg.	The	supernatant	was	
removed	and	the	cells	were	seeded	onto	8.8cm2	cell	culture	dishes	(Nunc	Nalgene,	
Rochester,	 NY,	 USA)	 with	 DMEM	 containing	 20%	 FCS	 and	 incubated	 in	 a	 37°C	
incubator	with	5%	CO2.	After	approximately	1	week,	 the	cells	were	assessed	 for	
viability	and	morphology,	and	hRPE	cells	were	either	passaged	to	a	25cm2	flask	or	
frozen	for	later	use.	
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2.4.	Human	Retinal	Pigment	Epithelium	Cell	Culture	
 
Primary	 human	 retinal	 pigment	 epithelium	 (hRPE),	 and	 cell	 line	 ARPE19	
(American	 Cell	 Culture	 Bank,	 CRL‐2302,	 Manassas,	 VA,	 USA)	 were	 used	 in	
experiments.	Primary	cells	were	not	used	beyond	passage	5,	while	ARPE19	cells	
were	used	between	passages	19‐32.	Cells	were	grown	in	DMEM	cell	culture	media.	
After	 cells	 approached	 confluence,	 or	were	 required	 for	 experiments,	 they	were	
passaged	 by	 initially	 washing	 the	 cells	 with	 PBS,	 then	 trypsinised	 using	 1%	
trypsin/4mM	 EDTA	 in	 PBS	 was	 used.	 After	 the	 cells	 detached,	 the	 trypsin	 was	
‘inactivated’	by	the	addition	of	DMEM	cell	culture	media.	 	
The	cell/DMEM/trypsin	mixture	was	centrifuged	at	480xg	for	5	minutes	at	room	
temperature,	 the	 supernatant	 removed,	 and	 cells	 resuspended	 in	 DMEM	 cell	
culture	media	and	seeded	onto	25cm2	flasks	(Nunc).	
For	storage	of	the	cells,	after	the	centrifugation	and	supernatant	removal	step,	the	
cells	 were	 resuspended	 in	 DMEM	 cell	 culture	 media	 with	 20%	 FCS	 and	 10%	
Dimethyl	sulfoxide	(DMSO,	Sigma	Aldrich)	at	a	concentration	no	higher	than	2	x	
106	 cells/ml	 and	 aliqouted	 in	 Cyrotube	 vials	 (Nunc	 Nalgene).	 Cells	 were	
maintained	in	liquid	nitrogen	for	long‐term	storage.	 	 	
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2.5.	Human	Choroidal	Fibroblast	cells	
 
Primary	 human	 choroidal	 fibroblasts	 (hCF)	 were	 isolated	 from	 human	
postmortem	 eyes	 obtained	 from	 the	 Lions	 NSW	 Eye	 Bank	 (Sydney,	 NSW,	
Australia)	 with	 consent	 and	 ethical	 approval	 from	 the	 University	 of	 Sydney	
Human	Research	Ethics	Committee.	Cells	were	grown	from	choroidal	explants	and	
then	subcultured	by	A/Prof.	Michele	Madigan	(Save	Sight	 Institute,	University	of	
Sydney,	 Sydney).	
Fibroblasts	 were	 cultured	 in	 DMEM	 cell	 media,	 and	 for	 passaging,	 0.5%	
trypsin/4mM	EDTA	in	PBS	was	used.	Choroidal	fibroblasts	were	not	used	beyond	
passage	5.	
	
2.6.	Human	Choroidal	Endothelial	cell	culture	
 
Human	choroidal	endothelial	cells	(CEC)	were	 isolated	from	postmortem	human	
eyes	 obtained	 Lions	NSW	Eye	 Bank	 (Sydney,	 NSW,	 Australia)	with	 consent	 and	
ethical	approval	from	the	University	of	Sydney	Human	Research	Ethics	Committee	
(Li	Wen	Save	Sight	Institute,	University	of	Sydney,	Sydney).	CECs	were	cultured	in	
M199	media	 (Gibco,	 Invitrogen)	 containing	 human	 serum	 (10	%	AB	blood	 type	
only,	 Lonza),	 20%	 FCS	 Bovine	 Brain	 extract	 (Lonza,	 Basel,	 Switzerland),	
Endothelial	cell	growth	supplement	(Sigma	Aldrich),	Glutamax	(1x,	Sigma	Aldrich)	
and	Heparin	(12.5mg/L,	Sigma	Aldrich).	Choroidal	endothelial	cells	were	not	used	
beyond	passage	5.	 	 	
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2.7.	Infection	of	cells	with	WNV	
	
The	method	of	infecting	cells	with	WNV	was	the	same	for	all	cells	types	used,	as	
follows.	 Cells	were	 seeded	 at	 a	 set	 density	per	well,	 and	 a	 counting	plate	 of	 the	
same	size	(e.g.,	6	well	counting	plate	for	experiments	involving	6	well	plates)	was	
also	 seeded	 at	 the	 same	 density.	 After	 the	 required	 adherence/growing	 period,	
the	counting	plate	cells	were	trypsinsed	and	counted.	The	multiplicity	of	infection	
(MOI,	a	ratio	of	PFU	per	cell)	required	plus	the	cells/well	was	used	to	calculate	the	
required	viral	stock	in	order	to	achieve	the	desired	viral	titre	in	a	final	volume	for	
infection,	which	was	150µl	for	6	well	plates,	100µl	for	12	well	plates	and	50µl	for	
96	well	plates.	The	plates	were	 incubated	 in	a	37°C	 incubator	with	5%	CO2	and	
rocked	manually	every	10	minutes.	After	1	hour,	 the	cells	were	washed	3	 times	
with	PBS	and	then	replaced	with	fresh	media.	 	
Cells	were	also	 treated	with	various	proteins/antibodies	 to	 examine	 their	 effect	
on	viral	 replication,	as	well	as	 for	 the	RTCA	experiments	(Section	2.20),	and	are	
listed	in	Table	2.1.	A	range	of	MOIs	were	used	from	high	virus	concentrations	to	
relatively	low	concentrations	in	order	to	vary	the	likely	viral	load	per	cell,	thereby	
testing	any	variation	in	their	responses	over	this	range.	This	allowed	us	to	see	any	
differences	 in	 several	 of	 experimental	 parameters	 between	 infection	 of	 a	
relatively	 low	 level	 of	 virus	 compared	 with	 a	 relatively	 high	 level	 of	 virus,	
especially	in	terms	of	cell	death.	An	intermediate	level	of	viral	PFU	(MOI	5),	was	
also	 selected	 to	 view	 potential	 dose‐dependent	 responses.	 Previous	 work	 with	
hCF	 (unpublished)	 showed	 that	 these	 cells	 were	 more	 susceptible	 to	 WNV	
infection,	and	thus	a	lower	MOI	was	used.    
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Cytokine/compound  Source  Concentrations
Poly I:C  R&D systems  0.1‐1µg/ml 
Immiquimod  Invivogen  0.3‐3µg/ml 
S‐nitro‐N‐acetyl‐DL‐penicillamine Sigma Aldrich  200µM 
Recombinant human CCL2  Biolegend  63.3‐6.33ng/ml
Recombinant human CCL5  Biolegend  15.8‐1.58ng/ml
Recombinant human IL6  Biolegend  31.6‐3.16ng/ml
Recombinant human IL8  Biolegend  15.8‐1.58ng/ml
Recombinant human TNFα  Biolegend  10‐0.1ng/ml 
Recombinant human VEGF‐165  Biolegend  50‐0.5ng/ml 
Recombinant human G‐CSF  Biolegend  2ng/ml 
Recombinant human GM‐CSF  Biolegend  1ng/ml 
Recombinant human IFNλ1  Biolegend  5ng/ml 
Recombinant human IFNλ2  eBiosciences  5ng/ml 
Recombinant human IFNβ1  Peprotech  0.5‐5ng/ml 
LEAF Anti‐ human IFNβ1  Biolegend  5µg/ml 
Anti‐ human IFNλ1  R&D systems  5µg/ml 
Anti‐ human IFNλ2  R&D systems  5µg/ml 
LEAF Mouse IgG1   Biolegend  5µg/ml 
CuCPT 4a  Tocris  5mM 
 1‐Methyl‐L‐tryptophan   Sigma Aldrich  500µM 
 1‐Methyl‐D‐tryptophan   Sigma Aldrich  500µM 
L‐Tryptophan  Sigma Aldrich  100µM 
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Table	2.1.	 Table	of	 soluble	 factors	used	 to	 treat	hRPE	 cells	 for	 viral	production	
and	RTCA	experiments.	
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2.8.	Murine	WNV	infection	procedures	
 
Female	 C57BL/6	 mice	 were	 purchased	 from	 the	 Animal	 Resources	 Centre	
(Canning	Vale,	WA,	Australia)	and	housed	in	HEPA	cages	within	a	specific	infected	
animal	 holding	 room	 in	 a	 PC2	 animal	 housing	 facility	 (Charles	 Perkins	 Center	
Animal	House,	University	of	Sydney,	Sydney)	on	arrival,	offered	food	and	water	ad	
libitum	 and	 treated	 as	 per	 the	 University	 of	 Sydney	 Animal	 Ethics	 Committee	
guidelines	(Animal	ethics	number	K20/11‐2011/3/5638).	
 
2.8.1.	Anesthetic	preparation	
 
Avertin	was	prepared	by	dissolving	1g	of	2,2,2‐tribromoethanol	 (Sigma	Aldrich)	
in	1ml	of	2‐methyl‐2‐butanol	(Sigma	Aldrich)	and	vortexing	the	mixture	until	all	
tribromoethanol	was	dissolved.	Then,	 49ml	of	 boiling	 tap	water	was	 added	and	
the	 solution	 was	 mixed	 thoroughly	 before	 being	 filtered	 using	 0.2μm	 syringe	
filters	 (Corning)	and	aliquoted	 for	 storage	at	 ‐30°C.	 For	each	procedure,	 avertin	
was	 thawed	 and	 warmed	 to	 37°C	 in	 a	 water	 bath.	 Any	 unused	 avertin	 was	
discarded.	
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2.8.2.	Intravitreal	infection	
 
Mice	 were	 sedated	 by	 an	 intraperitoneal	 injection	 of	 avertin	 and	 checked	 for	
complete	sedation	(reflexive	twitch	absent	when	footpad	is	gently	pinched)	before	
commencing	procedure.	The	intravitreal	injection	procedure	was	aided	by	the	use	
of	 a	 Wild	 M7S	 dissecting	 microscope	 (Wild‐Heerbrugg,	 Switzerland)	 was	
performed	 as	 follows:	 An	 initial	 puncture	 point	was	 placed	 just	 below	 the	 orra	
serrata	in	the	murine	eye	using	a	30‐gauge	needle	(BD	Biosciences,	San	Jose,	CA,	
USA).	A	33‐gauge	needle	 (Hamilton,	Reno,	NV,	USA)	 attached	 to	 a	10μl‐capacity	
glass	 syringe	 (Hamilton)	 was	 inserted	 into	 the	 puncture	 and	 guided	 until	 the	
needle	 tip	made	 contact	with	 the	 retina.	 0.6	μl	 of	WNV	 in	PBS	or	 PBS	only	was	
then	 administered	 with	 the	 assistance	 of	 the	 PB600‐1	 precise	 dispenser	
(Hamilton),	 which	 when	 used	 in	 conjunction	 with	 a	 Hamilton	 10	 μl	 syringe,	
delivered	liquid	in	0.2	μl	increments.	Intravitreal	viral	loads	used	were	1.44x106,	
1.44x105,	 1.44x104,	 1.44x103,	 1.44x102,	 and	 1.44x101	 pfu/mouse.	 For	 initial	
technique	 evaluation	 experiments,	 the	 injection	 solution	 contained	 0.75%	
monastral	 blue	 (Sigma	 Aldrich).	 After	 the	 procedure	 was	 completed,	 topical	
chloramphenicol	 (1%	 w/v,	 Chlorsig,	 Aspen	 Pharma,	 Durban,	 KwaZulu‐Natal,	
South	Africa)	was	applied	to	reduce	the	likelihood	of	bacterial	infection	as	well	as	
Genteal	 (Novartis,	 Sydney,	 NSW,	 Australia)	 to	 hydrate	 the	 eye	 until	 the	 mouse	
recovered	from	anesthesia.	
Mice	 were	 weighed	 daily	 and	 monitored	 for	 signs	 of	 pathology	 including	 pilo‐
erection,	face	washing,	hunching	and	ability	to	maintain	an	upright	position.	
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2.8.3.	Intranasal	infection	
 
Mice	were	anaesthetised	using	avertin	(as	described	in	section	2.8.2),	laid	supine,	
and	 checked	 for	 complete	 sedation	 before	 commencing	 procedure.	 For	 LD50	
experiments,	6	x103	PFU	(LD50)	of	WNV	in	a	total	volume	of	10µl	(5µl	into	each	
nostril)	with	 a	 10µl	 pipette.	 For	 re‐challenge	 experiments,	 the	 procedures	were	
the	 same	 but	 a	 viral	 load	 of	 6	 x104	 PFU	 (LD100)	was	 used	 instead.	Mice	were	
observed	daily	for	weight	changes	and	aforementioned	signs	of	pathology.	
	
2.9.	Flow	cytometry:	
2.9.1.	Flow	cytometry	for	cells	for	cell	cycle	analysis	
 
After	hRPE	cells	were	 trypsinised	and	 the	 trypsin	was	subsequently	neutralized	
with	DMEM	cell	culture	media,	cells	were	centrifuged	for	5	minutes	at	480xg,	then	
washed	in	PBS	and	centrifuged	again	under	the	same	conditions,	and	resuspended	
and	 placed	 into	 round‐bottom	 96	 well	 plates.	 Cells	 were	 then	 fixed	 and	
permeabilized	on	 ice	with	 ice‐cold	70%	ethanol,	 and	washed	several	 times	with	
PBS.	Cells	were	then	stained	with	either	mouse	IgG1	anti	non‐structural	protein‐1	
(NS1)‐FITC	 conjugated	 antibody	 (a	 kind	 gift	 from	 Dr	 Roy	 Hall,	 University	 of	
Queensland,	 Australia)	 and	 isotype	 mouse	 IgG1	 control	 FITC	 (BD	 Biosciences),	
both	at	1:100	dilutions	in	PBS	for	40	min.		
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Finally,	 DNA	was	 stained	with	 a	 solution	 of	 propidium	 iodide	 (50µg/ml,	 Sigma	
Aldrich)	 and	 RNase	 (100µg/ml,	 Sigma	 Aldrich)	 in	 PBS	 for	 30	 minutes	 at	 room	
temperature.	The	cells	were	then	washed	3	times	with	PBS,	resuspended	in	FACS	
buffer	(10mM	EDTA,	5%	FCS	in	PBS),	and	filtered	through	Nytex	into	polystyrene	
5ml	tubes	(BD	Biosciences).	The	cells	were	then	processed	on	the	BD	FACSCalibur	
flow	 cytometer	 (BD	 Biosciences).	 Data	 were	 processed	 with	 Flowjo	 (Version	
9.8.5.,	 Treestar	 Inc,	 Ashland,	 OR,	 USA),	 using	 the	Watson	 (pragmatic)	 model	 in	
Flowjo.		
 
2.9.2.	14‐colour	murine	organ	flow	cytometry	
 
Mice	 were	 anesthetized	 with	 avertin	 (as	 described	 in	 section	 2.8.2)	 and	 then	
perfused	with	PBS	via	a	cardiac	puncture.	Eyes	were	then	enucleated	and	attached	
intraocular	muscles	 and	 conjunctiva	 excised.	With	 the	 assistance	of	 a	Wild	M7S	
dissecting	 microscope,	 the	 anterior	 portion	 of	 the	 eye	 was	 separated	 from	 the	
posterior	by	performing	an	incision	just	under	the	limbus.	The	lens	was	removed	
and	 the	 eyecup	 and	 retina	 placed	 on	 a	 70μm	 nylon	 cell	 strainer	 insert	 (BD	
Biosciences)	mounted	 in	 a	50ml	 tube	 (BD	Biosciences).	Cervical	draining	 lymph	
nodes	were	carefully	excised	from	mice	and	also	placed	on	cell	strainers.	Organs	
were	then	mechanically	dissociated	through	the	cell	strainer	and	mixed	with	FACS	
buffer	on	ice.	 	
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After	an	additional	wash	with	FACS	buffer,	organ	cells	were	counted	for	viability	
using	 trypan	 blue	 and	 a	 haemocytometer.	 Cells	were	 then	 subsequently	 treated	
with	Fc	block	(Biolegend,	San	Diego,	CA,	USA)	and	stained	with	LIVE/DEAD	fixable	
blue	dead	cell	 stain	kit	 (Life	Technologies,	Carlsbad,	CA,	USA)	and	antibodies	as	
seen	in	Table	2.2.	After	washing	the	cells	with	FACS	buffer,	they	were	fixed	using	a	
fixation	buffer	(Biolegend)	for	10	minutes,	followed	by	3	washes	with	FACS	buffer.	
Cells	 were	 resuspended	 in	 FACS	 buffer	 and	 filtered	 through	 nytex	 into	
polystyrene	 5ml	 tubes	 for	 processing	 on	 the	 LSRII	 flow	 cytometer	 (BD	
Biosciences),	and	generated	data	were	processed	with	Flowjo,	as	above.	
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Antibody  Flurophore  Isotype  Source 
CD11b  BUV395  Rat IgG 2b  BD Biosciences 
Ly6C  BV421  Rat IgG2a, κ  Biolegend 
MHCII  BV510  Rat IgG2b, κ  Biolegend 
NK1.1  BV605  Mouse IgG2a, κ  Biolegend 
CD8a  BV711  Rat IgG2a, κ  Biolegend 
B220  BV785  Rat IgG2a, κ  Biolegend 
Ly6G  FITC  Rat IgM, κ  Biolegend 
CD45  PerCP/Cy5.5  Rat IgG2b, κ  Biolegend 
CD3e  PE/CF594  Ar Ham IgG1, κ  BD Biosciences 
CD28  PE/Cy7  Mouse IgG2b, κ  Biolegend 
CD11c  APC  Hamster IgG  Biolegend 
CD4  AF700  Rat IgG2a, κ  BD Biosciences 
CD86  APC/Cy7  Rat IgG2a, κ  Biolegend 
Fc Block  ‐  Rat IgG2a, κ  Biolegend 
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Table	2.2.	 Table	 of	 antibodies	 used	 in	murine	 flow	 cytometry.	 Listed	 are	 their	
target	antigens,	 fluorophores,	 antibody	 isotype	and	 their	 commercial	 source.	All	
antibodies	were	used	at	 a	dilution	of	1:100,	 approximately	1µg	of	 antibody/106	
cells.	
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2.10.	Histology	and	Immunofluorescent	staining:	
 
2.10.1.	Immunofluorescence	(Cells)	
 
Cells	were	seeded	onto	10mm	glass	coverslips	(Marienfeld	laboratory	glassware,	
Lauda‐Königshofen,	 Germany)	 placed	 in	 6	 well	 plates	 (Corning)	 at	 a	 density	 of	
6x105	cells/well,	and	infected	with	WNV	at	an	MOI	of	5	after	3	days	post‐seeding.	
After	 the	 infection	 period,	 the	 cells	 were	 fixed	 with	 buffered	 4%	
paraformaldehyde	(PFA)	(Sigma	Aldrich)	and	permeabilized	with	0.05%	Triton	X	
(Packard	 Instrument	 Co.,	 Meriden,	 CT,	 USA).	 The	 cells	 were	 washed	 3x	 with	
Tween‐PBS	(Amresco),	blocked	with	10%	FCS/Tween‐PBS	and	then	stained	with	
primary	 and	 secondary	 antibodies	 per	 Table	 2.3,	 in	 addition	 to	 DAPI	 (Sigma	
Aldrich).	 Antibodies	 were	 raised	 in	 10%	 FCS/Tween‐PBS.	 The	 coverslips	 were	
then	 mounted	 onto	 Superfrost	 Plus	 microscope	 slides	 (Menzel‐Glaser,	
Braunschweig,	 Germany)	 with	 ProGold	 anti‐fade	 mounting	 media	 (Invitrogen)	
and	 sealed	 with	 clear	 nail	 polish	 (Manicare,	 McPhersons	 Consumer	 Products,	
N.S.W.,	Australia).	
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Antibody  Isotype  Source  Dilution 
α‐NS1 FITC  Mouse IgG1  Roy Hall, UQ  1:100 
α‐NS1 Biotin  Mouse IgG1  Roy Hall, UQ  1:100 
α‐Lectin FITC  ‐  Sigma  1:50 
Strepavidin AF594  ‐  Life Technologies  1:200 
α‐human IDO Biotin  Rabbit IgG1  Abcam  1:50 
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Table	2.3.	List	of	antibodies	and	target	antigens	used	for	immunohistochemistry	
IHC.	Table	of	 antibodies	used	 for	 immunohistochemistry.	 Listed	 are	 their	 target	
antigens,	 fluorophores,	 antibody	 isotype,	 commercial	 source	 and	 working	
dilution.	UQ	=	University	of	Queensland.	
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2.10.2	Immunofluorescence	(Tissues)	
 
Tissues	(murine	eyes	and	brains)	were	embedded	in	Tissue‐Tek	Cryo‐OCT	(Fisher	
Scientific,	Waltham,	MA,	USA)	immediately	after	PBS	perfusion	of	mice.	OCT‐tissue	
samples	were	 then	snap‐frozen	 in	 liquid	nitrogen	and	then	stored	at	 ‐80°C	until	
cryosectioning.	 Cryosectioning	 of	 the	 tissue	 was	 achieved	 using	 a	 Cryotome/E	
cryostat	(Thermo	Fisher	Scientific,	Waltham,	MA,	USA)	and	disposable	microtome	
blades	 (Reichart‐Jung,	 Heidelberg,	 Germany).	 Tissue	 sections	 were	 cut	 to	 a	
thickness	of	7μm	and	mounted	onto	microscope	slides,	 and	stored	at	 ‐80°C.	For	
histology	and	immunofluorescence,	slides	were	thawed	and	then	marked	around	
the	 perimeter	 with	 a	 delimiting	 pen	 (Dako,	 Glostrup,	 Denmark).	 Cells	 were	
washed	2x	with	Tween‐PBS	to	remove	OCT	and	then	subsequently	blocked	with	
10%	FCS	in	Tween‐PBS	for	at	least	1	hour	at	4°C.	Tissues	were	then	stained	with	
primary	 antibodies,	 secondary	 flurophore	 conjugates,	 or	 antibody‐flurophore	
conjugates	(Table	2.3)	and	DAPI	at	4°C.	Primary	antibodies	were	incubated	for	1‐2	
hours	while	secondary	antibodies	were	incubated	for	30	minutes	to	1	hour.	After	
the	final	3	washes	with	Tween‐PBS,	ProGold	mounting	media	was	applied	to	the	
slides	 before	 the	 addition	 of	 a	 coverslip	 (Menzel‐Glaser)	 and	 sealing	with	 clear	
nail	polish.		
Fluorescent	 images	were	 obtained	with	 the	 BX51	microscope	 (Olympus,	 Tokyo,	
Japan)	 and	 DP73	 CCD	 camera	 (Olympus).	 The	 images	 were	 captured	 using	
CellSens	Standard	software	(Version	1.12,	Olympus).	 	
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2.10.3.	Histology:	
 
Cryosections	 on	 slides	 were	 thawed,	 rinsed	 in	 PBS	 and	 immersed	 in	 Harris’	
haematoxylin	 (Sigma	 Aldrich)	 for	 3	 minutes,	 washed	 in	 tap	 water	 and	 briefly	
dipped	in	acid	alcohol	(3%	HCL,	95%	ethanol,	Sigma	Aldrich)	before	an	additional	
water	wash.	 Slides	were	 then	dipped	 in	Scott’s	blueing	 solution	 (Sigma	Aldrich)	
for	30	seconds	and	given	another	wash	in	water	and	once	more	in	70%	ethanol.	
Slides	were	 then	dipped	 into	 two	different	changes	of	5%	eosin	(Sigma	Aldrich)	
for	 40	 seconds	 each	 before	 dehydration	 of	 the	 slide	 via	 ascending	 ethanol	
concentration	dips.	 Finally,	 slides	were	 further	dipped	 in	 two	 changes	of	 xylene	
(LabScan/	Lomb	Scientific,	Sydney,	NSW,	Australia)	and	mounted	with	DPX	resin	
(Lomb	Scientific).	
 
2.11.	Multiplex	assay	
 
hRPE	 cells	 were	 plated	 on	 12	 well	 plates	 at	 a	 density	 of	 1	 x105	 cells/well	
(Corning)	 and	 cultured	 in	 DMEM	 cell	 culture	media.	 Once	 confluent,	 cells	were	
infected	with	WNV	at	MOIs	of	5	and	10.	Once	the	supernatants	were	collected	at	
24,	 48	 and	 72	 hours	 post‐infection	 and	 pooled	 from	 triplicates,	 they	 were	
processed	using	either	 the	TGFβ	3‐plex	(TGFβ	‐1,	2	and	3)	or	 the	custom	8‐plex	
(CCL‐2,	CCL‐5,	IL‐6,	IL‐8,	TNFα,	VEGF‐A,	G‐CSF	GM‐CSF)	Fluorokine	MAP	kit	(R&D	
Systems,	Minneapolis	MN,	 USA),	 following	 the	 protocols	 provided.	 For	 the	 pan‐
TGFβ	 multiplex,	 supernatant	 was	 obtained	 from	 cells	 grown	 in	 TGFβ	 depleted	
media.		
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This	 was	 achieved	 via	 several	 rounds	 of	 immunoprecipitation	 using	 pan‐TGFβ	
antibody	 (R&D	 Systems)	 and	 Protein	 A‐conjugated	 agarose	 (Thermo	 Fisher	
Scientific).	 In	order	to	measure	total	 latent	and	active	TGFβ	 in	samples,	samples	
were	 activated	 by	 the	 addition	 of	 20µl	 of	 1M	 HCL	 (Sigma	 Aldrich)	 to	 100µl	 of	
sample,	and	incubation	of	the	mixture	for	10	minutes	at	room	temperature	before	
the	 addition	of	 20µl	 of	 1.2M	of	NaOH	 (Sigma	Aldrich)/0.5M	HEPES	 (Ameresco).	
50µl	of	 standard	or	pre‐activated	 sample	was	added	 to	 the	 supplied	96	well,	 as	
well	 as	 50µl	 of	 the	 microparticle	 mixture.	 The	 plate	 was	 then	 incubated	 on	 a	
MixMate	orbital	microplate	shaker	(Eppendorf,	Hamburg,	Germany)	for	2	hours	at	
room	temperature,	and	washed	3	times	with	100µl/well	of	the	kit	supplied	wash	
buffer	 and	 the	Hydroflex	 plate	washer	 system	 (Tecan,	Männedorf,	 Switzerland).	
The	biotin	antibody	cocktail	was	then	added	to	the	plate,	 incubated	for	an	hour,	
washed	3	times	again,	before	the	addition	of	the	streptavidin‐PE	antibody	cocktail,	
a	 30	 minute	 incubation	 at	 room	 temperature	 and	 the	 final	 3	 washes.	
Microparticles	were	 then	resuspended	with	100µl	of	wash	buffer	before	using	a	
Luminex	200	system	(Luminex	Corp,	Austin,	TX,	U.S.A.)	to	determine	the	levels	of	
cytokines.		 	
The	 custom	 8‐plex	 kit	 follows	 the	 same	 procedure	 with	 the	 exception	 of	 the	
activation	step.		
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2.12.	ELISA	
 
Selected	supernatants	from	section	2.11	were	tested	for	levels	of	certain	cytokines	
not	 covered	 by	 the	 multiplex	 assay.	 ELISA	 kits	 for	 human	 IFNβ‐1	 (PBL	 Assay	
Science,	 Piscataway,	 NJ,	 USA),	 TNFα	 (Biolegend)	 and	 IL‐29	 (eBioscience,	 San	
Diego,	 CA,	 USA)	 were	 purchased	 and	 used	 according	 to	 the	 manufacturer’s	
instructions.	The	procedures	for	each	ELISA	were	essentially	the	same,	and	are	as	
follows:	
Supplied	 96	well	 plates	were	 coated	with	 100µl	 of	 capture	 antibody	 in	 coating	
buffer,	 the	plate	was	 sealed	and	 left	 to	 incubate	overnight	 at	4°C.	The	next	day,	
standards	 were	 prepared	 by	 adding	 a	 batch‐specific	 amount	 of	 the	 relevant	
cytokine	standard	to	the	assay	diluent	to	produce	a	top	concentration	standard	of	
1ng/ml	 for	 IFNβ‐1,	 500pg/ml	 for	 TNFα	 and	 1ng/ml	 for	 IL‐29.	 Six,	 two‐fold	
dilutions	were	 created	 from	 the	 top	 standards	 for	 the	 generation	 of	 a	 standard	
curve.	 Samples	 for	 the	 interferons	were	 also	 pre‐diluted.	 Plates	were	washed	 3	
times	 with	 Tween‐PBS	 before	 the	 addition	 of	 standards	 and	 samples	 and	
subsequent	incubation	at	room	temperature	on	a	Mixmate	orbital	shaker	for	1‐2	
hours.		Plates	are	then	washed	3	times	with	Tween‐PBS	before	the	addition	of	the	
detection	 antibody	 in	 assay	 diluent	 and	 incubation	 for	 another	 1‐2	 hours.	 The	
final	 avidin‐HRP	 in	 assay	 diluent	 was	 added	 after	 another	 three	 washes	 with	
Tween‐PBS,	 incubated	 for	 30	minutes	 and	 then	was	washed	 for	 a	 final	 5	 times	
with	Tween‐PBS.		
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Supplied	TMB	substrate	solution	was	added	to	the	plates	and	incubated	for	~10	
minutes	before	 the	 addition	of	H2PO4	 (41.6mM,	Sigma	Aldrich).	The	absorbance	
readings	at	450nm	for	quality	control	and	570nm	for	data	output	were	read	and	
recorded	on	the	FLUOstar	Omega	(BMG	Labtech,	Offenburg,	Germany).		
 
2.13.	LDH	assay	
	
hRPE	cells	were	seeded	onto	a	white	96	well	culture	plate	(Corning)	at	a	density	
of	2.5x104	cells/well.	After	treatment	of	the	cells	with	WNV	MOIs	of	1,	5	and	10,	
levels	 of	 LDH	 activity	 indicating	 cell	 integrity	 was	 assessed	 with	 CytoTox‐ONE	
Homogeneous	Membrane	Integrity	Assay	(Promega,	Madison,	WI,	USA)	at	24,	48	
and	72	hours	post‐infection.	A	total	cell	population	death	control	was	used	by	the	
addition	 of	 the	 supplied	 lysis	 solution.	 A	 no	 cell	 control	 was	 also	 included,	
consisting	 of	 only	 the	 culture	media	 used	 in	 the	 experiments.	 Assay	 buffer	was	
added	to	the	substrate	mix	and	100µl	was	added	to	each	well.	The	plate	was	left	
for	 15	 minutes	 away	 from	 light	 and	 then	 the	 fluorescence	 of	 the	 assay	 was	
measured	with	the	FLUOstar	Omega.	Excitation	and	emission	wavelength	settings	
were	544	nm	and	590	nm,	respectively.	
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2.14.	Caspase	3/7	assay	
	
hRPE	cells	 grown	and	 infected	 in	 the	 same	manner	as	 in	 section	2.13.	After	 cell	
treatments	and	incubations,	caspase	3/7	activity	was	detected	using	Caspase‐Glo	
3/7	 Assay	 (Promega).	 A	 negative	 control	 was	 used	 consisting	 of	 only	 culture	
media.	 The	 positive	 control	 consisted	 of	 recombinant	 caspase	 3	 (Millipore,	
Billerica,	MA,	USA)	at	concentrations	of	4,	2	and	1	U/well	(40,	20	and	10	U/ml).	
The	plate	was	placed	on	a	rocker	before	the	removal	of	50µl	of	supernatant	per	
well	(leaving	50µl).	Fifty	microlitres	of	the	Caspase‐Glo	buffer	and	substrate	mix	
was	added	 to	 the	wells.	 Luminescence	produced	by	 the	assay	was	measured	on	
the	Spectra	Max	(Molecular	Devices)	in	conjunction	with	the	FLUOstar	Omega	50,	
70	and	90‐minute	 time	points	post‐addition	 to	 the	plate,	 and	 the	optimum	time	
point	readout	was	selected	for	analysis,	based	on	the	difference	of	basal	caspase	
activity	in	wells	(mock‐infected)	compared	with	the	negative	control.	 	
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2.15.	 Measurement	 of	 L‐Tryptophan	 and	 kynurenine	 levels	 in	
supernatant. 
 
Supernatants	were	taken	from	virus‐infected	hRPE	cells,	grown	and	treated	in	the	
same	manner	 as	 cells	 in	 section	 2.11.	 Then,	 90µl	 of	 the	 supernatant	was	mixed	
with	30µl	of	ice	cold	20%	trichloric	acetic	acid.	The	mixture	was	spun	down	on	a	
mini‐centrifuge	(Model	5415	R,	Eppendorf)	at	16,100	xg	for	15	minutes	in	1.5	ml	
Eppendorf	 tubes.	 The	 mixture	 was	 stored	 at	 ‐20°C	 and	 transferred	 to	 UNSW	
(Centre	for	Vascular	Research)	by	Dr	Amanda	Yeung	for	HPLC	measurements	of	L‐
tryptophan	 (L‐Trp)	 and	 kynurenine	 on	 the	 Aglient	 2100	HPLC	 system	 (Aglient,	
Santa	Clara,	USA)	with	a	Hypersil	3	μm	ODS	C18	column	(Phenomenex,	Torrance,	
CA,	 USA).	 The	 samples	 were	 eluted	 with	 100	 mM	 chloroacetic	 acid	 and	 9%	
acetonitrile	(pH	2.4)	at	a	rate	of	0.5	ml/min.	The	molecules	were	detected	by	UV	
absorbance	using	280nm	for	L‐Trp	and	364nm	for	kynurenine.		
 
2.16.	DAF‐FM	Assay	
 
Cells	were	cultured	at	5	x104	cells/well	in	12‐well	plates	for	3	days	before	mock‐
infection	 or	 infection	 with	 1,	 5	 or	 10	 MOI	 or	 WNV.	 Cells	 were	 harvested	 and	
processed	 for	 flow	 cytometry	 as	 previously	mentioned,	 at	 24,	 48	 and	 72	 hours	
post‐infection.	 During	 the	 staining	 step,	 cells	 were	 incubated	 with	 DAF‐FM	 (4‐
amino‐5‐methylamino‐2',7'‐difluorofluorescein,	Invitrogen)	and	analysed	with	the	
FACSCalibur	flowcytometer	(BD	Biosciences).	Data	was	processed	with	Flowjo	as	
previously	mentioned	in	section	2.9.1.	
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2.17	Greiss	Assay	
 
Nitrate	and	nitrite	 levels	were	quantified	using	a	nitric	oxide	kit	(Enzo	Biochem,	
Farmingdale,	NY,	U.S.A)	according	to	the	manufacturer’s	instructions.	Briefly,	cell	
culture	supernatant	from	mock‐infected	or	WNV‐infected	hRPE	(1,	5	or	10	MOI	or	
WNV)	 at	 24,	 48	 and	 72	 hours	 post‐infection	was	 collected	 and	 filtered	 through	
NanoSep	10kDa‐cutoff	 filter	 (Pall	 Corporation,	 Port	Washington,	NY,	U.S.A).	 The	
resultant	filtrate	was	then	placed	in	a	96‐well	plate	capable	of	absorbance	reading.	
For	nitrate	measurements,	NADH	and	nitrate	reductase	was	added	to	the	samples,	
before	 incubation	 with	 proprietary	 greiss	 reagents	 and	 subsequent	 reading	 of	
absorbance	 with	 a	 microplate	 reader	 (Spectra	 Max)	 at	 540	 ±	 20nm.	 Nitrite	
measurements	 were	 performed	 in	 the	 same	 manner	 as	 nitrate	 measurements	
with	 the	 omission	 of	 NADH	 and	 nitrate	 reductase.	 SNAP	 (S‐nitro‐N‐acetyl‐DL‐
penicillamine)	was	used	as	a	positive	control.	
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2.18.	Nucleic	acid	experiments	
 
2.18.1.	RNA	extraction	
 
For	 microarray	 work	 and	 confirmation	 with	 qPCR,	 primary	 hRPE	 cells	 were	
seeded	 at	 a	 density	 of	 2.5	 x105	 in	 a	 6	 well	 plate	 (Corning).	 When	 cells	 were	
confluent,	they	were	mock‐infected	or	infected	with	WNV	at	an	MOI	of	1,	5	or	10.	
Cells	were	harvested	at	24,	48	and	72	hours	post‐infection	by	washing	them	with	
PBS	and	then	lysing	with	350µl/well	of	TRI	reagent	(Sigma	Aldrich),	homogenized	
with	 a	 27‐gauge	 needle	 (BD	 Biosciences)	 attached	 to	 a	 1ml	 syringe	 (Terumo	
Corporation,	Tokyo,	Japan),	and	the	TRI	reagent/cell	lysate	was	frozen	overnight	
at	‐80°C.	The	next	day	the	lysate	was	thawed,	and	an	aqueous	layer	was	extracted	
after	the	addition	of	150µl	of	chloroform	(Sigma	Aldrich).	The	RNA	was	purified	
and	 isolated	 using	 the	 RNeasy	 kit	 (Qiagen,	 Venlo,	 Limburg,	 Netherlands)	
according	 to	 the	 manufacturer’s	 instructions.	 Quantification	 of	 RNA	 levels	 was	
achieved	 with	 the	 use	 of	 the	 ND‐1000	 Nanodrop	 spectrophotometer	 (Thermo	
Fisher	Scientific).	
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2.18.2.	cDNA	generation	
 
Using	 RNA	 extracted	 as	 previously	 described	 in	 section	 2.18.1,	 cDNA	 was	
generated	using	 the	SensiFast	 cDNA	kit	 (Bioline,	London,	UK)	as	 follows:	1µg	of	
mRNA	was	added	to	4	µl	of	5x	TransAmp	buffer,	1µl	of	reverse	transcriptase	and	
nuclease‐free	water	 to	a	 final	 combined	volume	of	20µl.	The	samples	were	 then	
placed	in	a	T‐100	thermal	cycler	(Bio‐Rad,	Hercules,	CA,	USA)	with	the	following	
settings:	10	minutes	at	25°C	for	primer	annealing,	15	minutes	at	42°C	for	reverse	
transcription	and	5	minutes	at	85°C	for	inactivation.	Samples	were	stored	at	‐30°C	
until	required	for	qPCR.	
 
2.18.3.	Quantitative	Real	Time	‐	Polymerase	Chain	Reaction	(qPCR)	
 
Predesigned	 Taqman	 Gene	 probes	 (Table	 2.4,	 Life	 Technologies)	 were	 used	 to	
investigate	 differential	 expression	 of	 genes	 via	 qPCR.	 0.5µg	 of	 cDNA,	 0.5µl	 of	
Taqman	 probe/primer	 and	 5µl	 of	 2x	 SensiFast	 Probe	 (Bioline)	 was	 added	 per	
sample	with	nuclease‐free	water	to	make	up	a	final	volume	of	10µl.	Volumes	were	
loaded	onto	a	384‐well	qPCR	plate	(Roche,	Basel,	Switzerland)	with	the	aid	of	the	
Freedom	EVO75	robotic	workstation	(Tecan),	and	sealed	with	the	supplied	plate	
sealer.	Samples	were	run	on	the	Light	Cycler	480	(Roche).	 	Run	settings	were	as	
follows:	Heat	activation	step	at	95°C	for	10	minutes,	cycle	runs	at	a	high	of	95°C	
for	15	seconds,	followed	by	a	low	of	60°C	for	1	minute.	The	plates	were	run	for	50	
cycles.	
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For	relative	quantification	of	WNV	mRNA,	custom	Taqman	probes	(CTC	AAC	CCC	
AGG	AGG	ACT	GG),	forward	primers	(AAG	TTG	AGT	AGA	CGG	TGC	TG)	and	reverse	
primers	(AGA	CGG	TTC	TGA	GGG	CTT	AC)	were	obtained	from	Life	Technologies.	
Primer	 and	 probe	 sequences	 were	 obtained	 from	 (222),	 and	 correspond	 to	 a	
region	of	the	NS1	protein,	which	is	only	expressed	during	active	replication	of	the	
virus.	1µg	of	cDNA,	1µl	each	of	WNV	probe,	 forward	primer	and	reverse	primer,	
10µl	 of	 2x	 SensiFast	 Probe	 (Bioline)	 was	 added	 per	 sample	 with	 nuclease‐free	
water	 to	make	up	 a	 final	 volume	of	 20µl	 and	 loaded	onto	 a	 96‐well	 qPCR	plate	
(Roche),	sealed	and	run	on	the	Light	Cycler	480.	
Data	 analysis	 of	 qPCR	 output	was	 achieved	with	 the	 Light	 Cycler	 480	 software	
(Version	1.5,	Roche).		
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Entrez 
Gene ID 
Gene 
name 
Protein name 
Taqman 
primer/probe set 
Amplicon 
length (bp) 
4843  NOS2  Nitric oxide synthase 2  Hs01075529_m1  67 
3620  IDO1  indoleamine 2,3 dioxygenase  Hs00984148_m1  66 
3383  ICAM1  Intercellular adhesion molecule 1  Hs99999152_m1  99 
1499  CTNNB1  Beta‐catenin  Hs99999168_m1  134 
7082  TJP1  Tight junction protein 1/ZO1  Hs01551861_m1  148 
999  CDH1  E‐cadherin  Hs00170423_m1  117 
1000  CDH2  N‐cadherin  Hs00169953_m1  96 
100506658  OCLN  Occuldin  Hs00170162_m1  68 
8531  CSDA  ZONAB  Hs01124964_m1  88 
4313  MMP‐2  Matrix metalloproteinase 2  Hs00234422_m1  83 
4318  MMP‐9  Matrix metalloproteinase 9  Hs00957562_m1  67 
7422  VEGFA 
Vascular endothelium growth 
factor 
Hs99999070_m1  63 
1490  CTGF  Connective tissue growth factor  Hs00170014_m1  60 
7077  TIMP‐2 
Tissue inhibitor of 
metalloproteinases 2 
Hs00234278_m1  73 
7040  TGFB1 
Transforming growth factor beta 
1 
Hs00998133_m1  57 
7042  TGFB2 
Transforming growth factor beta 
2 
Hs00234244_m1  92 
836  CASP3  Caspase 3  Hs00234387_m1  100 
840  CASP7  Caspase 7  Hs00169152_m1  76 
330  BIRC3 
Baculoviral IAP repeat containing 
3 
Hs00154109_m1  72 
54739  XAF1  XIAP associated factor 1  Hs00213882_m1  114 
8743  TNFSF10 
Tumor necrosis factor 
superfamily member 10/TRAIL 
Hs00921974_m1  97 
9131  AIFM1 
Apoptosis inducing factor, 
mitochondria associated 1  
Hs00377585_m1  75 
331  XIAP 
X‐linked inhibitor of apoptosis 
protein 
Hs01597783_m1  143 
598  BCL2L1  BCL2 Like 1  Hs00236329_m1  65 
581  BAX  BCL2 like protein 4  Hs00180269_m1  62 
355  FASLG  Fas ligand  Hs00910107_m1  104 
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Entrez 
Gene ID 
Gene 
name 
Protein name 
Taqman 
primer/probe set 
Amplicon 
length (bp) 
8717  TNFRSF1A 
Tumor necrosis factor receptor 
superfamily member 1A 
Hs00182558_m1  92 
7133  TNFRSF1B 
Tumor necrosis factor receptor 
superfamily member 1B 
Hs00153550_m1  61 
8797 
TNFRSF10
A 
Tumor necrosis factor receptor 
superfamily member 10A 
Hs00269491_m1  83 
8795 
TNFRSF10
B 
Tumor necrosis factor receptor 
superfamily member 10B 
Hs00366278_m1  62 
8794 
TNFRSF10
C 
Tumor necrosis factor receptor 
superfamily member 10C 
Hs00182570_m1  81 
8793 
TNFRSF10
D 
Tumor necrosis factor receptor 
superfamily member 10D 
Hs00388742_m1  93 
3105  HLA‐A  Human leukocyte antigen A  Hs01058806_g1  70 
3106  HLA‐B  Human leukocyte antigen B  Hs00741005_g1  150 
3107  HLA‐C  Human leukocyte antigen C  Hs03044135_m1  84 
3133  HLA‐E  Human leukocyte antigen E  Hs03045171_m1  130 
3134  HLA‐F  Human leukocyte antigen F  Hs01587837_g1  145 
719  C3AR1 
Complement component 3a 
receptor 1 
Hs00269693_s1  82 
3456  IFNB1  Interferon beta 1  Hs01077958_s1  73 
282618  IFNL1  Interferon lambda 1  Hs00601677_g1  101 
282616  IFNL2  Interferon lambda 2  Hs00820125_g1  167 
7124  TNF  Tumour necrosis factor alpha  Hs99999043_m1  85 
2597  GAPDH 
Glyceraldehyde 3‐phosphate 
dehydrogenase 
Hs02758991_g1  93 
60  ACTB  Beta actin  Hs01060665_g1  171 
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Table	2.4.	Table	of	Taqman	primer/probe	sets	used	in	qPCR	assays.		
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2.19.	Gelatin	Zymography	
 
hRPE	cells	were	plated	on	12	well	plates	and	cultured	in	DMEM	cell	culture	media.	
Once	confluent,	cells	were	infected	with	WNV	at	an	MOI	of	1,	5	or	10,	rinsed	with	
PBS,	 and	 wells	 replenished	 with	 serum‐free	 DMEM	 containing	 1x	 ITS+3	 liquid	
media	supplement	(Sigma	Aldrich).	Supernatants	were	collected	at	24,	48	and	72	
hours	 post‐infection,	 then	 concentrated	 using	 10kDa	 molecular	 weight‐cutoff,	
Nanosep	columns.	Supernatants	in	non‐reducing	Lamelli	buffer	were	then	loaded	
onto	a	polyacrylamide	gel	(8%,	375mM	Tris	0.1%	SDS,	Thermo	Fisher	Scientific)	
gel	 with	 2%	 porcine	 gelatin	 (Sigma	 Aldrich),	 and	 run	 for	 2‐3	 hours	 at	 120V	 in	
Tris/glycine	 running	buffer	using	 a	Mini‐PROTEAN	Tetra	Cell	 system	 (Bio‐Rad).	
Samples	were	not	heated	prior	 to	 loading.	Once	 the	 run	was	 completed,	 the	 gel	
was	renatured	via	SDS	removal	in	a	2.5%	Triton	X‐100	solution	for	40	minutes	at	
room	 temperature.	 Matrix	 metalloproteniases	 were	 activated	 via	 a	 20‐hour	
incubation	 in	 a	 buffer	 containing	 50mM	 Tris	 HCL	 (pH	 7.8),	 0.15M	 NaCl,	 10mM	
CaCl2	 and	 3mM	NaN3.	 Gels	were	 stained	 for	 an	 hour	 in	 a	 10%	 acetic	 acid/25%	
methanol	 solution	 containing	 0.05%	 Coomassie	 Blue	 R250,	 and	 then	 destained.	
Gels	were	imaged	using	a	ChemiDoc	MP	imaging	system	(Bio‐Rad),	and	analysed	
using	the	ImageLab	(Version	5.2.1	build	11,	Bio‐Rad).	
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2.20.	Real‐Time	Cell	Analysis,	Single	Plate	(RTCA	SP),	for	
measurement	of	hRPE	monolayer	integrity.	
 
96‐well	 E‐plates	 (Roche)	 were	 initially	 filled	 with	 100µl/well	 of	 DMEM	 and	
warmed	 to	 37°C	 in	 order	 to	 establish	 a	 baseline	 electrical	 impedence	
measurement	using	the	xCELLigence	Real‐Time	Cell	Analysis,	Single	Plate	(RTCA‐
SP)	 analyzer	 (ACEA	 Biosciences,	 San	 Diego,	 CA,	 USA).	 After	 this	 measurement,	
media	was	aspirated	and	 replaced	with	100µl/well	of	DMEM	and	RPE	cells	 at	 a	
density	of	2.5x104	cells/well.	During	 the	cell	adherence/growth	phase,	electrical	
impedence	 measurements	 were	 taken	 every	 6	 hours	 until	 the	 increase	 in	
impedence	 reached	 a	 plateau	 (~4‐5	 days).	 Once	 this	 was	 achieved,	 cells	 were	
treated	 with	 DMEM	 cell	 culture	 media,	 WNV	 at	 an	 MOI	 of	 5	 or	 a	 variety	 of	
cytokines	 and	 immunomodulatory	 factors	 as	 shown	 in	 Table	 2.1	 (PeproTech,	
Rocky	Hill,	NJ,	USA),	(Tocris	Bioscience,	Minneapolis,	MN,	USA)	and	measured	for	
electrical	impedence	every	3	hours	for	5	days.	Data	were	then	analysed	using	the	
RTCA	Software	1.2	(ACEA	Biosciences).	
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2.21.	Data	processing,	statistics	and	analysis	
 
Data	 were	 processed	 on	 Excel	 (Microsoft	 Corporation,	 Redmond,	 Washington,	
USA).	 Statistics	 were	 performed	 with	 Prism	 software	 (Version	 6.0f	 Graphpad	
Software	San	Diego,	CA,	USA).	Statistics	analysis	comparing	 two	conditions	used	
throughout	 the	 studies	 included	 2‐tailed	 t‐tests,	 and	 in	 cases	 where	 the	
differences	 between	 control	 and	 experimental	 values	 were	 consistent	 but	 the	
measure	values	between	biological	replicates	varied	by	several	fold,	a	ratio	t‐test	
was	 used	 instead.	 One‐way	 ANOVAs	 incorporating	 a	 Dunnet	 post‐test	 and	 a	
Geisser‐Greehouse	correction	were	used	to	compare	between	multiple	values.	
Statistical	 analysis	 of	 qPCR	 data	 were	 achieved	 with	 GenEx	 software	 (MultiD,	
Göteburg,	Sweden),	which	normalised	Ct	values	relative	to	the	highest	Ct	number.	
A	2‐tailed	paired	 t‐test	with	 a	95%	CI	was	performed	on	 the	Log2	 values	of	 the	
normalized	Ct	values.	Experimental	values	derived	from	WNV‐infected	cells	were	
compared	with	mock‐infected	cells	 that	were	collected	at	the	same	time	as	their	
infected	counterparts.		
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Chapter 3: Human RPE cell responses to WNV 
infection. 
 
3.1	Introduction	
 
	The	 outer	 BRB	 provides	 a	 defence	 against	 pathogen	 entry	 into	 retina	 from	 the	
choroid	plexus.	 	The	ability	of	the	RPE	(which	makes	up	the	outer	BRB)	to	 limit,	
clear	 infection	 and	 potentially	 resolve	 inflammation	 is	 thus	 important	 in	
minimizing	 the	 effects	 of	 both	 viral	 and	 adaptive‐immune	 system‐mediated	
damage	to	the	neural	retina.	
	
There	 are	 limited	 investigations	 into	 the	 functional	 effects	 of	 (West	 Nile	 Virus)	
WNV	 infection	 of	 human	 RPE	 	 (hRPE)	 cells.	 	 To	 date,	 the	 effects	 of	 virus‐free	
conditioned	 cell	 culture	 media	 from	 WNV‐infected	 RPE	 cells	 and	 IFN‐β1	
separately	have	been	shown	to	mediate	an	inhibitory	response	on	both	WNV	and	
HCMV	replication	in	hRPE	cell	cultures	(221).	Additionally,	WNV	has	been	shown	
to	induce	high	levels	of	STAT1	and	STAT2	proteins	(involved	in	the	upregulation	
of	 interferon	 stimulated	 genes/ISGs)	 and	 increased	 phosphorylation	 of	 these	
proteins	in	hRPE	(221).	
	
The	 previous	 investigations	 using	 gene	 microarray	 to	 study	 the	 entire	 mRNA	
transcriptome	in	WNV‐infected	hRPE	showed	differential	regulation	of	a	plethora	
of	 immune	 system‐related	 genes,	 which	 include	 OAS1,	 STAT1,	 MX1	 and	 CCL5	
(220).		
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Investigating	the	production	of	cytokines	produced	by	WNV‐infected	hRPE	gives	
an	 insight	 into	 the	 possible	 leukocyte	 profile	 that	 could	 occur	 during	 WNV	
infection	 of	 the	 retina.	 As	 a	 useful	 guide,	 several	 cytokines	 found	 in	 our	
microarray	have	also	been	shown	to	play	an	 important	role	 in	WNV‐infection	of	
the	brain	(201,	223,	224),	which	include	CCL2,	CCL5,	IL‐6	and	IL8.	This	may	not	be	
surprising,	 given	 that	 there	 are	 common	 elements	 to	 both	 tissues.	 Of	 particular	
interest,	was	 the	upregulation	of	 the	 relatively	 recently	discovered	 type‐III	 IFNs	
(IFN‐λ	 group,	 see	 section	1.3.4).	Based	on	 these	 findings,	 the	 current	 study	was	
designed	 to	 further	 investigate	 the	effects	of	WNV	on	a	 selection	of	 these	genes	
and	proteins	at	different	post‐viral	infection	time‐points	and	viral	titres.	
Since	WNV	increases	MHC‐I	and	MHC‐II	surface	expression	on	various	cell	types	
during	WNV	 infection	 (225),	 and	 our	microarray	 showed	 increased	 HLA‐E	 and	
HLA‐F	gene	expression	(220),	more	thorough	quantification	of	HLA‐A,B,C,E	and	F	
mRNA	was	done.	
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Furthermore,	 since	 initial	 gene	 microarray	 results	 highlighted	 the	 tryptophan‐
metabolising	protein,	IDO1,	as	a	gene	of	particular	interest	in	WNV‐infected	hRPE,	
we	 investigated	 this	 enzyme	 at	 the	 transcriptional,	 translational	 and	 functional	
level.	 IDO1	 is	 known	 to	 play	 major	 roles	 in	 leukocyte	 regulation	 and	 display	
antiviral	activity	(226‐228).	The	increase	in	IDO	expression	at	the	gene	level	was	a	
surprising	 result	 given	 that	 earlier	preliminary	experiments	 indicated	 increased	
production	 of	 nitric	 oxide	 in	 WNV‐infected	 hRPE	 (personal	 communication,	 Li	
Wen).	Several	studies	have	reported	inhibition	of	IDO1	by	nitric	oxide	(229‐231),	
thus	 given	 our	 previous	microarray’s	 finding	 of	 increased	NOS2	mRNA,	we	 also	
investigated	 this	 enzyme,	 as	well	 as	 the	 contributions	 the	 aforementioned	 IFNs	
might	have	on	 IDO1	activity.	The	effects	of	 the	 IFNs	and	 the	activity	of	 IDO1	on	
viral	replication	were	also	assessed.	 	 	 	
	
Cell	cycle	arrest	at	various	stages	can	confer	certain	beneficial	effects	for	the	virus	
and	is	a	common	strategy	utilised	by	viruses.	Viral	infection	can	result	in	specific	
block	of	 the	G1,	G0	 (232)	and	S‐phases	(233)	of	 the	cell	cycle.	Cell	 cycle	delay	or	
arrest	over	several	phases	such	as	G1	/	G2	by	paramyxovirus	(234)	and	S	/	G2	by	
avian	 coronavirus	 (235)	 has	 also	 been	 reported.	 Furthermore,	 production	 of	
infectious	 coxsackievirus	 is	 higher	 in	 cells	 arrested	 at	 the	 G1	 /	 S	 phase,	 than	 in	
cells	at	the	G0	or	G2/M	phase	(236).	Infection	of	cells	at	the	G0	phase	however,	can	
confer	 persistence	 of	 infection,	 as	 the	 virus	 may	 be	 produced	 whenever	 the	
infected	cells	enter	the	cell	cycle	(236).	A	large	number	of	genes	involved	with	the	
cell	cycle	were	also	observed	to	be	upregulated	in	the	initial	WNV‐infected	hRPE	
gene	microarray	study	(220).	As	such,	a	 further	aim	of	 the	current	study	was	to	
investigate	the	effects	of	WNV	infection	on	the	cell	cycle	profile	of	hRPE	cells.	
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The	 cytopathic	 effects	 of	 WNV	 infection	 on	 RPE	 cells	 have	 also	 not	 been	 fully	
investigated.	Thus,	the	current	studies	also	aimed	to	examine	in	more	detail	WNV‐
induced	RPE	cell	death	and	explore	possible	pathways	that	may	be	involved.		The	
discovery	of	the	downregulation	of	TNFRSF10D	and	increase	in	TNFSF10	(TRAIL)	
in	 the	 gene	 microarray	 and	 preliminary	 qPCR	 results	 (220)	 led	 to	 further	
investigation	 of	 the	 TNF	 receptor	 superfamily	 (TNFRSF)	 in	 the	 current	 studies.	
TNF	 signalling	 occurs	 through	 one	 of	 two	 receptors,	 TNFRSF1A	 or	 TNFRSF1B.	
TNFRSF1A	expression	 is	ubiquitous	across	most	cell	 types,	while	 the	expression	
of	TNFRSF1B	is	believed	to	be	restricted	to	immune	cells,	endothelial	cells	and	a	
certain	 subset	 of	 neural	 cells	 (237).	 Most	 TNF‐attributed	 processes	 occur	 via	
TNFRSF1A	 (237),	 and	 since	 TNFRSF1B	 is	 lacking	 a	 death	 domain,	 TNFRSF1B‐
mediated	 cell	 death	 effects	 are	 believed	 to	 use	 a	 different	 pathway	 from	 that		
employed	 by	 TNFRSF1A	 (238).	While	 both	 receptors	 have	 pleiotropic	 effects,	 it	
appears	 that	 TNFRSF1A	 mediates	 pro‐apoptotic	 responses	 and	 TNFRSF1B	
mediates	 cell	 survival	 responses,	 although	 each	 is	 capable	 of	 the	 opposite	
response.	Furthermore,	TNFRSF1B	 is	 capable	of	 enhancing	TNFRSF1A‐mediated	
cell	 death	 (239,	 240).	 TNFSF10	 (also	 known	 as	 TRAIL)	 is	 part	 of	 the	 TNF	
superfamily	but	works	as	a	separate	system,	and	has	been	mostly	characterised	in	
terms	of	its	pro‐apoptotic	anti‐cancer	properties	(241).	Several	studies	have	also	
shown	 that	 it	 is	 induced	 in	 type	 I	 and	 II	 IFN	 responses	 in	 various	 cell	 types	 in	
immunomodulatory	roles	(241).			
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There	 are	 five	 known	 receptors	 that	 can	 bind	 TNFSF10;	 pro‐apoptotic,	
membrane‐bound	 TNFRSF10A	 (death	 receptor	 4,	 DR4)	 and	 TNFRSF10B	 (death	
receptor	5,	DR5),	membrane	bound	anti‐apoptotic	 receptors	TNFRSF10C	(decoy	
receptor	 1,	 DcR1)	 and	 TNFRSF10D	 (decoy	 receptor	 2,	 DcR2),	 and	 soluble	
osteoprotegerin,	involved	in	regulation	of	bone	remodelling	(242).	
Expression	 of	 TNFSF10	 is	 believed	 to	 be	 absent	 in	 immune‐privileged	 sites	
(specifically	 the	 brain	 and	 testes)	 (241).	 The	 eye	 however	 appears	 to	 be	 an	
exception,	as	TNFSF10	has	been	shown	to	play	an	important	role	 in	maintaining	
the	immune	privilege	of	the	eye	(243).	Interestingly,	in	atopic	dermatitis	TNFSF10	
shows	a	possible	anti‐inflammatory	role	(244).		
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3.2.	Results	
 
3.2.1.	Production	of	Cytokines	by	WNV‐infected	hRPE	
 
Cells	were	plated,	grown	and	infected	with	WNV	as	described	in	section	2.7,	and	
cytokine	levels	were	measured	using	the	procedures	as	described	in	sections	2.11	
and	2.12.	
Increases	in	CCL5	production	in	WNV‐infected	hRPE	cells,	compared	with	mock‐
infected	cells	were	 found	at	48	and	72	hours,	while	 levels	of	 IL6,	 IL8	and	G‐CSF	
(Figure	3.1	A,	C,	D	&	E)	were	 increased	but	not	 statistically	 significant,	with	 the	
exception	of	 IL6	at	48	hour	with	both	MOIs	 tested.	No	differences	 in	expression	
between	WNV	and	mock‐infected	hRPE	for	CCL2	and	GM‐CSF	were	found	(Figure	
3.1	B	&	F).	
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Figure	3.1.	 Supernatant	 levels	of	CCL5	(A),	CCL2	(B),	 IL6	(C),	 IL8	 (D)	G‐CSF	(E)	
and	GM‐CSF	(F)	for	mock	and	WNV‐infected	hRPE	cells	at	MOI	of	5	and	10	at	24,	
48	 and	 72	 hours	 post‐infection	 measured	 using	 Luminex	 multiplex	 assay.	 The	
dotted	line	represents	the	minimal	detectable	level	of	protein,	not	easily	seen	on	
(C)	 and	 (D)	 due	 to	 the	 scale	 used.	 Levels	 of	 G‐CSF	 in	 all	mock	 samples	 are	 not	
noted	in	(E)	due	to	very	low	signal	levels.	Note	the	break	in	y‐axis	on	(A)	and	(B).	
Statistical	analysis	was	performed	via	a	one‐way	ANOVA	with	a	Dunnet	post‐test	
and	a	Geisser‐Greenhouse	correction.	n=4,	C.I.=95%,	*=	p<0.05,	**=	p<0.01.	
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3.2.2.	Production	of	IFNs	and	TNF	in	WNV‐infected	hRPE		
	
Cell	culture	procedures	were	undertaken	and	cytokine	measurements	assessed	as	
previously	described.	All	 qPCR	described	 in	 subsequent	 results	were	performed	
as	 described	 in	 section	 2.18.	 Temporal	 increases	 in	 IFN‐β1	 (Figure	 3.2	 A)	 and	
IFNλ‐1	 (Figure	 3.2	 B)	 occurred	 in	WNV‐infected,	 compared	with	mock‐infected	
hRPE	cells	treated	with	an	MOI	of	5	or	10.	No	differences	in	either	IFN	were	noted	
between	 the	 two	 viral	 titres	 used.	 Upregulation	 of	TNF	mRNA	 in	WNV‐infected	
hRPE	 cells	 occurred	 at	 24	 hours	 post‐infection	 (~5x104‐fold),	 compared	 with	
uninfected	 cells.	 This	 decreased	 sharply	 by	 48	 and	 72	 hours	 post‐infection	
(~2x102‐fold)	 (Figure	 3.2	 C).	TNF	mRNA	was	 also	 upregulated	 in	WNV‐infected	
hCF	cells	compared	to	levels	seen	in	24	hour	post‐infection	hRPE,	at	both	24	and	
72	hours	post‐infection	(Figure	3.2	D).	 	
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Figure	3.2.	Levels	of	IFN‐β	(A)	and	IFNλ‐1	(B)	protein	in	the	supernatant	of	hRPE	
mock‐infected	or	 infected	with	WNV	at	MOI	of	5	and	10,	at	24,	48	and	72	hours	
post	infection,	as	measured	by	ELISA.	Histograms	representing	the	fold	change	of	
TNF	mRNA	in	WNV‐infected	hRPE	(C)	and	hCF	(human	choroidal	fibroblasts)	(D)	
compared	with	uninfected	cells,	at	MOI	ranges	of	0.1	to	10,	as	measured	via	qPCR,	
are	 also	 shown.	 mRNA	 levels	 were	 quantitated	 at	 24,	 48	 and	 72	 hours	 post‐
infection	 for	hRPE	cells,	but	only	at	24	and	72	hours	post‐infection	 in	hCF	cells.	
Also	 shown	 are	 TNF	 levels	 in	 mock	 and	 WNV‐infected	 hRPE	 supernatant	 as	
measured	 by	 multiplex	 assay	 (E).	 Note	 the	 log	 scale	 y‐axis	 for	 	 (C)	 and	 (D).	
Statistical	 analysis	was	 performed	 via	 one‐way	 ANOVA	with	 a	 Dunnet	 post‐test	
and	a	Geisser‐Greenhouse	correction	(A,	B	&	E)	and	a	two‐tailed	paired	t‐test	on	
log2	 normalized	 Ct	 values	 (C&D).	 n=	 4,	 C.I.=95%,	 *=	 p<0.05,	 **=	 p<0.01,	
***=p<0.001,	****=p<0.0001.	
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3.2.3.	Differential	regulation	of	MHC‐I	genes		
	
Genes	 involved	 in	 the	 production	 of	 the	 MHC‐I	 complex	 were	 found	 to	 be	
upregulated	in	hRPE	in	response	to	WNV‐infection,	peaking	at	48	h.	However,	no	
particular	HLA	allele	showed	a	transcriptional	profile	distinctive	from	the	others	
in	this	study.		 	 	
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Figure	3.3.	qPCR	quantification	of	HLA	gene	variants	A,	B,	C,	D	and	E	at	24,	48	and	
72	hours	post‐infection	in	WNV‐infected	hRPE	cells	at	MOI	of	1,	5	and	10	relative	
to	mock‐infected	 cells.	 Note	 the	 log	 scale	 on	 the	 y‐axis	 of	 all	 figures.	 Statistical	
analysis	was	performed	using	two‐tailed	paired	t‐test	on	the	Log2	normalized	Ct	
values.	n=6,	C.I.	=	95%,	*=	p<0.05.	
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3.2.4.	Effects	of	WNV	infection	on	expression	of	other	immune	genes	and	
genes/proteins	of	interest	in	hRPE	
 
C3AR1,	 found	 to	 be	 upregulated	 in	 the	 initial	 gene	microarray	 study	 (220),	was	
further	investigated	with	qPCR.	Given	the	role(s)	of	the	complement	system	in	the	
pathogenesis	of	AMD	discussed	in	section	1.6.3	(164,	245),	this	gene	was	further	
explored	 in	 the	 current	 study.	 Statistically	 significant	 increases	 in	 C3AR1	
transcription	were	found	in	WNV‐infected	hRPE	for	all	viral	MOI,	compared	with	
mock‐infected	cells,	and	at	all	 time‐points.	This	occurred	at	 the	highest	 levels	at	
48	hours	post‐infection.	(Figure	3.4A).	Quantification	of	C3AR1	at	the	protein	level	
was	not	performed	due	to	the	difficulty	in	obtaining	a	human‐specific	ELISA.		
	
ICAM1	was	 significantly	 upregulated	 across	 all	 time	 points	 and	 titres,	 with	 the	
exception	of	MOI	1	at	24	hours	(Figure	3.4	B).	Despite	statistically	significant	2‐
fold	 increases	 (48	 hours	 post‐infection)	 and	 4‐fold	 increases	 (72	 hours	 post‐
infection)	 of	VEGFA	 in	WNV‐infected	 hRPE	when	 compared	with	mock‐infected	
cells,	 no	 changes	 in	 VEGF	 protein	 production	 were	 found	 (Figure	 3.4	 D).	
Measurements	of	 ICAM‐1	protein	surface	expression	are	shown	 in	 the	 following	
chapter	(Figure	4.1B).	
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Figure	3.4.	qPCR	quantification	of	C3AR1	 (A),	 ICAM1	(B),	VEGFA	 (C)	mRNA,	and	
multiplex	 quantification	 of	 VEGF‐A	 (D)	 protein	 at	 24,	 48	 and	 72	 hours	 post‐
infection	 in	 WNV‐infected	 hRPE	 cells	 at	 MOI	 of	 1,	 5	 and	 10,	 relative	 to	 mock‐
infected	cells.	Note	the	break	in	y‐axis	for		(A).	Statistical	analysis	was	performed	
using	a	two‐tailed	2‐tailed	paired	t‐test	on	the	Log2	normalized	Ct	values	(A,	B	&	
D)	 and	 a	 one‐way	 ANOVA	 with	 a	 Dunnet	 post‐test	 and	 a	 Geisser‐Greenhouse	
correction	(D).	n=6	(A&B),	n=4	(C),	C.I.=95%,	*=	p<0.05	**=	p<0.01.	***=p<0.001.	
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3.2.5.	Transcription,	production	and	activity	of	IDO1	and	NOS2,	and	contributions	of	
IFNs	to	IDO1	activity.	
 
Measurement	 of	 IDO1	 activity	 by	 HPLC	 and	 measurement	 of	 NOS2	 activity	 by	
Greiss	assay	and	DAF‐FM	were	performed	as	described	in	sections	2.15,	2.16	and	
2.17.	 	 Fluorescent	 IHC	 staining	 of	 IDO1	was	 performed	 as	 described	 in	 section	
2.10.1,	 using	 FITC	 α‐NS1	 and	 biotin	 isotype	 as	 primary	 antibodies,	 and	
streptavidin‐Alexa	Flour	594	as	a	secondary	antibody.	 	While	qPCR	experiments	
showed	upregulation	 of	 both	 IDO1	 and	NOS2	mRNA	 at	 all	 time‐points	 and	 viral	
titres	 (there	was	 a	~100‐fold	 abundance	 of	 IDO	 transcripts	 compared	 to	NOS2,	
Figures	 3.6	 A	 and	 D),	 there	 was	 no	 detectable	 intracellular	 (Figure	 3.5	 G)	 or	
extracellular	 (Figure	 3.5	 E)	 production	 of	 nitric	 oxide	 in	mock	 or	WNV‐infected	
hRPE	 supernatant;	 tryptophan	 to	 kynurenine	 catabolism	 was	 detected	 by	 48	
hours	post‐infection	(Figure	3.5	B)	and	this	continued	to	at	 least	72	hours	post‐
infection	(Figure	3.5	C).	Immunostaining	for	IDO1	in	infected	hRPE	(that	was	also	
immunostained	 for	WNV	NS‐1),	 showed	patchy	expression	of	 IDO1	(Figure	3.6),	
with	some	demonstrably	 infected	cells	producing	IDO1	while	others	produced	 it	
without	appearing	to	stain	for	NS‐1.	This	indicates	a	heterogeneous	production	of	
this	enzyme	within	hRPE	cells.			
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Figure	3.5.	Bar	graphs	of	qPCR	relative	quantification	of	IDO1	(A)	and	NOS2	(D)	
mRNA	in	WNV‐infected	hRPE	at	MOI	of	1,	5	and	10	relative	to	mock‐infected	at	24,	
48	 and	 72	 hours	 post‐infection.	 HPLC	 assays	 measuring	 IDO1	 activity	 by	
quantification	of	supernatant	 levels	of	 tryptophan	and	kynurenine	at	48	(B)	and	
72	 (C)	 hours	 post‐infection	 (which	 are	 then	 converted	 into	
tryptophan/kynurenine	ratios)	are	shown.	Nitric	oxide	levels	in	mock	and	WNV‐
infected	 hRPE	 supernatant	 at	 72	 hours‐post‐infection	were	measured	 by	 Greiss	
assay	(E)	and	internal	presence	of	nitric	oxide	in	the	same	cells	via	flow	cytometry	
after	DAF‐FM	staining	(F).	A	DAF‐FM	positive	control	of	brain	macrophages	taken	
from	a	C57BL/6	mouse	 intranasally‐administered	with	an	LD50	dose	of	WNV	at	
day	6	post‐infection	was	analysed	concurrently	with	the	hRPE	(G).	The	red	curve	
in	the	histogram	represents	uninfected	hRPE	cells	or	brain	leukocytes,	while	the	
blue	curve	represents	WNV‐infected	hRPE	cells	or	brain	leukocytes	derived	from	
a	WNV‐infected	mouse.	Note	the	log	scale	y‐axis	of	(A)	and	(D).	Statistical	analysis	
was	 performed	 via	 a	 two‐tailed	 paired	 t‐test	 on	 the	 Log2	 normalized	 Ct	 values	
(A&D),	a	two‐tailed	paired	t‐test	(B&C)	and	one‐way	ANOVA	with	a	Dunnet	post‐
test	 and	 a	 Geisser‐Greenhouse	 correction	 (E).	 n=6,	 C.I.=95%,	 *=	 p<0.05,	 **=	
p<0.01,	***=p<0.001,	****=p<0.0001.	
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Figure	3.6.	Fluorescence	microscopy	images	of	cultured	hRPE	cells	infected	with	
WNV	at	an	MOI	of	5,	at	48	hours	post‐infection.	Cells	stained	with	DAPI	for	nuclei,	
anti	WNV	NS1‐FITC	(green),	anti‐human	IDO1	biotin	and	streptavidin‐Alexa	Fluor	
594	(red).		
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Based	on	 the	production	 of	 IFN‐λ1	 in	WNV	 infected‐hRPE	 (section	3.2.2),	 and	 a	
recent	 finding	 of	 IDO1	 upregulation	 in	 influenza‐infected	 human	 and	 murine	
bronchial	 epithelial	 cell	 lines	 (110),	 	 and	 an	 upregulation	 of	 IDO1	 mRNA	 in	
primary	hRPE	cells	treated	with	IFN‐β1	(246),	we	investigated	the	possible	role	of	
IFN‐λs	and	IFN‐β1	in	our	observed	WNV‐mediated	IDO	production	in	hRPE	cells.	
No	 changes	 in	 the	 ratio	 of	 tryptophan	 to	 kynurenine	 were	 observed	 in	 mock‐
infected	cells	 treated	with	 IFN‐λ1,	 IFN‐λ2	or	 IFN‐β1	(Figure	3.7,	administered	at	
levels	 found	 from	results	 shown	 in	Figure	3.2)	but	a	notable	attenuation	of	 IDO	
activity	 was	 observed	 in	 WNV‐infected	 hRPE	 cultures	 treated	 with	 blocking	
antibodies	against	either	IFN‐λ1	or	IFN‐λ2	at	48	hours	post‐infection	(Figure	3.7).	
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Figure	 3.7.	 Ratios	 of	 tryptophan/kynurenine	 levels	 in	 hRPE	 cells	 supernatants	
(mock‐infected,	mock‐infected	 cells	 treated	with	 recombinant	 IFNλ‐1	 or	 IFNλ‐2,	
WNV‐infected	 (MOI	 5)	 hRPE,	 WNV‐infected	 hRPE	 (MOI	 5)	 +	 neutralizing	
antibodies	 against	 IFNλ‐1	 or	 IFNλ‐2,	 or	 an	 isotype	 antibody)	 as	 measured	 by	
HPLC.	 Tryptophan	 /kynurenine	 ratios	 were	 quantitated	 at	 48	 hours	 post‐
infection/treatment.	 Statistical	 analysis	 was	 performed	 via	 a	 one‐way	 ANOVA	
with	 a	Dunnet	post‐test	 and	 a	Geisser‐Greenhouse	 correction.	 n=5,	 C.I.=95%,	 *=	
p<0.05,	**=	p<0.01.	
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3.2.6.	Effects	of	antiviral	proteins,	tryptophan	supplementation	and	IDO	inhibitors	on	
viral	titre	of	WNV‐infected	hRPE.	
 
Treatment of hRPE immediately after WNV-infection with recombinant human IFN-
β1	decreased	the	production	of	WNV	mRNA	(Figure	3.8),	indicative	of	an	anti‐
WNV	effect	from	this	cytokine	in	hRPE	cells,	which	has	been	previously	reported	
(221).	Of	particular	interest,	treatment	with	recombinant	IFN-λ1	leads	to	
increased	production	of	WNV	mRNA,	while	recombinant	IFN-λ2	appears	to	have	a	
small	amount	of	(non‐significant)	anti‐WNV	activity.	Combining	IFN-λ1	with	IFN-
λ2	or	IFN-λ2	and	IFN-β1	appears	to	abrogate	IFN-λ1’s	pro‐WNV	effect.	The	IDO	
activity	we	observed	appears	to	have	a	minimal	anti‐WNV	effect,	with	only	a	fold	
increase	of	1.13	of	WNV	mRNA	induced	by	the	IDO1	inhibitor	1‐L‐MT.	The	
concentrations	of	the	interferons	used	were	based	on	the	results	of	experiments	
shown	in	Figure	3.2.	
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Figure	3.8.	Relative	WNV	mRNA	levels	in	treated	MOI	5	WNV‐infected	hRPE	at	48	
hours	 post‐infection.	 Cells	 were	 treated	 with	 recombinant	 IFN‐β1	 (1ng/ml),	
recombinant	IFN‐λ1	(5ng/ml)	and	recombinant	IFN‐λ2	(5ng/ml)	either	separately	
or	 in	combination.	Cells	were	also	supplemented	with	L‐tryptophan	(100µM),	or	
treated	 with	 the	 IDO1	 inhibitors	 1‐L‐MT	 and	 1‐D‐MT	 (both	 at	 500µM).	 Fold	
changes	 are	 relative	 to	 untreated	 WNV‐infected	 hRPE.	 Statistical	 analysis	 was	
performed	using	 a	 2‐tailed	 paired	 t‐test	 on	 the	 log2	 normalized	Ct	 values.	 n=	 4,	
C.I.=95%,	*=	p<0.05,	**=	p<0.01	
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3.2.7.	WNV‐induced	cell	cycle	effects	in	ARPE19	cells	
	
Due	 to	 the	 variability	 of	 the	 rate	 of	 cell	 growth	 and	 senescence	 observed	with	
different	isolates	of	hRPE	(data	not	shown),	the	effects	of	WNV	on	cell	cycle	profile	
were	investigated	in	the	hRPE	cell	line	ARPE19,	instead	of	primary	hRPE	cells	to	
control	for	these	issues.	Measurement	of	cellular	DNA	distribution	was	performed	
as	described	in	section	2.9.1.	Additionally,	a	comparison	of	the	cell	cycle	profiles	of	
NS1‐positive	 and	 non‐NS1	 positive	 hRPE	 within	 a	 WNV‐infect	 population	 was	
performed.	 	The	 rationale	 for	 this	 is	 to	 examine	and	 compare	 the	differences	 in	
cell	cycle,	if	any,	between	cells	that	are	infected	as	determined	by	NS1	and	those	
that	are	not.		
	
NS1‐positive	staining	for	both	MOI	5	and	10	at	24	hours	is	~10%,	as	determined	
by	 flow	 cytometry.	 By	 48	 hours	 and	 72	 hours	 post‐infection,	 the	 proportion	 of	
NS1‐positive	cells	is	between	29%	to	41%	(Figure	3.9	B).	
WNV‐infected	 ARPE19	 cells	 showed	 no	 significant	 changes	 at	 24	 hours	 post‐
infection	compared	with	mock‐infected	cells	(Figure	3.9	A).	However	a	reduction	
of	cells	in	the	G1/G0	and	G2/M	phase	of	infected	cells	and	corresponding	increase	
of	cells	in	the	S‐phase	by	48	and	72	hours	post‐infection	was	observed	(Figure	3.9	
C	&	F).	
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Approximately	24%	more	of	 the	 cell	population	was	 in	S‐phase	 in	 infected	cells	
than	in	uninfected	cells	at	48	hours	and	72	hours	post‐infection	(Figure	3.9	D,	E,	G,	
H).	However	the	decrease	of	the	cell	population	in	G1/G0	between	uninfected	and	
infected	 cell	 populations	 was	 ~12%	 at	 48	 hours	 but	 ~22%	 at	 72	 hours.	 This	
decrease	 is	 explained	 almost	 entirely	 as	 a	 result	 of	 the	 ~12%	 increase	 of	
uninfected	cells	in	G1/G0	between	48	and	72	hours.	G2/M	decrease	is	also	reduced	
between	48	and	72	hours	post	infection	(~%12	to	~6%	respectively,	Figure	3.9C	
and	F).	NS1‐positive	cells	appear	to	have	a	larger	skew	towards	the	S‐phase	and	
away	from	G2/M‐phase	than	non‐NS1	staining	cells	at	48	hours	post‐infection,	for	
both	MOI	(Figure	3.9	D	&	G).	Cell	cycle	profiles	between	NS1	and	non‐NS1	positive	
cells	at	72	hours	post‐infection	however	were	almost	identical	(Figure	3.9	G	&	H).	
The	increased	S‐phase	in	WNV‐infected	cells	compared	with	mock‐infected	cells	is	
noticeable	 when	 observing	 their	 respective	 histograms	 (Figure	 3.9	 I,	 J	 &	 K).
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Figure	3.9.	Bar	 graphs	 representing	 the	 percentage	 of	 cells	 in	 the	G1/G0,	 S	 and	
G2/M	stages	of	the	cell	cycle	in	ARPE19	cells	mock‐infected	or	infected	with	WNV	
at	MOI	 of	 5	 and	 10,	 in	 addition	 to	 a	 graph	 of	 NS1‐positive	 hRPE	 (B).	 Cell	 cycle	
analysis	 was	 performed	 at	 24	 hours	 (A),	 48	 hours	 (C)	 and	 72	 hours	 (F)	 post‐
infection	 by	 the	 flow	 cytometry	 analysis	 of	 ethanol‐fixed	 cells	 stained	 with	
propidium	 iodide	 on	 whole	 ARPE19	 populations.	 The	 percentage	 of	 cells	 in	
different	 stages	 of	 the	 cell	 cycle	 was	 calculated	 using	 the	 Watson	 (pragmatic)	
model	in	Flowjo.	
Cell	 cycle	profiles	were	 compared	between	NS1‐positive	and	NS1‐negative	 cells,	
as	well	 as	mock‐infected	 cells	 at	 48	 hours	 post‐infection	 (D	&	 E)	 and	 72	 hours	
post‐infection	 (G	&	H).	 Significance	 for	 G1/G0‐phase	 is	 represented	 by	 asterisks	
(*),	hashes	for	S‐phase	(#)	and	∅	for	G2/M.	
Representative	 histograms	 of	 DNA	 profiles	 from	 hRPE	 that	were	mock‐infected	
(I),	and	infected	with	WNV	at	an	MOI	of	5	(J)	or	10	(K)	are	also	included.	
Statistical	analysis	was	performed	using	one‐way	ANOVA	with	a	Dunnet	post‐test	
and	 a	 Geisser‐Greenhouse	 correction.	 n=	 4,	 C.I.=95%,	 *=	 p<0.05,	 **=	 p<0.01,	
***=p<0.001,	****=p<0.0001.	
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3.2.8.	WNV‐induced	cell	death	in	hRPE	cells	
 
Cell	death,	as	determined	by	LDH	assay	(described	in	section	2.13),	was	observed	
at	48	hours	post‐infection	(Figure	3.10	A).	Significant	 increases	 in	CASP3,	CASP7	
(Figure	3.10	C	and	D)	and	functional	activity	as	measured	by	the	Caspase‐Glo	3/7	
assay	(described	in	section	2.14,	Figure	3.10	B)	was	observed	variously	across	all	
time	 points	 and	 viral	 titres	 suggesting	 apoptotic	 cell	 death	 as	 a	 result	 of	WNV	
infection	in	hRPE	cells.		
	
In	contrast	however,	for	the	selection	of	genes	involved	in	apoptosis	investigated,	
there	was	little	increase	in	pro‐apoptotic	XIAP,	AIFM1	and	BAX	(Figure	3.11	A,	B	&	
C),	with	a	substantial	and	statistically	significant	increase	in	anti‐apoptotic	genes,	
XAF1	 and	 BIRC3	 (Figure	 3.11	 D	 &	 E).	 No	 significant	 change	 in	 expression	 of	
BCL2L1	(Figure	3.11	F),	was	found	–	this	can	be	anti	or	pro‐apoptotic,	depending	
on	the	isoform	(247).	
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Figure	3.10.	Cell	death	in	mock	and	WNV‐infected	hRPE	cells	at	MOI	of	1,	5	and	
10.	Supernatants	from	cells	were	taken	at	24,	48	and	72	hours	and	levels	of	LDH	
activity	 	 (A)	measured	via	a	 colourimetric	determination	of	 the	 levels	of	 lactose	
dehydrogenase	 in	 supernatant,	 an	 indicator	 of	 cell	membrane	 damage.	 Relative	
values	compared	to	a	total	cell	death	control	were	measured.	Levels	of	activity	of	
the	 pro‐apoptotic	 terminator	 caspases	 3	 and	 7	 were	 also	 determined	 with	 a	
luminescent	 caspase	 substrate‐based	 assay	 (B).	 The	 relative	 mRNA	 levels	 of	
CASP3	 and	 CASP7	 genes	 in	 WNV‐infected	 hRPE	 compared	 with	 mock‐infected	
cells	were	quantified	using	qPCR	(C	&	D).	Statistical	analysis	was	performed	using	
one‐way	 ANOVA	 with	 a	 Dunnet	 post‐test	 and	 a	 Geisser‐Greenhouse	 correction	
(A),	 a	 two‐tailed	 paired	 ratio	 t‐test	 (B)	 and	 two‐tailed	 paired	 t‐test	 on	 the	 Log2	
normalized	 Ct	 values	 (C&D).	 n=	 3	 (A&B),	 n=6	 (C&D),	 C.I.=95%,	 *=	 p<0.05,	 **=	
p<0.01,	***=p<0.001.	
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Figure	3.11.	qPCR	determination	of	relative	levels	of	mRNA	of	apoptosis‐related	
genes	in	hRPE	cells	WNV‐infected	at	MOI	of	1,	5	and	10	at	24,	48	and	72	hours	
post‐infection	relative	to	mock‐infected	cells.	Both	pro	(A,	B	&C)	and	anti–
apoptosis	(D,	E)	genes	were	investigated,	along	with	the	mRNA	of	BCL2L1	(F)	Note	
the	use	of	log	scale	on	the	y‐axis	of	(C),	(D)	and	(E).	Statistical	analysis	was	
performed	using	a	two‐tailed	paired	t‐test	on	the	Log2	normalized	Ct	values.	n=6,	
C.I.=95%,		*	=	p<0.05,	**	=	p<0.01,	***	=	p<0.001.	
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3.2.9	TRAIL/TNFSF10	and	the	TNF‐receptor	superfamily	(TNFRSF)	genes	
Small	statistically	significant	increases	were	noted	for	TNFRSF1A	(Figure	3.12	A)	
with	 larger	 changes	 in	 TNFRSF1B	 (Figure	 3.12	 B)	 for	 WNV‐infected	 hRPE.	
TNFRSF10	was	upregulated	to	very	high	 fold	 from	24	to	48	hours	post‐infection	
across	 all	 MOI	 (Figure	 3.12	 C).	 While	 highly	 statistically	 significant,	 especially	
compared	with	TNFRSF1B	increases,	TNFRSF1A	increases	were	relatively	small,	at	
most	 ~2.7	 fold,	 compared	with	 the	maximum	 >180‐fold	 increase	 in	TNFRSF1B.	
The	 pro‐apoptotic	 receptor	 genes	 TNFRSF10A	 and	 TNFRSF10B	 were	 both	
upregulated	at	48	and	72	hours	post‐infection	(Figure	3.12	D&E),	while	the	anti‐
apoptotic	TNFRSF10D	seemed	to	show	a	downregulation	at	24	and	72	hours	but	
upregulation	 at	 48	 hours	 post‐infection	 (Figure	 3.12	 F),	 however	 these	 changes	
were	not	significant.		
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Figure	 3.12	 qPCR	 determination	 of	 relative	 levels	 of	 mRNA	 from	 TNF‐
related	 apoptosis	 family	 genes	 in	 hRPE	 cells	WNV‐infected	 at	MOI	 of	 1,	 5	
and	10	at	24,	48	and	72	hours	post‐infection	relative	to	mock‐infected	cells.	
The	 genes	 were:	 TNF	 receptors	 TNFRSF1A	 (A),	 and	 TNFRSF1B	 (B),	 the	
ligand	TNFRSF10/TRAIL	 (C)	 and	 genes	 encoding	 the	TNFRSF10	 receptors	
TNFRSF10A	(D),	TNFRSF10B	(E),	TNFRSF10D	(F).	Note	the	log	scale	on	the	
y‐axis	 of	 (A),	 (B),	 (C)	 and	 (D).	 Statistical	 analysis	 was	 performed	 using	 a	
two‐tailed	paired	t‐test	on	the	Log2	normalized	Ct	values.	n=6,	C.I.=95%,		*=	
p<0.05,	**=	p<0.01,	***=p<0.001.	
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3.3.	Discussion	
	
The	 RPE	 plays	 a	 crucial	 role	 in	 the	 recruitment	 of	 leukocytes	 and	 in	
modulating	local	innate	and	adaptive	local	responses	within	the	retina	and	
choroid.	Neuritis,	uveitis	 and	cottonwool	 spots	are	 symptoms	seen	during	
WNV	infection	of	the	eye	result	of	immunological	responses	(191,	211,	248).	
The	 types	 of	 leukocytes	 recruited	 and	 the	 immune	 profiles	 adopted	 once	
recruited	 will	 strongly	 influence	 the	 outcome	 of	 WNV	 infection	 in	 hRPE,	
whether	it	be	complete	viral	clearance	with	minimal	damage,	or	incomplete	
viral	clearance	and	an	ongoing	retinal	inflammation.		
	
CCL5,	 a	 chemoattractant	 for	 memory	 T	 cells,	 monocytes	 and	 eosinophils	
(249)	is	important	in	the	recruitment	of	macrophages	and	T‐cells	to	sites	of	
WNV	 infection,	 both	 of	 which	 are	 essential	 to	 viral	 clearance	 (223,	 250,	
251).	 The	 early	 production	 of	 CCL5	 in	 the	 current	 study	 (Figure	 3.1	 A)	
highlights	 the	significance	of	 this	 chemokine	 in	WNV‐infection	of	hRPE,	 in	
contrast	to	the	production	of	CCL2.	CCL2	is	also	a	powerful	chemoattractant	
for	 inflammatory	 monocytes	 (249)	 and	 has	 been	 shown	 to	 be	 strongly	
upregulated	 in	 infected	 brain	 neurones	 during	 murine	 WNV	 infection.	
Furthermore,	 neutralisation	 of	 this	 chemokine	 extends	 the	 life	 of	 infected	
mice	(201).	From	the	current	study	(Figure	3.1	B),	WNV‐infection	of	hRPE	
may	not	 lead	 to	 significantly	 increased	CCL2‐mediated	chemoattraction	of	
inflammatory	monocytes.	
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The	 relatively	 high	 basal	 expression	 of	 CCL2	 however,	 is	 of	 interest	
(~7ng/ml	 in	 uninfected	 hRPE	 at	 72	 hours‐post‐infection),	 given	 that	
10ng/ml	 of	 recombinant	 CCL2	 can	 induce	 chemotaxis	 in	 10%	 of	 CD8+	 T‐
cells	 in	 a	 luminescence	 based	 in	 vitro	 chemotaxis	 assay	 (252).	 This	 high	
CCL2	 basal	 level	 of	 found	 in	 the	 hRPE	 cell	 cultures	 may	 be	 an	 artificial	
response	 resulting	 from	 the	 differences	 between	 the	 in	 vitro	 and	 in	 vivo	
environment.		
	
The	 noticeable	 increases	 observed	 after	 24	 hours	 post‐infection	 of	 the	
inflammatory	 mediators	 IL6	 and	 IL8	 (Figures	 3.1	 C	 and	 D)	 and	 G‐CSF	
(Figure	3.1	E)	indicate	the	presence	of	a	late	stage	environment	that	could	
potentially	modulate	 recruited	 leukocytes	 by	WNV‐infected	 hRPE,	 despite	
these	increases	not	being	statistically	significant.		
	
Statistically	 significant	 levels	 of	 IFN‐β1	were	 observed	 by	 48	 hours	 post‐
infection,	 roughly	 doubling	 by	 72‐post	 infection.	 However,	 IFNλ‐1	 was	
produced	 at	 even	 higher	 concentrations,	 especially	 at	 24	 hours	 post‐
infection	 (Figure	3.2	B).	These	 temporal	differences	 in	 IFN	subtype	 levels,	
strongly	suggest	that	for	WNV‐infection	of	hRPE,	type	III	interferons	are	the	
predominant	 interferon	during	early	 infection,	and	may	be	responsible	 for	
the	 ISGs	 found	 in	 our	 previous	 microarray	 (which	 looked	 at	 the	
transcriptome	at	24	hours	post‐infection)	(220).	
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The	initial	high	upregulation	of	TNF	in	WNV‐infected	hRPE	cells	at	24	hours	
post‐infection	 that	was	reduced	to	100‐fold	 less	by	48	and	72	hours	post‐
infection	 was	 striking	 (Figure	 3.2	 C).	 Interestingly,	 human	 choroidal	
fibroblasts	 (hCF)	 located	 within	 the	 choroidal	 stoma	 adjacent	 to	 the	 RPE	
upregulated	 TNF	 to	 high	 levels	 but	 maintained	 these	 levels	 for	 up	 to	 72	
hours	 post‐infection	 (Figure	 3.2	 D).	 In	 conjunction	 with	 the	 lack	 of	
detectable	 TNF	 protein	 (Figure	 3.2	 E)	 in	 WNV	 or	 mock‐infected	 hRPE	
supernatant	(as	measured	with	both	Luminex	and	ELISA	assays),	it	strongly	
suggests	 the	 presence	 of	 a	 potent	 post‐translational	 modification	 of	 TNF	
mRNA	 and	 subsequent	 inhibition	 of	 TNF	 protein	 production.	 A	 similar	
action	is	elicited	by	IL‐10,	which	can	inhibit	the	production	of	TNF	without	
affecting	TNF	mRNA	in	LPS‐treated	RAW264.7	cells	(a	macrophage	cell	line)	
(253).	 Currently,	 there	 are	 no	 reports	 in	 the	 literature	 confirming	
production	 of	 IL‐10	 by	 RPE	 cells	 under	 any	 circumstances,	 so	 another	
cytokine	or	mechanism	is	likely	responsible	for	our	TNF	suppression.	
This	 repression	 may	 be	 a	 response	 by	 the	 cell	 to	 avoid	 the	 deleterious	
effects	 of	 TNF,	 such	 as	 MMP9	 production	 (254)	 (which	 can	 lead	 to	
degradation	of	the	outer	BRB	integrity)	and	TNF‐induced	apoptosis	(255).		
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The	classical	MHC‐I	HLAs,	which	interact	with	surveillant	CD8+	T‐cells	and	
form	 an	 important	 part	 of	 the	 self/non‐self	 recognition	 process	 (256),	 all	
showed	 	 a	 similar	 upregulation	 in	 the	 current	 study,	 although	 only	HLAB	
was	 	 statistically	 significantly	 increased.	 HLA‐E,	 a	 non‐classical	 HLA	 is	
involved	in	NK	cell	and	CTL	inhibition	(257)	showed		statistically	significant	
increases	 in	 	mRNA	expression,	 	suggesting	a	possible	survival	strategy	by	
WNV.	 Current	 research	 on	 HLA‐F,	 another	 non‐classical	 HLA	 which	 is	
upregulated	in	this	study,	is	insufficient	to	hypothesize	on	a	possible	role	for	
this	molecule.		
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The	 C3AR1	 protein,	 despite	 its	 name,	 is	 not	 only	 a	 receptor	 for	 the	
anaphylatoxin	C3a,	but	also	 for	C4a.	Expression	of	 this	receptor	occurs	on	
various	cell	types,	although	it	is	normally	expressed	at	relatively	low	levels	
on	 leukocytes	 (258).	 The	 effects	 of	 activation	 of	 this	 receptor	 vary	
depending	 on	 the	 cell	 type,	 ranging	 from	 chemotaxis	 for	 plasmacytoid	
dendritic	 cells	 (259)	 to	 modification	 of	 cell	 migration	 during	 brain	
histogenesis	 (260).	 While	 the	 role	 of	 C3AR1	 in	 hRPE	 has	 not	 been	
elucidated,	research	on	C3AR1	knockout	mice	has	shown	that	 the	absence	
of	the	receptor	results	in	degeneration	of	both	the	neural	retina	(especially	
the	ONL)	and	a	disturbed	RPE	phenotype	after	light	exposure,	which	is	not	
seen	 in	 wildtype	 mice	 for	 the	 given	 exposure	 level	 (261).	 This	 is	 an	
interesting	 finding	 in	 the	 light	 of	 recently	 published	work,	which	 showed	
that	 microglia/macrophages	 producing	 C3	 mRNA	 in	 the	 aged	 rat	 retina	
were	primarily	localised	in	the	retinal	vasculature	and	the	ONL	(262).	These	
older	 rats	 (107	 weeks	 old)	 also	 had	 thinner	 ONL	 than	 younger	 rats	 (14	
weeks	old).	These	two	studies	may	indicate	that	C3	‐	C3AR1	interactions	are	
required	for	maintenance	of	the	aged	neural	retina.	
	
Despite	 the	 reported	 apparent	 absence	 of	 C3AR1	 expression	 in	 hRPE	 in	
human	 retinal	 sections	 from	eyes	with	no	history	of	 ocular	disease	 (263),	
the	presence	of	this	receptor	could	be	increased	in	hRPE	during	ocular	viral	
infection	given	the	in	vitro	increase	observed	in	C3AR1	mRNA	in	this	study.	
If	 this	 is	 the	 case,	 the	 absence	 of	 functional	 C3AR1	 may	 also	 result	 in	
degeneration	of	RPE	and	the	subsequent	loss	of	photoreceptor	function.		
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The	 relatively	 low	 upregulation	 of	 ICAM1	 observed	may	 be	 related	 to	 the	
production	of	 IFN‐β1,	as	 IFN‐β1	 is	believed	to	attenuate	 the	production	of	
ICAM	 during	 viral	 infection	 of	 hRPE	 (264)	 as	 an	 immunoregulatory	
mechanism.	 However,	 ICAM1	 upregulation	 has	 been	 reported	 to	 occur	 in	
cells	 via	 binding	 of	 TNF	 to	 hRPE‐expressed	 TNFRSF1A	 (265).	 Despite	 the	
upregulation	of	TNFRSF1A	in	the	current	study,	given	the	low	mean	levels	of	
detectable	TNF	protein,	it	seems	unlikely	that	ICAM‐1	was	induced	by	TNF	
in	the	current	study.		
While	ICAM1	is	important	in	adhesion	of	various	leukocytes	via	interaction	
with	the	integrin	LFA‐1/CD11a	(that	may	subsequently	be	involved	in	viral	
clearance),	ICAM1	is	also	found	to	be	important	in	WNV	entry	into	the	CNS	
(266)	 and	 thus	 ICAM1	 upregulation	 noted	 in	 the	 current	 study	may	 be	 a	
WNV	replication	strategy	(267).	
	
VEGF	 has	 been	 extensively	 investigated	 related	 to	 its	 role	 in	 new	 vessel	
growth	 in	 exudative	 or	 wet	 AMD	 (268‐270).	 Currently,	 the	 key	 therapies	
targeting	VEGF	for	wet	AMD	involve	intravitreal	injections	of	the	anti‐VEGF	
antibody	 bevacizumab	 and	 the	 VEGF	 binding	 fusion	 protein	 aflibercept	
(271).	 While	 present	 in	 detectable	 quantities	 in	 the	 current	 studies,	 no	
significant	increase	in	VEGFA	protein	was	found	in	WNV‐infected	hRPE	cells	
compared	with	uninfected	cells,	despite	significant	temporal	increases	in	its	
mRNA,	 possibly	 by	 post‐translational	 modifications	 set	 up	 to	 inhibit	 an	
angiogenic	response.	This	suggests	that	any	CNV	manifestations	observed	in	
WNV‐infected	eyes	in	ophthalmic	case	reports	(section	1.8.4)	may	not	be	a	
result	of	hRPE‐produced	VEGFA	over	the	acute	phase	of	the	infection.		
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The	observed	presence	of	IDO1	activity	and	the	lack	of	NOS2	are	consistent	
with	 the	 tryptophan	kynurenine	pathway	being	 favoured	 in	WNV‐infected	
hRPE.	 	 While	 both	 IDO1	 and	 NOS2	 are	 upregulated,	 post‐transcriptional	
processes	 appear	 to	 favour	 reduction	 or	 repression	 of	 nitric	 oxide	
production.	 NOS2	 activity	 has	 been	 determined	 to	 be	 able	 to	 control	
pathogen	replication	or	modulate	immune	responses	in	various	cell	types	in	
response	to	different	pathogens	(226,	246,	272,	273),	including	WNV	(274,	
275).	
	
Co‐staining	 of	 IDO1	 and	WNV	 occurred	 in	 only	 a	 few	 cells	 in	 the	 current	
studies,	 indicating	 that	 stimulation	 of	 IDO1	 production	 is	 likely	 due	 to	 a	
soluble‐factor	mediated	process,	rather	than	a	direct	response	 from	WNV‐
infected	 cells.	While	 several	 papers	 have	 shown	 IDO1	 to	 be	 induced	 as	 a	
result	of	IFN‐γ	stimulation	(230,	276,	277),	this	cytokine	is	produced	solely	
by	leukocytes	(106),	making	this	an	unlikely	cause.	Our	investigations	have	
determined	 that	 the	 production	 of	 IFN‐λ1	 and	 IFN‐λ2	 (but	 not	 IFN‐β1)	 is	
partially	responsible	for	the	production	of	this	enzyme	in	hRPE	in	the	scope	
of	WNV	infection.	Whether	type	III	interferons	are	produced	in	response	to	
other	common	eye	pathogens	in	hRPE	is	unknown	and	will	require	further	
investigation.	
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While	 the	 effect	 of	 IFN‐β1	 in	 WNV	 replication	 in	 hRPE	 cells	 is	 already	
known	and	was	confirmed	by	our	results	(Figure	3.8),	the	increase	of	viral	
replication	in	cells	treated	with	IFN‐λ1	was	quite	surprising.	Only	one	paper	
has	 investigated	 the	 effects	 of	 IFN‐λ1	 on	 WNV	 replication	 (278),	 which	
found	 that	 while	WNV	 infection	was	 reduced	 in	 hepatocyte‐derived	 HU.7	
cells	 and	HeLa	 cells	pre‐	 (24	hours	before	 infection)	 and	post‐treated	 (24	
hours	after	infection)	with	IFN‐α,	WNV	replication	was	not	impeded	in	HeLa	
cells	 post‐treated	 with	 IFN‐λ1,	 suggesting	 that	WNV	 employs	 anti‐IFN‐λ1	
strategy	 that	 is	 cell‐type	 dependent.	 Our	 finding	 of	 increased	 viral	
replication	with	 IFN‐λ1	suggests	 that	 this	cytokine	on	 its	own	may	 induce	
an	ISG	profile	that	is	more	permissive	to	WNV	infection.	While	treatment	of	
hRPE	cells	with	IFN‐λ2	(not	measured	in	WNV	supernatants	due	to	lack	of	
suitable	ELISA)	does	not	 increase	or	decrease	viral	 replication,	 combining	
IFN‐λ1	 and	 IFN‐λ2	 appears	 to	 abrogate	 the	 pro‐WNV	 effect	 of	 IFN‐λ1	
(Figure	3.8),	 suggesting	 that	while	 the	 two	 IFN‐λs	have	overlapping	 roles,	
they	can	exert	regulatory	effects	on	each	other.	The	combination	of	IFN‐λ1	
and	IFN‐λ2	with	IFN‐β1	does	not	appear	to	add	to	or	diminish	the	anti‐WNV	
replicative	effect	of	IFN‐β1.	
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While	 RPE‐mediated	 IDO	 activity	 has	 been	 shown	 to	 have	 antimicrobial	
activity	(246,	279)	and	IDO	has	antiviral	activity	against	WNV	in	monocyte‐
derived	macrophages	 (274),	 the	WNV‐induced	 IDO1	activity	 in	hRPE	cells	
we	 observed	 is	 not	 likely	 to	 be	 anti‐viral	 in	 these	 cells	 given	 the	 lack	 of	
increased	 viral	 production	when	 infected	 cultures	 are	 supplemented	with	
tryptophan,	or	 the	meagre	 increase	noted	with	one	of	 the	 IDO1	 inhibitors	
(Figure	 3.8).	 Instead	 it	 is	 likely	 that	 IDO	 activity	 is	 a	 method	 of	
immunomodulation	 as	 noted	 by	 other	 studies	 (272,	 280),	 to	 limit	 the	
damage	leukocytes	can	inflict	on	the	retina	during	WNV‐infection.	
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Given	that	IFN‐β	has	been	shown	to	induce	S‐phase	arrest	in	lymphoma	and	
glial	 cells	 (281,	 282),	 whether	 the	 S‐phase	 arrest	 noted	 in	 the	 current	
studies	is	a	direct	result	of	WNV	infection	or	subsequent	production	of	IFN‐
β,	or	a	combination	of	both	 is	nor	clear.	However,	analysing	the	data	with	
respect	 to	WNV	 NS‐1	 staining,	 several	 clues	 to	 the	 mechanisms	 involved	
may	be	suggested.		As	the	presence	of	WNV	NS1	generally	indicates	actively	
replicating	WNV	(283),	cells	staining	positive	for	WNV	NS1	are	likely	to	be	
shedding	virus.	Within	WNV‐infected	hRPE	cells	at	48	hours	post‐infection,	
NS1‐positive	 cells	 had	 a	 reduced	 S‐phase	 percentage	 increase	 and	 G2/M	
phase	 decrease	 compared	 to	 NS1‐negative	 cells	 	 (Figure	 3.9	 D	 &	 E).	 The	
higher	 incidence	 of	 NS1‐negative	 S‐phase	 cells	 strongly	 suggests	 these	
changes	are	driven	in	part	by	the	release	of	a	soluble	factor	rather	than	the	
replicative	 mechanisms	 of	 the	 virus,	 given	 that	 these	 cells	 are	 either	
currently	uninfected	and/or	do	not	contain	replicative	WNV.	Given	the	pro‐
WNV	 effect	 of	 IFNλ‐1	 in	 hRPE	 (Figure	 3.8),	 it	would	 be	 interesting	 to	 see	
how	 this	 cytokine	affects	 the	 cell	 cycle.	 It	 is	 feasible	 that	pre‐treatment	of	
hRPE	 cells	 with	 this	 cytokine	 shifts	 the	 population	 towards	 a	 cell	 cycle	
phase	 that	 is	 more	 receptive	 to	 viral	 invasion/replication.	 Further	
experiments	would	be	required	to	investigate	this	hypothesis,	as	well	as	the	
effects	 IFNλ1	 may	 have	 on	 hRPE	 replication,	 and	 whether	 IFNλ2	
counteracts	IFNλ1	at	the	cell	cycle	level.	
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Both	TNF‐depleted	mice	and	TNFRSF1A	knockout	mice	infected	with	WNV	
had	 lower	 survivability	 compared	 with	 wild‐type	 mice,	 highlighting	 the	
importance	 of	 TNF/TNFRSF1A	 interactions	 in	 controlling	 cerebral	 WNV	
infection.	This	reduced	survivability	was	attributed	to	impaired	CD8+	T‐cell	
recruitment	(284).	The	lack	of	TNF‐mediated	CD8+	T‐cell	responses	may	be	
a	measure	of	reducing	leukocyte	mediated‐damage	to	the	retina,	at	a	cost	of	
reduced	viral	clearance.	
	
	Given	the	higher	TNFRSF1B	upregulation	compared	with	TNFRSF1A,	WNV	
infection	 in	 hRPE	 appears	 to	 favour	 a	 TNFRSF1B‐mediated	 response	 to	
exogenous	 TNF	 over	 TNFRSF1A‐mediated	 responses.	 The	 higher	
predisposition	 of	 TNFRSF1A‐mediated	 TNF	 signalling	 compared	 with	
TNFRSF1B	 within	 the	 current	 study	 may	 indicate	 WNV‐infected	 hRPE	
become	 skewed	 away	 from	 a	 pro‐apoptotic	 response	 in	 the	 face	 of	
exogenous	TNF	that	would	be	produced	by	various	other	cells	in	the	vicinity	
in	response	to	WNV	infection	in	vivo.	
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With	 the	 presence	 of	 other	 ISGs	 in	 WNV	 infected‐hRPE,	 it	 would	 be	
reasonable	 to	 assume	 that	 the	 high	 upregulation	 of	 TNFSF10	 observed	 in	
the	 current	 studies	 plays	 a	 role	 in	 the	 anti‐viral	 response	 of	 the	 immune	
system.	Murine	 TRAIL‐R	 (homologous	 to	 human	DR4	 and	DR5)	 knockout	
mice	show	an	increased	anti‐viral	response	to	murine	CMV	(285),	TNFSF10	
may	 play	 a	 role	 in	 the	 regulation	 of	 the	 immune	 response	 to	 the	 virus,	
possibly	by	 inhibiting	TLR	 signalling	 (285).	While	 in	CMV‐infected	human	
foreskin	 fibroblasts,	 DR4	 and	 DR5	 expression	 was	 upregulated,	 and	 was	
correlated	 with	 TNFSF10‐mediated	 cell	 death.	 Thus,	 TNFSF10	 signalling	
through	 its	 pro‐apoptotic	 receptors	 can	 have	 deleterious	 consequences	
during	 viral	 infection,	 both	 through	 apoptotic	 and	 non‐apoptotic	
mechanisms.	
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The	 relatively	 low	 expression	 of	 pro‐apoptotic	 TNFSF10	 receptors	
(TNFRSF10A	and	TNFRSF10B)	versus	the	high	TNFSF10	in	the	current	study	
suggests	 that	 immune	modulation	 of	 leukocytes	 is	 a	more	 likely	 outcome	
than	 an	 autocrine‐based	 self‐apoptotic	 mechanism	 by	 hRPE	 cells	 during	
WNV	infection.	This	is	further	reinforced	by	the	relatively	low	rate	of	WNV‐
induced	cell‐death	observed	in	hRPE	(~≤20%	by	72‐h	post‐infection,	Figure	
3.12	A).	Additionally,	upregulation	of	TNFSF10,	TNFRSF10A	and	TNFRSF10B	
has	 been	 reported	 in	 cultured	 hRPE	 cells	 (passage	 number	 0)	 when	
compared	to	freshly	isolated	hRPE,	but	without	a	corresponding	increase	in	
cell	death.	However,	the	authors	attributed	this	finding	to	parallel	increases	
in	 the	anti‐apoptotic	TNFRSF10C	and	TNFRSF10D	mRNA	(286),	which	was	
not	seen	in	the	current	study.	While	the	downregulation	of	TNFRSF10D	may	
appear	to	be	a	pro‐apoptotic	response,	despite	the	presence	of	an	apparent	
non‐functional	 death	domain,	 binding	 of	 TNFSF10	 to	TNFRSF10D	 induces	
NF‐κB	signalling	(287),	which	may	have	functional	effects	beyond	the	anti‐
apoptotic	ones,	and	it	may	be	these	effects	that	the	WNV‐infected	hRPE	may	
need	to	abrogate,	such	as	TNFRSF10D‐mediated	cell	proliferation	(288).	
	
Currently,	 only	 one	 study	 has	 examined	 the	 effects	 of	 TNFSF10	 in	 the	
context	of	WNV	infection;	this	study	suggests	that	TNFSF10	is	important	in	
controlling	 WNV	 infection	 in	 cortical	 neurons,	 via	 CD8+	 T‐cells	 (289).		
Defining	 the	 role(s)	 of	 the	 upregulation	 of	TNFSF10	 and	 its	 pro‐apoptotic	
receptors	in	WNV‐infected	hRPE	requires	further	study	using	both	 in	vitro	
and	in	vivo	models.			
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Taken	together,	the	findings	in	this	chapter	illustrate	the	various	effects	of	
WNV	infection	on	the	anti‐viral	defences	and	immune	modulating	strategies	
that	 may	 be	 induced	 in	 hRPE	 cells.	 These	 findings	 also	 highlight	 the	
susceptibility	 of	 hRPE	 to	 WNV‐mediated	 cell	 death,	 elucidate	 several	
possible	 mechanisms	 that	 may	 underlie	 this	 observation,	 and	 provide	
further	 insights	 as	 to	 potential	 markers	 or	 mechanisms	 that	 may	 be	
involved	 in	 the	 dysregulated	 immune	 environment	 involved	 in	 the	
pathogenesis	of	AMD.	Additionally,	the	effects	of	WNV	on	the	cell	cycle	and	
production	 of	 cytokines	 in	 hRPE	 provided	 the	 rationale	 for	 further	
investigations	 using	 this	 model	 of	 outer	 BRB	 breakdown	 and	 immune	
dysregulation	in	vitro	(Chapter	4)	and	in	vivo	(Chapter	5).		
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Chapter 4: WNV‐mediated changes in hRPE 
barrier integrity 
	
4.1.	Introduction	
 
The	 retinal	 pigment	 epithelium	 (RPE)	 maintains	 a	 tight	 barrier,	 with	 the	
outer	blood	retinal	barrier	(BRB)	so	formed,	separating	the	choriocapillaris	
and	 the	 neural	 retina.	 The	 choroidal	 capillaries	 are	 fenestrated	
predominantly	 on	 the	 apical	 side	 adjacent	 to	 the	 RPE.	 They	 maintain	 an	
oxygen	and	nutrient	 gradient	 supplying	 the	outer	 retina,	while	 selectively	
limiting	 the	 transcellular	 and	 paracellular	 passage	 of	 macromolecules	
across	 it.	 Epithelial	 tight	 junctions,	 generated	 and	 regulated	 by	 complex	
molecules	 such	 as	 zonula	 occludens‐1	 (ZO‐1),	 E‐catenin	 and	 ZONAB,	
between	RPE	cells	are	clearly	important	in	maintaining	the	selectivity	of	the	
paracellular	seal,	but	the	mechanism(s)	for	the	control	and	maintenance	of	
this	seal	are	not	well	understood	(30).	Breakdown	of	this	barrier	occurs	in	
exudative	 age‐related	 macular	 degeneration	 (AMD)	 and	 other	 exudative	
retinopathies,	where	anatomical	disruption	by	choroidal	neovascularisation	
and	leakage	of	macromolecules	beyond	the	RPE	is	associated	with	gradually	
increasing	blindness	(290).		
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Apart	from	mechanical	disruption	of	the	RPE,	the	integrity	of	the	RPE	may	
also	 be	 altered	 by	 viral	 infection.	 The	 RPE	 is	 a	 target	 of	 viral	 infection,	
particularly	 in	 the	 immunosuppressed	 patient	 (291).	 Reports	 have	 also	
implicated	the	emerging	flavivirus,	West	Nile	virus	(WNV),	in	chorioretinitis	
and	uveitis	(292‐294).	
How	WNV	gains	entry	into	the	CNS	is	currently	unknown.	Following	the	bite	
of	an	infected	mosquito,	local	replication	is	followed	by	viraemia	and	spread	
to	 other	 organs,	 including	 the	 CNS.	 Entry	 into	 the	 CNS	 via	 fenestrated	
endothelium	at	the	olfactory	epithelium	has	been	inferred	from	the	kinetics	
of	 flaviviral	 spread	 in	murine	models	 of	Murray	Valley	 encephalitis	 (295)	
and	 Saint	 Louis	 encephalitis	 (296).	 Endothelial	 fenestrations	 are	 also	
present	in	the	choriocapillaris,	adjacent	to	the	RPE,	raising	the	question	of	
whether	viral	infection	of	the	RPE	could	occur	via	this	route.	Alternatively,	
phagocytosis	 of	 apoptotic	 rod	 outer	 segment	 photoreceptors	 by	 RPE	may	
enable	 the	 transmission	 of	 WNV	 from	 infected	 neuronal	 tissue	 to	 RPE.		
Furthermore,	a	case	report	suggested	that	WNV	transmission	into	the	retina	
could	occur	via	the	optic	nerve	from	infected	CNS	(218).	
Previously,	 we	 found	 that	 WNV	 infection	 in	 hRPE	 results	 in	 substantial	
upregulation	 of	 TNF	 mRNA	 (220)	 although	 in	 the	 absence	 of	 detectable	
protein.	TNF	has	been	implicated	in	several	BBB	and	BRB	studies	to	play	a	
significant	role	 in	 the	degradation	of	 the	barrier	 integrity	 (200,	297,	298).	
Whether	this	can	occur	 in	the	absence	of	significant	protein	 is	unclear	but	
TNF	is	readily	produced	by	cells	adjacent	to	the	blood	barriers,	whether	of	
structural	or	leukocyte	origin,	in	response	to	infection.	
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The	presence	of	CNV	in	ophthalmological	cases	of	WNV	infection	(293,	299)	
also	lends	credence	to	the	idea	that	WNV	infection	in	the	eye	results	in	BRB	
breakdown.	 Whether	 the	 breakdown	 is	 a	 result	 of	 innate	 or	 adaptive	
mechanisms	or	a	combination	of	both	is	unknown.	
In	 this	 study	 we	 show	 that	 West	 Nile	 virus	 infection	 of	 the	 RPE	 in	 vitro	
resulted	in	increased	transendothelial/epithelial	resistivity	(TEER).	This	did	
not	 correspond	 with	 the	 upregulation	 in	 expression	 of	 various	 cellular	
adhesion	 molecules,	 but	 was	 associated	 with	 morphologically	 detectable	
increases	 in	 the	density	 of	 ZO‐1	 and	E‐catenin,	 involved	 in	 tight	 junctions	
between	 these	 cells.	 Additionally,	 we	 looked	 at	 changes	 in	 mRNA	
production	of	several	proteins	 involved	 in	 the	 formation	and	maintenance	
of	 outer	 BRB	 integrity,	 as	 well	 as	 mRNA	 and	 protein	 levels	 of	 several	
cytokines	known	to	have	a	role	in	barrier	integrity.	Finally,	we	investigated	
the	 effects	 of	 previously	 measured	 cytokine	 levels,	 on	 their	 own	 and	 in	
combination,	 on	 the	 electrical	 impedance	 levels	 (a	 measure	 analogous	 to	
TEER)	 of	 WNV‐infected	 hRPE	 using	 the	 Real‐Time	 Cell	 Analysis	 System,	
Single	Plate	(RTCA‐SP).	
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4.2.	Results	
 
4.2.1.	Increases	in	TEER	and	Adhesion	Molecule	Expression	on	RPE	after	WNV	
infection	
	
Figure	 1A	 shows	 a	 representative	 graph	 of	 the	 aggregated	 TEER	 values	
measured	 at	 the	 intervals	 indicated	 from	 0‐150	 h	 across	 triplicate	
monolayers	of	RPE	grown	in	Transwells	and	infected	with	WNV	at	either	10	
pfu/cell	 or	 5pfu/cell	 or	mock‐infected.	 TEER	was	measured	 as	 previously	
described	in	(300).	Briefly,	using	the	Millipore	Electrical	Resistance	System,	
the	 resistance	 between	 electrodes	 placed	 above	 and	 below	 the	 hRPE	
monolayer	was	measured.	 In	 infected	monolayers	at	both	multiplicities	of	
infection,	 a	 statistically	 significant	 increase	 in	 the	 TEER	 was	 clearly	
demonstrable	 at	 24	 and	 48	 h,	 compared	 to	 mock‐infected	 control	
monolayers.	After	48	h,	the	TEER	gradually	decreased	with	time,	compared	
to	 the	 mock‐infected	 controls,	 which	 maintained	 a	 relatively	 high	 TEER	
until	the	termination	of	the	assay	at	150	h.	This	experiment	was	completed	
in	triplicate	with	5	biological	replicates.	
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Flavivirus	 infection	 is	 accompanied	 by	 upregulated	 expression	 of	 several	
different	cell	surface	molecules	(267,	301‐304).	We	thought	it	possible	that	
these	 molecules	 might	 enhance	 the	 tightness	 of	 cell‐cell	 junctions	 in	
infected	monolayers	and	that	the	changes	in	TEER	could	be	related	to	this.	
Therefore,	we	examined	the	kinetics	of	expression	of	a	range	of	cell	surface	
adhesion	 molecules.	 These	 included	 Immunoglobulin	 Superfamily	 (IgSF)	
molecules,	 ICAM‐1,	 VCAM‐1	 and	 Class	 I	 and	 II	 major	 histocompatibility	
complex	antigens	(MHC‐I	and	II),	the	selectin,	CD62E	(E‐selectin),	and	CD31	
(PECAM).	 Figure	 4.1B	 shows	 the	 expression	 of	 cell	 surface	 ICAM‐1	 and	
MHC‐I	 on	 RPE	 after	 WNV	 infection	 at	 various	 intervals	 from	 0‐72	 h,	 as	
determined	by	flow	cytometry.	It	can	be	seen	that	both	ICAM‐1	and	MHC‐I	
increase	 over	 time	 with	 expression	 from	 24	 h	 onwards	 becoming	
increasingly	statistically	significant	 for	both	molecules	compared	to	mock‐
infected	RPE.	
No	expression	of	CD106,	MHC‐II,	CD62E	or	CD31	was	observed	in	this	time	
and	no	changes	occurred	at	any	of	the	timepoints	after	WNV	infection	(data	
not	 shown).	 Thus	 over	 the	 period	 in	 which	 the	 TEER	 increased	 in	 RPE	
monolayers,	 there	 was	 no	 temporal	 association	 with	 the	 kinetics	 of	
changing	 expression	 of	 these	 molecules	 associated	 with	 WNV	 infection.	
There	 was	 a	 significant	 decrease	 in	 cell	 viability	 in	 WNV‐infected	 hRPE	
when	compared	to	uninfected	cells	as	seen	in	the	previous	chapter	(Figure	
3.10),	 while	 flow	 cytometry	 actually	 showed	 an	 increase	 in	 MHC‐I	 and	
ICAM‐I	surface	expression	in	WNV‐infected	hRPE.	
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Figure	4.1.	Measurements	of	transepithelial	resistance	(A),	and	MHC‐I	and	
ICAM	levels	(B)	 in	both	uninfected	and	WNV‐infected	hRPE	across	various	
multiplicities	 of	 infection	 and	 post‐infection	 timepoints.	 TEER	
measurements	 were	 investigated	 using	 a	 Millipore	 ERS	 resistance	 meter	
and	 showed	 an	 initial	 increase	 in	 TEER	 in	 WNV‐infected	 cells	 before	
dropping	 when	 compared	 to	 mock‐infected	 cells.	 Statistical	 analysis	 was	
performed	 using	 a	 2‐tailed	 t‐test.	 C.I.	 >95%*	 =	 p<0.05,	 **	 =	 p<0.01,	 n=5.	
Figure	is	produced	from	data	generated	by	Li	Wen.	
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4.2.2.	WNV	infection	affects	localization	of	ZO‐1	and	E‐catenin	in	hRPE	in	a	time‐
dependent	manner.	
	
hRPE	 cells	 used	 in	 Figure	 4.2	were	 fixed	with	 4%	 paraformaldehyde	 and	
permeabilized	 with	 0.05%.	 WNV‐infected	 and	 mock‐infected	 RPE	 were	
stained	 for	 CD31,	 ZO‐1,	 and	 E‐catenin	 on	 coverslips.	 No	 constitutive	
expression	of	CD31	or	changes	 in	expression	 induced	after	WNV	 infection	
was	observed	(data	not	shown).	
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Figures	4.2A,	C	and	E	shows	the	expression	of	ZO‐1,	demonstrated	by	dual	
colour	 immunohistochemical	 staining	 and	 confocal	 fluorescence	
microscopy.	It	can	be	seen	that	intensity	of	ZO‐1	staining	in	infected	cells	at	
the	 junction	 borders	 and	 nucleus,	 had	 increased	 by	 48	 h	 after	 infection	
(Figure	 4.2C)	 compared	 to	 mock‐infected	 RPE	 (Figure	 4.2A)	 and	 by	 96	
hours	post‐infection,	staining	was	dimmer	and	diffused	throughout	the	cell	
(Figure	4.2E).	This	was	associated	with	detectable	infection	of	some,	but	not	
all,	 of	 these	 cells	 at	 these	 timepoints	 (Figure	 4.2D	 and	 F),	 compared	 to	
mock‐infected	 RPE	 (Figure	 4.2B).	 These	 changes	were	 not	 as	 obvious	 for	
E	catenin,	the	density	of	which	had	increased	marginally	at	48	hours	post‐
infection	 (Figure	 4.2	 I)	but,	 similar	 to	 ZO‐1,	 had	 also	 become	 fragmented	
and	began	to	disappear	by	96	h	(Figure	4.2	K),	compared	to	mock‐infected	
(Figure	4.2	G).	Figures	4.2	H,	J	and	L	show	the	distribution	of	infected	cells	
in	 these	 fields	 of	 view,	 which	 is	 patchy	 in	 WNV‐infected	 cultures.	 To	
investigate	 whether	 these	 changes	 corresponded	 to	 changes	 in	 protein	
levels,	mock‐infected	and	WNV‐infected	hRPE	were	stained	for	ZO‐1	and	E‐
catenin	and	 their	 levels	were	measured	by	 flow	cytometry	 (Figures	4.2	M	
and	N,	respectively).	While	each	of	 these	molecules	was	clearly	expressed,	
there	 were	 no	 detectable	 changes	 in	 expression	 of	 these	 molecules	 after	
WNV	infection	between	0	and	48	h.	Figure	4.2	images	and	histograms	were	
provided	by	Li	Wen.
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Figure	 4.2.	 Confocal	 images	 (A‐L)	 and	 flow	 cytometry	 results	 (M,	 N)	 of	
hRPE	 labelled	 for	ZO‐1,	β–catenin	and	WNV‐NS1	 in	hRPE	cells.	hRPE	cells	
show	distinct	staining	of	ZO‐1	and	β–catenin	at	the	tight	junction	interfaces	
between	 cells	 in	 uninfected	 cells	 (A,	 G)	 while	 staining	 of	 ZO‐1	 in	 WNV‐
infected	 cells	 at	 48	 hours	 post‐infection	 show	 an	 increase	 of	 intensity	 at	
both	 the	 junctions	 and	 nucleus.	 At	 72	 hours‐post	 infection,	 ZO‐1	 shows	
diffuse	 staining,	 which	 correlates	 with	 β–catenin.	 β–catenin	 at	 48	 hours	
showed	a	gradual	decrease	in	junction	staining	intensity.	Flow	cytometry	of	
fluorescence‐labelled	 infected	 vs	 mock‐infected	 cells	 at	 48	 hours	 post‐
infection	 did	 not	 show	 any	 changes	 in	 ZO‐1	 (M)	 or	 β–catenin	 (N)	 protein	
levels	 in	 the	 cells,	 suggesting	 that	 the	 observed	 changes	 were	 due	 to	
rearrangements	 of	 these	 proteins,	 rather	 than	 increase	 in	 production	 or	
degradation.	
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4.2.3.	E‐cadherin	is	downregulated	while	ZONAB	is	upregulated,	and	MMP9	is	
upregulated	in	WNV‐infected	RPE	but	without	changes	in	activity.		
	
Figure	4.3	C	shows	a	1.8	 to	2.5	 fold‐increase	 in	mRNA	expression	of	CSDA	
(ZONAB)	 in	WNV‐infected	 hRPE,	 compared	with	mock‐infected	 cells	 from	
48	 hours	 post‐infection,	 while	 CDH1	 (E‐cadherin)	 shows	 a	 3‐fold	 and	 2.5	
fold	 decrease	 in	 mRNA	 expression	 in	 cells	 at	 24,	 48	 and	 72	 hours	 post‐
infection	(Figure	4.3	E).		
Figure	4.3	H	shows	a	general	increase	in	MMP9	mRNA	production	however,	
due	 to	 variability	 between	 donors,	 these	 increases	 are	 only	 statistically	
significant	 across	 all	 MOI	 at	 72	 hours	 post‐infection.	 Single	 significant	
results	 occur	 in	 OCLN/occludin	 (72	 hours	 post‐infection,	 MOI	 10,	 Figure	
4.3D)	and	MMP2	(24	hours	post‐infection,	MOI	1,	Figure	4.3G).	
Zymography	gels	 (performed	as	described	 in	 section	2.19,	 Figure	4.4)	did	
not	 show	 the	 presence	 of	 MMP9	 protein	 in	 hRPE	 supernatant	 in	 either	
mock‐	or	WNV‐infected	cells.	Active	MMP2	(63kDa)	was	present	in	all	hRPE	
cell	cultures,	however	there	was	no	difference	 in	enzyme	activity	between	
the	supernatants	derived	from	infected	and	uninfected	cells	(Figure	4.5).	
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Figure	4.3.	Graphs	of	the	fold	changes	of	CTNNB1/β‐catenin	(A),	TJP1/ZO1	
(B),	CSDA/ZONAB	 (C),	OCLN/occludin	 (D),	CDH1/E‐cadherin	 (E),	CDH2/N‐
cadherin	 (F),	MMP2	 (G),	MMP9	 (H)	 and	 TIMP2	 (I)	 transcription	 in	WNV‐
infected	hRPE	compared	to	mock‐infected	cells.	Note	the	dissimilar	axes	of	
(H)	 compared	 with	 the	 other	 graphs.	 This	 is	 due	 to	 the	 difference	 in	
dynamic	 range	 of	 this	 gene	 compared	with	 the	 others.	 Statistical	 analysis	
was	 achieved	 via	 the	 Genex	 program	 (MultiD	 Analyses	 AB,	 Götenborg,	
Sweden).	 Briefly,	 gene	 Ct	 results	were	 normalized	 against	 reference	 gene	
Ct’s,	before	being	normalized	to	a	relative	value	with	respect	to	the	highest	
Ct	value.	The	data	was	then	converted	to	log2	scale	before	being	subject	to	a	
parametric	t‐test.	*	p	<0.05,	**	p<0.01,	n=6.		
 
 
  
  164
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Figure	 4.4.	 Images	 of	 zymography	 gels	 (8%	 w/v	 acrylamide,	 1%	 w/v	
porcine	 gelatin)	 using	 supernatant	 from	 hRPE	 cells	 that	 had	 been	 mock‐
infected	or	infected	at	an	MOI	of	1	or	5	of	WNV,	collected	at	48	hours	(left)	
or	72	hours	post‐infection	(right).	Cells	were	grown	in	serum‐free	medium	
supplemented	 with	 ITS+3	 liquid	 media	 supplement.	 Recombinant	 human	
MMP2	 and	MMP9	were	 used	 as	 a	 positive	 control	 (P.C.),	 and	 all	 samples	
were	 run	 with	 a	 protein	 ladder.	 Images	 were	 taken	 before	 and	 after	
coomassie	blue	staining,	in	order	to	place	protein	ladder	standards	onto	the	
zymography	image.		
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Figure	 4.5.	 Fold	 change	 differences	 in	 zymography	 activity	 between	
supernatant	samples	derived	from	hRPE	cells	infected	with	WNV	at	an	MOI	
of	 5	 or	 10,	 compared	with	mock‐infected	 cells.	 Zymographic	 activity	 was	
measured	via	densitometry	using	the	Biorad	Image	Lab	software.	Statistical	
analysis	was	performed	using	a	paired	ratio	t‐test.	
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4.2.4	TGFβ	transcription	and	production	is	not	increased	in	WNV‐infected	cells	
 
As	 treatment	 of	 RPE	 cells	 with	 TGFβ	 can	 induce	 epithelial‐mesenchymal	
transition	(EMT)	(305,	306),	and	result	in	a	drop	in	TEER	in	other	cell	types	
(307,	308),	we	looked	at	both	the	protein	and	mRNA	levels	of	TGFβ‐1	and	
TGFβ‐2	in	mock	and	WNV‐infected	hRPE.	Figure	4.6	shows	the	fold	changes	
of	 TGFB1	 and	 TGFB2	 in	 infected	 cells,	 compared	 to	 mock‐infected	 cells.	
Neither	 of	 these	 genes	 shows	 a	 significant	 change	 and	 correspondingly,	
neither	 the	 levels	 of	 TGFβ‐1	 or	 2.	 While	 neither	 protein	 shows	 as	
statistically	significant	change,	we	can	see	a	decreasing	trend	with	TGFβ‐2	
in	infected	cells	at	the	protein	level.	
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Figure	4.6.	Fold	changes	of	TGFβ	mRNA	in	WNV‐infected	hRPE,	relative	to	
mock‐infected	cells	(A)	and	supernatant	levels	of	TGFβ	protein	from	mock‐
infected	 and	 WNV‐infected	 hRPE	 cells	 (B).	 No	 statistically	 significant	
changes	 between	 infected	 and	 uninfected	 cells	 of	 either	mRNA	or	 protein	
levels	of	TGFβ‐1	or	2	was	observed	at	any	timepoint	examined,	despite	the	
previously	 observed	 increase	 in	 TER.	 Statistical	 analysis	 for	 (A)	 and	 (B)	
achieved	via	the	Genex	program	(MultiD	Analyses	AB,	Götenborg,	Sweden).	
Briefly,	gene	Ct	results	were	normalized	against	reference	gene	Ct’s,	before	
being	 normalized	 to	 a	 relative	 value	with	 respect	 to	 the	 highest	 Ct	 value.	
The	 data	 was	 then	 converted	 to	 log2	 scale	 before	 being	 subject	 to	 a	
parametric	t‐test.	Statistical	analysis	for	(C)	and	(D)	was	performed	using	a	
paired	ratio	t‐test.	n=6	(A)	n=4	(B).	
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4.2.5	Initial	TEER	increase	in	WNV‐hRPE	may	not	be	TLR3/RIG‐I	mediated.	
 
hRPE	 cells	 were	 treated	 with	 a	 selected	 set	 of	 cytokines,	 neutralizing	
antibodies	and	chemicals	as	listed	in	Table	2.1	in	Chapter	2.	Cytokines	were	
tested	in	a	range	of	half‐log	concentrations	as	listed	in	the	Table	2.1,	as	well	
as	 in	 combination	 as	 listed	 in	Table	4.1.	 Cytokines	 tested	on	 the	RTCA‐SP	
system	 were	 cytokines	 that	 had	 previously	 shown	 to	 increase	 in	 protein	
production	 in	 our	 experiments	 (such	 as	 CCL2	 and	 IL6)	 or	 with	 known	
effects	on	BRB	or	BBB	integrity,	such	as	TNF	(298)	or	VEGF	(309).	
None	 of	 the	 cytokines	 tested	 had	 any	 statistically	 significant	 effect	 on	 the	
electrical	 impedance	(functional	equivalent	of	TEER)	of	 the	cells	 (data	not	
shown),	 as	 measured	 by	 the	 RTCA	 SP	 assay	 with	 the	 exception	 of	 an	
increase	in	hRPE	cells	treated	with	the	S‐nitro‐N‐acetyl‐DL‐penicillamine	as	
a	 positive	 control.	 Figure	 4.7	 shows	 the	 ratio	 of	 electrical	 impediance	
output,	 compared	 to	 the	 values	 obtained	 when	 the	 cells	 were	 originally	
plated	 onto	 the	 electrical	 resistance	 plate	 (Cell	 Index).	 As	 seen	 here,	 the	
addition	of	the	TLR3/RIG‐I	agonist,	poly	I:C,	did	not	induce	a	differential	cell	
index	 compared	 with	 mock‐infected	 cells.	 The	 addition	 of	 the	 TLR3	
inhibitor	CuCPT	4a	also	did	not	affect	the	cell	 index	of	WNV‐infected	cells,	
when	compared	with	untreated	WNV‐infected	cells.	
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Proteins tested solo on 
hRPE using the RTCA‐
SP system 
Protein combinations 
tested with hRPE using the 
RTCA‐SP system 
CCL2  CCL2, CCL5 
CCL5  IL6, IL8 
IL6  TNF, VEGF 
IL8  GM‐CSF, G‐CSF 
TNF  IFNL1, IFNL2 
G‐CSF  IFNL1, IFNL2, IFNB1 
GM‐CSF  CCL2, CCL5, IL6, IL8 
IFNB1  CCL2, CCL5, TNF, VEGF 
IFNL1  CCL2, CCL5, GM‐CSF, G‐CSF 
IFNL2  IL6, IL8, GM‐CSF, G‐CSF 
VEGF  CCL2, CCL5, IL6, IL8, TNF, 
VEGF, GM‐CSF, G‐CSF, 
IFNL1, IFNL2, IFNB1 
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Table	 4.1.	 Table	 of	 recombinant	 human	 cytokines	 and	 cytokine	
combinations	 used	 to	 treat	 hRPE	 cells	 for	 RTCA	measurements.	 Cytokine	
concentrations	used	 in	 the	 combinations	are	as	 follows:	20ng/ml	 	 (CCL2),	
5ng/ml	 (CCL5),	 10ng/ml	 (IL6),	 5ng/ml	 (IL8),	 3.16ng/ml	 (TNFα),	 1ng/ml	
(GM‐CSF),	 2ng/ml	 (G‐CSF),	 5ng/ml	 (IFN‐λ1),	 5ng/ml	 (IFN‐λ2),	 1.58ng/ml	
(IFN‐β1).	
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Figure	4.7.	Graph	of	cell	index	as	measured	by	the	Real	Time	Cell	Analysis‐	
Single	Plate	system,	of	hRPE	cells	taken	at	every	3	hours.	Cells	were	mock‐
infected,	infected	with	WNV	at	an	MOI	of	5,	treated	with	poly	I:C	(1µg/ml),	
TLR3	inhibitor	CuCPT	4a	(5mM),	or	a	combination	of	WNV	plus	CuCPT	4a.	
Note:	 The	 x‐axis	 starts	 from	 3	 hours	 post‐infection/treatment	 and	 error	
bars	have	been	omitted	for	clarity,	due	to	the	large	error	bars	as	a	result	of	
variability	between	donor	hRPE	responses.	N=4.	
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4.3	Discussion	
Due	to	the	relatively	recent	spread	of	WNV	across	the	western	hemisphere	
and	 ongoing	 spikes	 of	 neuroinvasive	 cases	 (310),	 it	 is	 likely	 that	 further	
occurrences	 of	 WNV	 ophthalmic	 manifestations	 will	 continue	 to	 occur.	
These	cases	may	also	have	implications	for	patient	health	beyond	the	acute	
condition.	
Chronic	 infection	 of	WNV	 is	 seen	 in	 certain	 cases	 (311)	 and	may	 lead	 to	
recurrent	 symptoms	 in	 several	 organs,	 including	 the	 eye.	 Indeed,	 a	 case	
report	published	recently	described	a	patient	with	chorioretinal	lesions	and	
WNV	 antibody	 titers	 increased	 from	 basal	 levels	 one	 year	 after	 an	 initial	
infection	(312).	An	ongoing	infection	and	subsequent	BRB	breakdown	may	
create	 an	 environment	 permissive	 to	 the	 formation	 of	 CNV,	 the	 sight‐
impairing	 complication	 noted	 in	 various	 ocular	 pathologies	 such	 as	 AMD	
and	 diabetic	 retinopathy.	 In	 support	 of	 this	 idea,	 a	 CNV	 membrane	 was	
associated	 with	 a	 healed	 WNV‐induced	 chorioretinal	 lesion	 in	 a	 patient	
(211).	 As	 approximately	 80%	 of	 patients	 with	 neurological	 infection	 can	
present	with	ophthalmic	manifestations	(313),	 these	complications	will	be	
an	 ongoing	 concern.	 While	 some	 reports	 have	 been	 published	 on	 the	
kinetics	and	gene	changes	in	WNV‐infected	RPE	(220,	221),	this	is	the	first	
study	that	has	looked	at	the	effects	of	this	virus	on	the	integrity	of	an	in	vitro	
model	of	the	outer	BRB.	
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The	 initial	 increase	 (24	 ‐	 48	 hours	 post‐infection)	 and	 eventual	 decrease	
(>48	hours	post‐infection)	of	TEER	correlated	with	the	increase	in	intensity	
of	ZO‐1	in	WNV‐infected	hRPE,	and	the	diffuse	staining	after	48	hours	post‐
infection	 of	 both	 ZO‐1	 and	 β‐catenin.	 As	 previously	 noted	 in	 Figure	 4.2M	
and	 N,	 the	 levels	 of	 these	 proteins	 are	 unchanged	 from	 uninfected	 cells,	
indicating	 that	 re‐arrangement	 of	 the	 proteins	 is	 the	 cause	 of	 the	 noted	
staining	 changes.	 	 This	 TEER	 and	 ZO‐1/β‐catenin	 correlation	 displays	 a	
connection	between	the	distribution	of	these	proteins	and	the	TEER	of	the	
cell	monolayer.	Given	that	WNV	infection	is	sporadic	across	the	monolayer	
while	the	re‐arrangement	of	ZO‐1	and	β‐catenin	is	global,	soluble	factors	are	
the	likely	agents	that	facilitate	this	process,	although	it	is	possible	that	this	
is	achieved	by	intercellular	juxtacrine	communication.	
We	 investigated	ICAM‐1	expression	as	 it	 is	an	adhesion	molecule	 involved	
in	 the	 diapedesis	 of	 leukocytes	 though	 blood	 barriers,	 and	 is	 usually	
upregulated	 during	 inflammatory	 events	 (314).	 Additionally,	
overexpression	 of	 ICAM‐1	 alone	 can	 result	 in	 increases	 in	 TEER	 in	 the	
human	 endothelial	 cell	 line	 HDMEC	 (315)	 and	 decrease	 in	 TEER	 in	 rat	
Sertoli	 cells	 (316).	 Our	 investigations	 showed	 that	 from	 24	 hours	 post‐
infection,	WNV‐infection	 caused	 an	 incremental	 increase	 in	 ICAM‐1	 levels	
(24	 ‐	 72	hours	 post‐infection),	 in	 contrast	 to	 the	 observed	TEER	 changes.	
Thus,	 ICAM‐1	 increases	 in	 our	 model	 are	 unlikely	 to	 be	 involved	 in	 the	
observed	resistance	changes.	
	
  178
From	 the	 tight	 junction	 protein	 genes	 investigated,	 we	 found	 that	 E‐
cadherin	(CDH1)	was	significantly	decreased	over	time	across	several	MOIs.	
As	N‐cadherin	is	the	predominant	cadherin	in	RPE,	research	into	the	role	of	
E‐cadherin	 in	 other	 epithelial	 cells	 may	 not	 be	 representative	 of	 the	
situation	in	RPE	(40).	It	is	normally	present	in	low	levels	in	RPE	cell	culture,	
and	thus	elevated	levels	of	E‐cadherin	could	conceivably	affect	RPE	function	
(40).	Our	finding	that	WNV‐infection	downregulates	E‐cadherin	mRNA	may	
be	of	interest,	however	current	research	of	this	protein	in	RPE	is	insufficient	
to	hypothesize	on	the	role	this	downregulation	could	have	on	the	observed	
TEER	values.	ZONAB	(CSDA)	was	upregulated	from	48	hours	post‐infection	
(Figure	 4.3	 C).	 This	 protein	 is	 known	 to	 localize	 to	 the	 cell	 nucleus	 and	
induce	the	transcription	of	differentiation	transcriptome	(31).	Inhibition	of	
the	 transcriptive	properties	 of	 this	 gene	 is	 achieved	by	ZO‐1	 sequestering	
ZONAB	 out	 into	 the	 cytoplasm.	 Consequently,	 increases	 in	 ZONAB	 or	
decreases	 in	 ZO‐1	 can	 result	 in	 a	 dedifferentiated	 state	 in	 RPE	 cells	 and	
subsequent	reduction	in	 the	 integrity	of	 the	outer	BRB	(32).	Since	CDSA	 is	
upregulated	 from	48	 hours	 and	 degradation	 of	 TEER	 and	 ZO‐1	 junctional	
localization,	it	is	conceivable	that	increased	ZONAB	could	contribute	to	this.	
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While	 we	 currently	 do	 not	 have	 any	 candidate	 cytokines/molecules	 or	
combinations	 thereof	 to	 explain	 the	 increase	 in	 TEER,	 we	 looked	 into	
possible	 mechanisms	 responsible	 for	 its	 eventual	 decrease.	 MMP9,	 a	
metalloproteinase	 known	 to	 affect	 tight	 junction	 integrity	 (317),	 was	
upregulated	 in	 WNV‐infected	 cells	 and	 thus	 may	 be	 contributing	 to	 the	
decrease	 in	TEER.	MMP9	mRNA	was	upregulated	over	time	across	several	
different	MOIs,	 indicating	 a	 possible	 role	 of	 this	metalloproteinase	 to	 the	
observed	TEER	degradation,	however	our	 zymography	gels	did	not	detect	
the	 presence	 of	 this	 protein.	 Activated	 MMP2	 was	 neither	 increased	 nor	
decreased	 in	 WNV	 supernatants	 relative	 to	 mock‐infected	 supernatants,	
likely	ruling	out	the	role	of	this	zymogen	in	BRB	breakdown.	
The	 production	 of	 the	 anti‐inflammatory	 cytokine	 isoforms	 of	 TGFβ	 has	
been	noted	in	several	cases	of	pathogenic	inflammation	in	RPE	cells,	such	as	
infection	with	Toxoplasmosis	gondii	(318)	and	CMV	(319).	And	as	previously	
noted	 in	 section	 4.2.4,	 TGFβ	 can	 induce	 EMT	which	 then	 results	 in	 TEER	
decrease.	We	found	that	TGFB1	and	TGFB2	were	not	upregulated	in	WNV‐
infected	cells	(Figure	5A),	nor	were	their	protein	counterparts	released	into	
the	 supernatant	 at	 higher	 levels	 than	 controls	 (Figure	 5B),	 making	 it	
unlikely	that	TGFβ‐mediated	EMT	is	involved	in	the	TEER	decrease.		
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The	 initial	 increase	 in	TEER	may	be	a	result	of	RPE	trying	to	maintain	the	
immune	 privilege	 environment	 of	 the	 outer	 BRB.	 A	 similar	 result	 can	 be	
seen	 in	 a	 study	 in	 which	 CaCo‐2	 epithelial	 cells	 increased	 in	 TEER	when	
treated	with	virus‐free	supernatant	of	HCMV‐infected	primary	retinal	glial	
cells	 (320).	 By	 maintaining	 the	 integrity	 of	 the	 BRB,	 the	 neural	 retina	 is	
protected	 from	 leukocyte‐mediated	 damage,	 albeit	 at	 the	 expense	 of	
increased	 viremia	 if	 the	 local	 immune	 environment	 cannot	 control	 the	
spread	of	infection.	The	lack	of	TLR3/RIG‐I	involvement	in	this	change	may	
indicate	another	viral	detection	pathway	is	responsible	for	this	change.	
Further	research	will	be	required	to	elucidate	the	soluble	factor/s	involved	
in	 the	 increase	 of	 TEER	 and	 the	 rearrangement	 of	 the	 tight	 junction	
proteins.	
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Chapter 5: Establishing a Murine Ocular Model of 
WNV Infection and BRB Breakdown.	
	
5.1.	Introduction	
 
In	Chapters	3	and	4,	 the	effects	of	WNV	on	the	cell	monolayer	that	single‐
handedly	 comprises	 the	whole	 outer	 blood	 retinal	 barrier,	 the	 RPE,	were	
investigated.	However,	cell	culture	models	are	limited	in	using	one	cell	type	
in	vitro,	and	while	the	use	of	co‐culture	models	can	enhance	data	however,	
they	 too	 are	 limited	 by	 scope.	 Establishing	 a	 murine	 model	 of	 WNV‐
infection	 is	 the	 next	 logical	 step	 for	 better	 understanding	 several	 in	 vivo	
effects	of	WNV	within	the	eye.		
Investigating	the	recruitment	of	leukocytes	from	the	bloodstream	to	the	eye	
during	 ocular	WNV	 infection,	 provides	 the	 best	 approach	with	 respect	 to	
elucidating	the	systemic	 immune	response	generated	as	a	result	of	a	WNV	
infection	localised	within	the	eye.	
	
As	 previously	 discussed	 in	 Chapter	 1	 (section	 1.8.4),	 systemic	 WNV	
infection	can	present	clinically	as	a	chorioretinopathy,	however	the	route	of	
infection	 remains	 unclear	 (218,	 219).	 Generating	 a	 mouse	 model	 that	
mimics	 the	 route	of	WNV	 infection	 in	 the	 central	 nervous	 system	and	 the	
retina	of	humans	is	difficult,	not	only	due	to	the	ambiguity	of	the	true	route	
of	WNV	into	 the	retina,	but	also	because	of	 the	difficulty	of	 inducing	WNV	
infection	in	the	mouse	that	minimizes	mortality	but	is	sufficient	to	establish	
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a	consistent	WNV	 infection	of	 the	retina.	 In	addition	 to	 this,	 to	 investigate	
the	 effects	 of	 a	 recurrent	 WNV	 retinal	 infection	 in	 a	 mouse	 previously	
exposed	to	the	virus,	we	intravitreally	infected	the	retinas	of	WNV‐immune	
mice	that	were	generated	via	intranasal	WNV	administration	approximately	
3	 months	 prior.	 As	 a	 result,	 we	 aimed	 to	 determine	 whether	 intravitreal	
WNV	administration	 resulted	 in	 localised	 replication,	 and	given	 the	direct	
neural	connection	of	the	retina	to	the	brain,	whether	retinal	WNV	infection	
resulted	productive	WNV	in	the	murine	brain.	Once	this	had	been	confirmed	
by	 IHC,	 we	 sought	 to	 determine	 a	 possible	 WNV	 LD50	 via	 titration	
experiments.		
	
While	it	would	have	been	ideal	to	investigate	the	recruited	leukocyte	profile	
in	 mice	 inoculated	 with	 a	 pre‐determined	 optimal	 WNV	 titre	 (sufficient	
retinal	 infectivity	 while	minimizing	mortality),	 given	 the	 time	 constraints	
and	the	difficulty	of	both	determining	the	threshold	titre	and	studying	the	
leukocyte	profile	recruited	to	the	site	of	a	retinal	WNV	infection,	we	opted	
to	 run	 WNV	 titration	 and	 leukocyte	 profiling	 experiments	 separately.	
Elucidation	 of	 the	 recruited	 leukocyte	 profiles	 in	 the	 WNV‐infected	
retina/choroid	complex	were	performed	using	the	highest	viral	titre	used	in	
the	titration	experiments.	
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5.2.	Results	
 
5.2.1.	Preliminary	histology	and	evaluation	of	injection	technique	
 
H&E	staining	was	performed	on	cryosections	of	retina	 in	order	 to	 identify	
cell	 retinal	 populations	 in	 subsequent	 experimental	 cryosections	 (Figure	
5.1).	
	
The	 initial	 experiments	 investigated	 the	 effectiveness	 of	 the	 intravitreal	
injections	 using	 0.75%	 monastral	 blue	 that	 could	 be	 observed	 during	
histological	 assessment.	 For	 successful	 injections,	 monastral	 blue	 is	
observed	only	within	the	posterior	segment	of	the	eye	(Figure	5.2	A).	
	
Attempts	at	subretinal	 injections	via	the	choroid	were	unsuccessful	due	to	
the	small	size	of	the	murine	eye	and	difficulty	in	injecting	through	the	sclera	
without	 penetration	 the	 retina,	 and	 were	 not	 pursued.	 As	 a	 result,	 the	
standard	intravitreal	injection	was	used,	and	the	injection	site	was	placed	as	
close	to	 the	retina	as	possible.	Over‐penetration	of	 the	needle	beneath	the	
retina	resulted	in	significant	trauma	of	the	surrounding	area	(Figure	5.2	B),	
so	this	too	was	avoided.	
 
 
 
 
 
  184
 
 
 
 
 
 
 
 	
  185
Figure	5.1.	A	bright‐field	image	of	a	mid‐sagittal	section	of	the	murine	eye	
stained	with	haematoxylin	and	eosin.	The	 layers	of	 the	retina	and	choroid	
are	indicated	as	follows:	GCL	=ganglion	cell	layer.	INL	=	inner	limiting	layer.	
ONL	=	outer	 limiting	 layer.	 IPL	and	OPL=	 inner	and	outer	plexiform	 layer,	
respectively.	 IS	and	OS	=	 inner	and	outer	segments	of	 the	photoreceptors,	
respectively.	RPE	=	retinal	pigment	epithelium.	Ch	=	choroid.		
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Figure	5.2.	Bright	field	images	of	sagittal	sections	of	murine	eyes	following	
intravitreal	 injection	 with	 a	 0.75%	monastral	 blue	 solution.	 The	 contrast	
and	brightness	for	(A)	were	adjusted	to	emphasise	the	two	monastral	blue	
clumps	 (red	 arrows)	 just	 above	 the	 neural	 retina.	 The	 haematoxylin	 and	
eosin	(H&E)	stained	section	(B)	shows	the	needle	penetration	point	(*)	and	
the	injected	solution	deposition	site	(#).	The	position	of	the	lens	in	relation	
to	 the	 injection	 path	 in	 the	 section	 is	 an	 artefact	 induced	 during	
cryosectioning.		
 	
  188
5.2.2.	Confirmation	of	WNV	infection	in	retina	
 
Initially,	the	highest	viral	titre	that	could	be	injected	(7.2	x105	PFU/eye)	was	
used.	To	avoid	effects	 in	 the	 contralateral	 eye	 retinitis	 issues	 such	 as	 that	
seen	in	HSV	retinitis	(321),	both	eyes	were	injected	with	WNV	rather	than	
having	 a	 PBS‐injected	 control	 eye	 and	 a	 WNV‐injected	 eye	 in	 the	 same	
mouse.	 By	 day	 6	 post‐injection,	mice	 exhibited	 symptoms	 consistent	with	
fatal	 WNV	 infection	 of	 the	 brain	 (that	 is,	 pilo‐erection,	 face	 washing,	
hunching	and	weight	loss),	and	were	euthanized	at	that	time.		
	
Immunofluorescence	 of	 sectioned	 eyes	 from	 day	 6	 post‐injection	 infected	
mice	with	antibodies	against	WNV	NS1	protein	revealed	WNV	 infection	 in	
the	retina,	specifically	with	cells	of	the	GCL	and	INL	(Figure	5.3	A).	Uniform	
infection	 was	 found	 in	 the	 GCL	 but	 infection	 in	 the	 INL	 was	 mostly	
restricted	to	cells	in	the	uppermost	region.		
Staining	of	the	retina	with	 lectin‐FITC,	which	 labels	the	blood	vessels,	also	
stained	 infiltrating	 leukocytes,	 likely	 of	 the	 myeloid	 lineage,	 in	 WNV‐
infected	eyes	(Figure	5.3	B).	
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Figure	5.3.	 Immunofluoresence	 images	 of	 sagittal	 murine	 retina	 sections	
infected	with	WNV,	 day	 6	 post‐injection.	 (A)	 stained	with	WNV	NS1‐FITC	
(green),	DAPI	nuclear	stain	(blue)	and	autofluorescence	in	the	610nm	long‐
pass	 filter	 to	 highlight	 the	 choroidal	 and	 scleral	 layers	 (red).	 (B)	 stained	
with	WNV	NS1‐biotin/AF594‐streptavidin	 (red),	DAPI	nuclear	 stain	 (blue)	
and	FITC‐lectin	(green).		
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5.2.3.	Confirmation	of	subsequent	WNV	infection	in	brain.		
 
As	noted	above	 (section	5.2),	 intravitreal	 injection	of	WNV	resulted	 in	 the	
mouse	showing	signs	indicative	of	fatal	WNV	infection	of	the	brain.	At	day	6	
post‐injection,	mouse	brains	were	harvested	and	stained	for	fluorescent	IHC	
that	revealed	the	presence	of	viral	infection	throughout	the	brain.	
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Figure	5.4.	 Immunofluorescence	 images	 of	 sagittal	 section	 of	 the	murine	
brain.	 (a)	 A	 composite	 image	 of	 a	 distal	 sagittal	 section	 of	 the	 cerebral	
cortex	 and	 the	 cerebellum.	 (b)	 High	magnification	 image	 of	murine	 brain	
highlighting	WNV‐infected	neurons.	Sections	were	stained	with	WNV	NS1‐
biotin/AF594‐streptavidin	(red),	DAPI	nuclear	stain	(blue).		
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5.2.4.	Mouse	weight	loss	as	a	measure	of	murine	WNV‐pathology	
 
Intranasal	WNV	model	studies	in	our	laboratory	(202,	322)	have	shown	that	
the	 percentage	 weight	 lost	 by	 a	 mouse	 was	 a	 reliable	 and	 consistent	
indicator	of	lethal	WNV	infection.	
At	 all	 viral	 titres	 used,	WNV‐infection‐induced	weight	 loss	 commenced	 at	
day	 4	 post‐injection	 (the	 initial	 weight	 loss	 a	 result	 of	 the	 anaesthetic	
procedure).	Viral	titres	above	1.44	x104	PFU/mouse	(Figures	5.5	A,	B	and	C)	
were	 uniformly	 lethal,	 however	 no	 surviving	 mice	 from	 the	 lower	 titres	
showed	immunity	to	an	intranasal	WNV	rechallenge,	as	described	in	section	
2.8.3	(Figures	5.5	I	and	J).	
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Figure	 5.5.	 Representative	 weight‐loss	 graphs	 of	 mice	 following	 various	
intravitreal	WNV	titres	or	PBS.	Both	eyes	of	the	mice	were	 injected	with	a	
total	 titre	 of	 1.44x106	 PFU	 (A),	 1.44x105	 PFU	 (B),	 1.44x104	 PFU	 (C),	
1.44x103	PFU	(D),	1.44x102	PFU	(E),	1.44x101	PFU	(F)	of	WNV,	or	PBS	(G).	A	
Kaplan‐Meier	 survival	 graph	 (H)	 was	 generated	 for	 the	 intravitreal	WNV	
titration	 mice	 in	 graphs	 A‐G.	 Mice	 that	 survived	 1.44x101	 and	 1.44x102	
WNV	PFU	intravitreal	infection	were	rechallenged	with	an	intranasal	LD100	
dose	 of	 WNV	 (6x104	 PFU)	 at	 3	 months	 after	 initial	 WNV	 infection,	 and	
weight	 loss	was	 recorded	 (I).	 A	 Kaplan‐Meier	 survival	 graph	 (J)	 was	 also	
generated	from	these	rechallenged	mice.	All	graphs	are	representative	of	a	
single	 experiment,	with	 six	mice	 per	 viral	 titre,	 and	 all	 experiments	were	
repeated	 twice,	 with	 the	 exception	 of	 the	 rechallenge	 experiment	 (I&J),	
which	was	performed	once.	
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5.2.5.	WNV	immunopathology	results	in	a	disturbed	retinal	phenotype.	
 
As	seen	in	Figure	5.6,	eyes	from	mice	intravitreally	injected	with	PBS	had	a	
normal	histology	day	6	post‐injection.	The	injection	site	can	be	seen	(Figure	
5.6	 A).	 In	 the	 WNV‐injected	 eye	 however,	 significant	 perturbations	 were	
noted	 throughout	 the	 retina,	 including	 what	 appear	 to	 be	 folding	 and	
blebbing	of	the	ONL	into	the	INL	and	a	general	 irregular	appearance	of	all	
the	layers	of	the	neural	retina,	although	the	GCL	appears	to	mostly	be	intact.	
  
  198
 
 
 
 
 
 
 
  
  199
Figure	5.6.	 Brightfield	 images	 of	 H&E‐stained	 sagittal	 sections	 of	murine	
eyes	from	mice	intravitreally	injected	with	PBS	(A	&	B)	and	WNV	(C	&	D)	at	
day	6	post‐injection.	The	asterisk	(*)	indicates	a	perturbation	as	a	result	of	
the	intravitreal	injection.	
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5.2.6.	Flow	cytometric	analysis	of	whole	retina	and	choroid,	and	associated	
draining	lymph	nodes,	in	mice	intravitreally	infected	with	WNV.	
 
Retinal	responses	
Leukocytes	from	the	murine	eyecup	were	collected	and	processed	for	FACS	
as	 described	 in	 section	 2.9.2.	 These	 cells	 are	 reflective	 of	 populations	 in	
both	the	retina	and	choroid	as	they	could	not	be	practically	separated.	
While	 certain	 leukocyte	 subsets	 (such	 as	 dendritic	 cells)	 ideally	 require	 a	
functional	assay	to	be	definitively	identified,	the	leukocyte	nomenclature	in	
these	experiments	is	based	only	their	phenotypic	marker	expression.		
Figure	 5.7	 shows	 the	 gating	 strategy	 used	 to	 define	 the	 phenotype	 of	 the	
leukocytes	based	on	their	marker	expression.	Minimum	expression	levels	of	
markers	were	defined	by	the	use	of	fluorescence	minus	one	(FMO)	controls.	
This	is	essentially	a	control	for	a	particular	fluorophore	that	contained	all	of	
the	other	 fluorophores	 in	 the	 flow	 cytometry	panel,	with	 the	 exception	of	
the	one	in	question	(323).	The	gating	strategy	for	monocytes	includes	both	
monocytes	 and	 macrophages.	 The	 schema	 for	 injecting	 mice	 is	 shown	 in	
Figure	5.8.	
	
Because	of	 the	 low	number	of	 leukocytes	present	 in	 the	 eye,	 especially	 in	
untreated	 eyes,	 each	duplicate	 is	 representative	of	 4	 eyes	pooled	 for	 flow	
cytometry.	 Flow	 cytometric	 analysis	 of	 murine	 eyes	 revealed	 primarily	 a	
myeloid	profile	of	 leukocyte	recruitment	to	the	WNV‐infected	eye	(Figures	
5.8	B&C,	Figures	5.9	B&C)	as	opposed	to	 the	 lymphocyte‐centric	profile	 in	
the	draining	lymph	nodes	of	the	intravitreally‐infected	mice	(Figure	5.10	A).		
  201
Within	the	naïve	group	(Figure	5.8),	all	defined	leukocytes	subsets	from	day	
6	WNV‐infected	mice	were	 present	 at	 higher	 levels	 than	 for	 PBS‐injected	
(mock‐infected)	 or	 untreated/uninjected	 mice.	 Total	 leukocytes	 in	 WNV‐
infected	eyes	were		>15‐fold	higher	than	PBS‐injected	eyes,	while	PBS	eyes	
had	a	2.17‐fold	higher	number	of	leukocytes	than	untreated	eyes.		
	
The	 largest	 disparity	 in	 cell	 populations	 between	 the	 untreated	 eyes	 and	
mock‐infected	was	the	almost	17‐fold	difference	 in	CD86+	cell	populations	
(Figure	5.9	G,	S	and	W).	With	the	exception	of	CD86+	and	CD28+	subsets,	the	
most	notable	increases	of	leukocyte	populations	between	WNV‐infected	and	
PBS‐injected	eyes	were	the	~70‐fold	increase	in	NK‐cells	(Figure	5.9	T)	and	
~120‐fold	increase	in	Ly6Chi	monocytes	(Figure	5.9	P).	CD28,	a	co‐receptor	
on	 T‐cells	 essential	 for	 T‐cell	 priming,	 is	 expressed	 in	 all	mouse	 CD4	 and	
CD8	T‐cells	(324)	and	is	essential	for	T‐cell	clonal	expansion	(325).	
	
CD86,	a	marker	of	activated	APC	cells	such	as	DCs	(326),	was	expressed	at	
similar	 levels	on	monocytes	 from	PBS	and	WNV‐infected	eyes	 (Table	5.1),	
but	 at	 higher	 levels	 in	WNV‐infected	 older	 naïve	mice	 and	 immune	day	 3	
mice	compared	with	age‐matched	PBS	controls	(Table	5.2).		
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Figure	 5.7.	 Representative	 gating	 strategy	 used	 to	 quantitate	 leukocyte	
populations	of	posterior	eyes	(A)	and	cervical	draining	lymph	nodes	(DLN),	
(B)	 of	 intravitreally‐infected	mice	 prepared	 for	 14‐colour	 flow	 cytometry.	
The	red	asterisk	(*)	and	the	red	hash	(#)	denote	where	the	gate	is	 further	
defined	 later	 in	 the	 diagram.	 After	 the	 initial	 cervical	 DLN‐specific	 gating	
(B),	gating	for	these	cells	continued	on	from	the	CD3e/B220	gate	denoted	in	
panel	A	by	a	red	‘Φ’.	Gating	for	most	subsets	was	decided	based	on	profile,	
with	 the	 exception	 of	 Ly6Clow	 monocytes,	 and	 CD28+	 or	 CD86+	 subsets,	
which	were	defined	from	FMOs.		
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Figure	5.8.	Layout	of	experimental	treatments	used	for	7‐9	week	old	naïve	
mice.	
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Figure	5.9.	Bar	graphs	of	leukocyte	populations	as	determined	by	14‐colour	
flow	cytometry.	Mice	were	(age	7‐9	weeks)	intravitreally	injected	with	WNV	
at	 total	 viral	 titre	 of	 1.44	 x	 106	 PFU	 per	 mouse	 or	 with	 PBS.	 Mice	 were	
harvested	 at	 6	 days	 post‐injection	 along	 with	 age‐matched	 non‐
intravitreally	 injected	mice	 (8‐10	weeks	old).	Populations	 shown	are	 total	
live	CD45+	 cells	 (A),	Myeloid	 cells	 (B)	Lymphocyte	 cells	 (C)	T‐cells	 (D),	B‐
cells	(E),	Microglia	(F),	CD86+	Microglia	(G),	NKT‐cells	(H),	CD4+	T‐cells	(I),	
CD8+	T‐cells	(J),	CD4‐	CD8‐	T‐cells	(K),	CD28+	NKT‐cells	(L),	CD28+	CD4+	T‐
cells	 (M),	 CD28+	 CD8+	 T‐cells	 (N),	 CD28+	 CD4‐	 CD8‐	 T‐cells	 (O),	 Ly6Chi	
monocytes	 (P),	 Ly6Cint	 monocytes	 (Q),	 Ly6Clow	 monocytes	 (R),	 CD86+	
monocytes	 (S),	 NK‐cells	 (CD3e‐,	 NK1.1+,	 T),	 Neutrophils	 (CD3e‐,	 NK1.1+,	
Ly6G+,	 U),	 Dendritic	 cells	 (CD3e‐,	 NK1.1+,	 Ly6G‐,	 MHC‐IImed+high,	 V),	 and	
CD86+	Dendritic	cells	(W).	Experiments	were	performed	on	three	separate	
occasions.	Statistical	analysis	was	performed	via	a	one‐way	ANOVA	with	a	
Dunnet	 post‐test	 and	 a	 Geisser‐Greenhouse	 correction.	 n=5,	 C.I.=95%,	 *=	
p<0.05,	**=	p<0.01,	***=p<0.001,	****=p<0.0001.	
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Mock‐
infected 
WNV  Untreated 
% CD28+ 
NKT-cells 27.3 65.2 55.3 
CD4+ T-cells 62.6 10.7 30.4 
CD8+ T-cells 70.6 5.1 17.8 
CD4- CD8- T-
cells 10.9  2.9  8.3 
% CD86+ 
Microglia 8.9 60.9 31.9 
Monocytes 49.1 44.9 44.3 
DCs 74.9 41.5 N/A 
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Table	 5.1.	 Percentages	 of	 CD3e+	 cells	 (NKT	 and	 T‐cells)	 in	 the	
retina/choroid	of	day	6	WNV‐infected	naïve	mice	 that	were	also	CD28+	 (a	
marker	 of	 activation),	 as	 well	 as	 myeloid	 lineage	 populations	 expressing	
CD86	 (expressed	 when	 APC	 cells	 are	 presenting	 antigen).	 N/A=not	
applicable,	as	we	did	not	detect	any	DCs	in	the	retinas	of	untreated	mice.		
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Because	of	time	constraints,	in	order	to	produce	a	“secondary”	retinal	WNV‐
infection	 in	 mice	 without	 the	 primary	 damage	 to	 the	 eye,	 immune	 mice	
generated	 from	 intranasal	 WNV‐infection	 were	 used	 (Figure	 5.10),	 since	
systemic	immunity	develops	from	this	model	and	terminal	characteristics	of	
WNV	 infection	 from	this	model	 (WNV‐mediated	encephalitis)	are	noted	 in	
the	 intravitreal	model.	 As	 such,	 it	 seemed	 likely	 that	 an	 immune	memory	
response	 similar	 to	 non‐lethal	 intravitreal	 WNV	 infection	 would	 be	
generated	in	this	mouse.	
	
Older	day	6	WNV‐infected	naïve	mice	had	statistically	significant	higher	cell	
counts	 in	 most	 defined	 leukocyte	 subsets,	 compared	 with	 mock‐infected	
mice	(Figure	5.11	A),	with	the	exception	of	microglia	(Figure	5.11	F),	CD86+	
microglia	 (Figure	 5.11	 G)	 and	 Ly6Clow	 monocytes	 (Figure	 5.11	 R)	 which	
were	higher	 in	 the	mock‐infected	mice	compared	to	untreated	naïve	mice,	
although	 these	 differences	 were	 not	 statistically	 significant.	 Numbers	 of	
Ly6Cint	monocytes	were	similar	between	the	two	groups	(Figure	5.11	Q).	
	
Surprisingly,	immune	day	1	post‐injection	mice	had	a	lower	leukocyte	count	
than	mock‐infected	mice.	 The	 reason	 for	 this	 is	 unknown,	 however	while	
most	defined	leukocyte	subsets	showed	lower	counts	in	immune	day	1	post‐
injection	 compared	with	mock‐infected	mice,	 both	 neutrophils	 and	 Ly6Chi	
monocytes	were	higher	(Figures	5.11	U	and	P,	respectively).	
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Total	leukocyte	numbers	in	day	3	post‐injection	immune	mice	were	slightly	
but	not	 significantly	higher	 than	 in	WNV‐infected	naïve	mice	 (Figure	5.11	
A),	 and	 this	 difference	 arose	 from	 a	 higher	 proportion	 of	 infiltrating	
lymphocytes	 (Figure	 5.11	 C);	 all	 lymphocyte	 subsets	 (Figures	 5.11	 D&E)	
with	the	exception	of	NKT	cells	(Figure	5.11	H)	were	higher	in	immune	day	
3	 post‐injection	 mice	 compared	 with	 WNV‐infected	 naïve	 mice,	 in	
particular,	 T‐cells	 (Figure	 5.11D).	 Overall,	 cell	 numbers	were	 very	 similar	
for	 the	 two	groups	 (Figure	5.11	B).	The	only	 two	myeloid‐lineage	 subsets	
higher	 in	 immune	 day	 3	 post‐injection	 mice	 compared	 to	 infected	 naïve	
mice	were	microglia	 (and	 its	CD86+	 subset,	Figures	5.11	F	and	G)	and	NK	
cells	(Figure	5.11	T).	
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Figure	5.10.	 Layout	 of	 experimental	 treatments	 used	 for	 19‐21	week	 old	
naïve	mice	in	conjunction	with	intranasal	WNV	LD50‐derived	immune	mice	
(denoted	by	the	blue	circles).	
  
  217
 
 
  
  218
Figure	 5.11.	 Bar	 graphs	 of	 leukocytes	 from	 retina/choroid	 from	 mice	
intravitreally	 infected	with	WNV	 at	 total	 viral	 titre	 of	 1.44	 x	 106	 PFU	 per	
mouse	or	with	PBS.	Mice	 that	were	 intravitreally	 administered	with	WNV	
were	either	WNV‐immune	mice	(generated	from	intranasal	LD50	infection	
and	 used	 12	weeks	 after	 intranasal	 infection)	 or	 age‐matched	 naïve	mice	
(19‐21	weeks	old).	Other	age‐matched	mice	were	also	injected	with	PBS	as	
a	control.	Naïve	WNV	and	PBS	mice	were	harvested	at	6	days	post‐injection	
while	 immune	mice	were	harvested	 at	 1	 or	3	days	post‐injection	 for	 flow	
cytometry	 analysis.	 Populations	 shown	 are	 total	 live	 CD45+	 cells	 (A),	
Myeloid	cells	(B)	Lymphocyte	cells	(C)	T‐cells	(D),	B‐cells	(E),	Microglia	(F),	
CD86+	Microglia	 (G),	NKT‐cells	 (H),	 CD4+	T‐cells	 (I),	 CD8+	T‐cells	 (J),	 CD4‐	
CD8‐	T‐cells	(K),	CD28+	NKT‐cells	(L),	CD28+	CD4+	T‐cells	(M),	CD28+	CD8+	
T‐cells	 (N),	 CD28+	 CD4‐	 CD8‐	 T‐cells	 (O),	 Ly6Chi	 monocytes	 (P),	 Ly6Cint	
monocytes	 (Q),	 Ly6Clow	 monocytes	 (R),	 CD86+	 monocytes	 (S),	 NK‐cells	
(CD3e‐,	 NK1.1+,	 T),	 Neutrophils	 (CD3e‐,	 NK1.1+,	 Ly6G+,	 U),	 Dendritic	 cells	
(CD3e‐,	 NK1.1+,	 Ly6G‐,	 MHC‐IImed+high,	 V),	 and	 CD86+	 Dendritic	 cells	 (W).	
Experiments	 were	 performed	 on	 three	 separate	 occasions,	 with	 the	
exception	 of	 the	 immune	 day	 3	 mice,	 which	 was	 performed	 on	 once	
occasion.	 Statistical	 analysis	was	 performed	 via	 a	 one‐way	ANOVA	with	 a	
Dunnet	 post‐test	 and	 a	 Geisser‐Greenhouse	 correction.	 n=6	 (with	 the	
exception	 of	 Immune	 day	 3,	 n=2),	 C.I.=95%,	 *=	 p<0.05,	 **=	 p<0.01,	
***=p<0.001,	****=p<0.0001.	
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Mock‐
infected 
WNV 
Immune 
day 1 
Immune 
day 3 
% CD28+ 
NKT-cells 96.4 88.5 92.7 12.2 
CD4+ T-cells 73.6 89.1 73.7 11.4 
CD8+ T-cells 52.3 89.3 58.0 18.1 
CD4- CD8- T-
cells 35.7  58.3  55.1  5.6 
% CD86+ 
Microglia 24.4 33.2 29.5 50.9 
Monocytes 51.2 78.1 43.3 75.0 
DCs 62.6 92.1 70.4 82.8 
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Table	5.2.	Percentages	of	CD3e+	cells	in	the	retina/choroid	of	mice	used	in	
the	 immune	experiments	 that	were	also	CD28+(a	marker	of	activation),	as	
well	as	myeloid	lineage	populations	expressing	CD86	(expressed	when	APC	
cells	are	activated).		
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Draining	cervical	lymph	node	responses	
Within	 the	 cervical	 lymph	 nodes,	 all	 defined	 subsets	 investigated	 were	
higher	 in	WNV‐infected	mice	 than	Mock‐infected	mice	 (Figure	 5.12),	with	
the	 exception	 of	 Ly6Clow	 monocytes	 (Figure	 5.12	 D).	 Due	 to	 technical	
limitations,	 this	 experiment	 could	 not	 be	 done	 on	 the	 immune	 cohort	 of	
mice.
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Figure	 5.12.	 Bar	 graphs	 of	 cervical	 draining	 lymph	 node	 populations	 in	
naïve	mice	(aged	19‐21	weeks)	 intravitreally	 injected	with	1.44	x	106	PFU	
per	mouse	(green)	or	PBS	(mock‐infected,	white)	and	harvested	at	6	days	
post‐infection.	Populations	shown	are	 total	 live	CD45+	cells/leukocytes,	T‐
cells	 and	 B‐cells	 (A),	 CD3e+	 leukocytes	 (B),	 CD28+	 CD3e+	 leukocytes	 (C),	
monocyte	subsets	(D)	and	other	subsets	(E).	Experiments	were	performed	
on	 three	 separate	 occasions.	 Statistical	 analysis	was	performed	via	 a	 one‐
way	ANOVA	with	a	Dunnet	post‐test	and	a	Geisser‐Greenhouse	correction.	
n=6,	C.I.=95%,	*=	p<0.05,	**=	p<0.01.	
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5.3.	Discussion	
 
The	fact	that	naïve	mice	that	survived	the	lower	doses	of	intravitreal	WNV	
at	 7‐9	 weeks	 of	 age,	 while	 still	 succumbing	 to	 an	 intranasal	 LD100	
rechallenge	~3	months	later,	suggests	that	the	initial	amount	of	virus	used	
was	not	sufficient	to	cause	WNV	infection	in	the	brain.	A	comprehensive	set	
of	intravitreal	WNV	dose	titrations	will	need	to	been	performed	in	order	to	
determine	 what	 WNV	 titre	 results	 in	 an	 LD50,	 or	 even	 whether	 the	
intravitreal	 route	 can	 result	 in	 protective	 immunity.	WNV	NS1	 staining	 of	
the	 eye	 and	 brain	 via	 IHC	 would	 be	 able	 to	 determine	 whether	 WNV	
infection	occurs	at	the	lower	viral	titres	tested	in	which	mice	survived.	
While	 the	 weight	 loss	 patterns	 in	 intravitreally	 injected	 mice	 were	 not	
different	 between	 the	 two	 age	 groups,	 anecdotal	 evidence	 from	 our	
laboratory	suggests	that	older	mice	are	less	affected	by	WNV	infection	than	
younger	mice	for	a	given	dose,	perhaps	as	a	function	of	the	greater	mass	of	
the	older	mice.	This	appears	to	be	consistent,	as	intravitreal	WNV‐infected	
naïve	 mice	 aged	 7‐9	 weeks	 showed	 an	 appreciable	 difference	 in	 total	
leukocyte	 counts	 	 (1.7x104	 cells/eye,	 Figure	 5.9	 A)	 compared	 with	
intravitreal	WNV‐infected	naïve	mice	aged	19‐21	weeks	(1.1x104	cells/eye,	
Figure	 5.11	 A).	 However,	 differences	 were	 not	 restricted	 to	 absolute	 cell	
counts,	significant	shifts	in	leukocyte	profiles	are	noted	and	detailed	within	
the	discussion	of	the	relevant	subsets	below.	Whether	the	older	or	younger	
murine	 leukocyte	 profiles	 we	 found	 in	 our	 results	 is	 more	
immunopathogenic	 is	 something	 that	 cannot	 be	 ascertained	 with	 this	
current	set	of	data.		
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Monocytes	
Ly6Chi	 monocytes	 are	 the	 largest	 population	 that	 infiltrate	 during	 WNV‐
infection	of	the	retina,	in	both	naïve	(40%	of	CD45+	cells)	and	immune	mice	
(61%	of	CD45+	cells).	This	parallels	the	involvement	of	Ly6Chi	monocytes	in	
the	 intranasal	 WNV	 infection	 model	 of	 the	 brain	 (201).	 As	 CCL2	
neutralisation	 in	 the	 intranasal	 model	 resulted	 in	 a	 decrease	 of	 Ly6Chi	
monocytes	 recruited	 into	 the	 WNV‐infected	 brain	 (and	 improved	 the	
survival	of	the	mice)	(201),	and	as	CCR2+	(a	receptor	for	CCL2)	monocytes	
mediate	 photoreceptor	 degeneration	 in	 a	 subretinal	 inflammation	 mouse	
model	(327),	 it	 is	 likely	that	this	 leukocyte	subset	may	also	be	responsible	
for	 the	 damage	 seen	 in	 the	 retina	 during	 WNV	 infection	 (Figure	 5.7).	 It	
would	 be	 interesting	 to	 see	 what	 effect	 abrogation	 of	 this	 subset	 using	
immunomodulatory	 particles	 (described	 in	 Getts	 et	 al	 (201))	 to	 decrease	
Ly6Chi	monocyte	recruitment	would	do	to	both	recruited	 leukocyte	profile	
and	whether	this	would	lead	to	decreased	retinal	damage.		
In	young	mice,	retinal	Ly6Clow	monocytes	counts	are	3‐fold	higher	in	WNV‐
infected	mice	 compared	 to	 PBS‐injected	mice	 and	 untreated	mice	 (Figure	
5.9	R).	In	contrast,	these	same	cells	are	~2‐fold	higher	levels	in	the	retinas	
of	 older	 mice	 intravitreally	 injected	 with	 PBS	 versus	 intravitreal	 WNV	
(Figure	 5.11	 R).	 Taken	 together	 with	 the	 lower	 T‐cell	 counts	 seen	 in	 the	
older	 WNV‐infected	 mice,	 this	 may	 be	 indicative	 of	 a	 less	 inflammatory	
response	 in	 the	 older	 mice	 compared	 with	 the	 younger	 mice,	 however	 a	
more	detailed	investigation	is	needed	to	confirm	this.	
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Microglia		
As	 previously	 mentioned	 in	 Chapter	 1.2.2,	 microglia	 are	 the	 primary	
resident	 leukocytes	 in	 the	 retina,	 however	 as	 seen	 in	 Figure	 5.9	 F,	 under	
normal	 homeostatic	 conditions,	 the	 number	 of	 these	 cells	 is	 low.	 The	
increased	numbers	of	microglia	we	see	 in	PBS	and	WNV‐injected	eyes	are	
presumably	 a	 result	 of	 microglial	 proliferation	 and/or	 infiltration	 of	
monocytes	 that	 subsequently	differentiate	 into	microglia	 (section	1.3.2.1	 ‐	
Monocytes).	Both	microglia	and	macrophages	are	considered	to	be	the	main	
leukocytes	 involved	 in	 the	 dysregulated	 immune	 environment	 that	 is	
permissive	for	AMD	pathogenesis	(328,	329).	
Of	particular	interest,	while	there	is	a	~2.5%	increase	in	CD45+	cells	in	older	
PBS‐injected	 retinas,	 compared	 with	 their	 younger	 counterparts,	 and	 a	
1.5%	decrease	in	older	WNV‐infected	retinas,	compared	with	their	younger	
counterparts,	the	proportion	of	microglia	in	older	and	younger	mice	are	the	
same,	 within	 their	 respective	WNV	 and	 PBS	 cohorts.	 However,	 there	 is	 a	
greater	disparity	between	the	proportions	of	WNV‐infected	CD86+	microglia	
and	PBS	CD86+	microglia	 from	young	 retinas	 (52%,	 Table	 5.1),	 compared	
with	older	mice	(8.8%,	Table	5.2).	
This	difference	may	reflect	a	higher	basal	level	of	activation	or	an	impaired	
activation	response	in	older	retinal	microglia	compared	with	microglia	from	
younger	mice.	
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During	 WNV‐infection	 in	 the	 brain,	 microglial‐derived	 TNF	 contributes	
significantly	to	immunopathology	and	BBB	breakdown	(225).	This	suggests	
that	 microglia	 may	 also	 contribute	 to	 the	 irregular	 appearance	 of	 WNV‐
infected	murine	retina	(Figure	5.5).	
	
T‐Cells	
The	 majority	 of	 current	 ocular	 T‐cell	 research	 is	 in	 the	 context	 of	
autoimmune	 diseases,	 such	 as	 posterior	 uveitis	 and	 sympathetic	
ophthalmia.	 Care	 must	 taken	 when	 extrapolating	 the	 findings	 of	 these	
studies	 to	 the	current	 findings,	given	that	 the	predominant	 infiltrating	cell	
in	these	diseases	are	CD4+	T‐cells	(330),	 in	contrast	to	the	majority	LyC6hi	
monocytes	of	 the	WNV	model.	 In	a	murine	posterior	uveitis	model	 (EAU),	
80%	 of	 lymphocytes	 found	 in	 the	 retina	 were	 CD4+	 T‐cells	 (330).	 In	
contrast,	only	marginally	higher	CD4+	T‐cell	numbers	were	observed	across	
all	WNV‐infected	mice	in	our	model	(Figure	5.9	I	&	J,	Figure	5.11	I&	J).	CD8+	
T‐cells	appear	in	the	later	stages	of	uveitis	and	appear	to	be	unnecessary	for	
disease	induction,	as	depletion	of	CD8+	T‐cells	does	not	appear	to	affect	the	
progress	of	the	disease	(331).		
	
	Infiltration	 of	 T‐cells	 is	 found	 in	 various	 diseases	 of	 non‐autoimmune	 or	
apparent	 non‐autoimmune	 aetiology.	 These	 include	 autosomal	 dominant	
neovascular	 inflammatory	 vitreoretinopathy	 (332),	 HSV‐induced	 retinitis	
(333),	murine	 cytomegalovirus	 (MCMV)	 infection	 (334),	 and	 appear	 to	be	
important	in	the	control	of	Toxoplasmosis	in	the	eye	(335).	
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Lymphocytes	 have	 a	 clear	 role	 in	 protecting	 against	WNV	 infection,	 given	
the	increased	susceptibility	of	RAG	knockout	mice,	which	lack	mature	T	and	
B‐cells,	to	WNV	infection.	Specifically,	T‐cells	appear	to	be	involved	in	viral	
clearance	as	passive	antibody	transfer	only	resolved	acute	infection	of	WNV	
(336),	 and	 transfer	 of	 CD8+	 T‐cells	 into	 these	 mice	 rescued	 the	 majority	
from	WNV‐mediated	death	(337).	The	role	of	CD8+	T‐cells	in	WNV	infection	
however	 is	 not	 straightforward,	 as	 CD8	 knockout	 mice	 exhibit	 decreased	
survival	at	low	doses	but	increased	survival	at	high	doses	(338).	Given	the	
high	titre	administered	to	mice	in	our	model,	it	seems	likely	that	the	CD8+	T‐
cells	 observed	 may	 fulfil	 more	 of	 an	 immunopathogenic	 role	 than	 a	
beneficial	one.	
	
CD4+	T‐cells	play	a	role	in	recruitment	of	macrophages	to	the	ocular	surface	
by	promoting	 local	 production	of	monocyte	 recruiting	 chemokines	 in	Aire	
knockout	dry	eye	model	 (339).	 	Given	the	presence	of	 these	T‐cells	 in	our	
model,	they	may	also	be	contributing	to	the	recruitment	of	monocytes	that	
we	also	find	in	the	retina/choroid.	CD4+	T‐cells	also	appear	to	have	a	vital	
role	 in	 anti‐WNV	 defences,	 believed	 to	 occur	 in	 the	 late	 stages	 of	 disease	
where	 CD4+	 T‐cells	 reinforce	 the	 efforts	 of	 CD8	 T‐cells	 and	 B‐cells	 (338),	
and	perhaps	even	via	direct	anti‐WNV	activity	(340).		
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Since	 the	 gating	 of	 CD28+	 cells	 (Figures	 5.9	 and	 5.11,	 L	 ‐	 O)	 is	 based	 on	
FMOs,	 the	 baseline	 of	 CD28+	 cells	 is	 not	 reflective	 of	 cells	 that	 do	 not	
express	CD28,	but	rather	a	minimum	fluorescence	threshold.	In	general,	T‐
cell	 CD28	 expression	 appears	 to	 decrease	 after	 activation	 and	 during	
replicative	senescence,	while	low	to	null	levels	of	CD28	expression	in	T‐cells	
have	 been	 noted	 during	 viral	 infections	 and	 chronic	 inflammatory	
conditions	 (341).	 Hence,	 a	 lower	 level	 of	 CD28	 expression	 is	 a	 good	
indicator	of	clonal	expansion.	In	young	naïve	mice,	the	lower	percentage	of	
CD28+	 T‐cells	 in	 infected	WNV,	 as	 defined	 by	 our	 gating,	 compared	 with	
PBS‐injected	 eyes,	 is	 indicative	 of	 significant	 T‐cell	 populations	 derived	
from	clonal	expansion	as	opposed	to	non‐clonally	T‐cells	(Table	5.1),	while	
the	biggest	proportions	of	 clonally	 expanded	T‐cells	 in	 the	older	mice	 are	
found	 in	 the	 immune	 day	 3	 cohort	 (Table	 5.2),	 indicative	 of	 a	 strong	
memory	response	in	the	immune	mice.	
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Finally,	 while	 not	 defined	 by	 this	 panel,	 the	 presence	 of	 T‐regs	 in	 the	
choroid/retinas	of	intravitreally‐infected	WNV	mice	is	almost	certain,	given	
the	role	of	this	cell	subtype	in	the	maintenance	of	 immune	privilege	(342)	
and	the	mediation	of	 immune	responses	during	WNV	infection	(206).	Low	
proportions	 of	 T‐regs	 are	 found	 in	 ocular	 conditions	 with	 autoimmune	
properties,	 such	 as	 birdshot	 chorioretinopathy	 (343),	 and	 T‐regs	 are	
considered	vital	to	the	resolution	of	autoimmune	uveitis	(344).	Additionally,	
lower	levels	of	peripheral	T‐regs	were	found	in	both	mice	and	humans	that	
were	more	symptomatic	during	WNV	infection	that	their	less	symptomatic	
counterparts.	 Nevertheless,	 ocular	 damage	 we	 see	 in	 Figure	 5.6,	 it	 is	
conceivable	 that	 the	proportion	of	T‐cells	 in	 the	WNV‐infected	 retina	 that	
are	T‐regs	could	be	low.	
	
Other	lymphocyte	subsets	
Investigations	 concerning	 the	 presence	 of	 B‐cells	 in	 the	 eye	 are	 limited,	
however,	B‐cells	are	reported	in	autoimmune	conditions,	such	as	EAU	(345)	
and	sympathetic	ophthalmia	(346,	347).	
B‐cells	are	believed	to	play	a	significant	role	in	the	anti‐WNV	defences,	and	
B‐cell	 recruitment	 and	 proliferation	 in	 the	 brain	 during	 infection	 and	
persistence	after	 infection	has	been	observed	 (348).	This	 recruitment	and	
persistence	 is	 likely	vital	 to	aid	viral	 clearance	and	avoid	viral	persistence	
within	the	given	organ,	and	is	most	likely	the	situation	in	our	model.	
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NK	 cells	 are	 important	 in	 the	 control	 of	 CMV	 infection	 in	murine	 retinas	
(349,	350).	NK	cells	also	appear	to	have	an	angiogenic	role	in	laser‐induced	
CNV	 in	 C57BL/6	 mice	 (350).	 Treatment	 of	 mice	 with	 ant‐NK1.1,	 which	
depletes	NK	cells	but	stimulates	IL‐4	production	in	NKT	cells	(351),	resulted	
in	 a	 reduction	 of	 EAU‐induced	 damage	 (352).	 An	 association	 of	 an	 NK	
receptor	allele	with	AMD	has	been	noted	in	a	case	study	that	used	a	cohort	
of	 93	 controls	 and	 104	 AMD	 cases	 (353),	 raising	 the	 possibility	 that	
defective	NK	signalling/recruitment	may	play	a	role	in	the	pathogenesis	of	
AMD.	
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The	 presence	 of	 infiltrating	 NK	 cells	 during	 WNV	 infection	 has	 been	
observed	in	several	studies	(see	review	(354)).	However,	the	effect	of	these	
cells	is	somewhat	contentious,	as	knockdown	of	NK1.1	expressing	cells	does	
not	 seem	 to	 affect	 murine	 mortality	 (355).	 This	 may	 be	 explained	 by	
another	study,	which	found	that	NK	knockdown	studies	do	not	completely	
abrogate	 NK	 populations	 in	 the	 mouse	 (356).	 In	 spite	 of	 these	 findings,	
other	 studies	have	 shown	 that	NK	 cells	 can	 control	 the	 spread	of	WNV	 to	
certain	 organs	 (356)	 and	 that	 the	MHC‐I	 upregulation	 observed	 in	WNV‐
infected	cells	may	be	an	evasion	strategy	by	WNV	against	NK	cells,	due	 to	
the	 associations	 of	 NK‐inhibitory	molecules	 to	 the	 MHC‐I	 complex	 (357).	
Additionally,	activated	NK	cells	inhibit	WNV	infection	of	Vero	cells	via	non‐
cytolytic	 means	 (358),	 and	 the	 interaction	 of	 WNV	 E‐protein	 with	 the	
NKp44	receptor	on	NK	cells	is	a	vital	process	in	initiating	the	cytolytic	and	
IFN‐γ	producing	 capabilities	of	NK	 cells	during	WNV	 infection	 (359).	NKT	
cells	 activated	 with	 α‐galactosylceramide	 administered	 into	 the	 vitreous	
cavity	contribute	to	CNV,	likely	via	VEGF	production	(360).		
	
With	 these	 findings	 in	 mind,	 as	 NK	 and	 NKT	 cells	 are	 increased	 in	 our	
model,	NK	 cells	may	 contribute	 to	 the	 retinal	perturbations	noted	 (Figure	
5.6)	and	within	a	WNV	titre	that	results	in	a	chronic	retinal	WNV	infection,	
NKT	cells	may	contribute	to	CNV.	
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Neutrophils	have	been	shown	to	be	important	in	controlling	WNV	infection	
in	 intraperitoneally–injected	mice	 (361),	 and	contribute	 to	CNV	 formation	
in	 photodynamic	 therapy‐treated	 mice	 (362).	 While	 our	 experimental	
timecourse	 currently	 may	 be	 too	 short	 to	 induce	 noticeable	 CNV,	 the	
relatively	 low	 levels	 of	 neutrophils	 found	 in	 our	 model	 suggests	 that	
neutrophil‐mediated	CNV	is	not	a	likely	issue	during	retinal	WNV‐infection.	
	
Dendritic	 cells	 are	 not	 detected	 in	 untreated	 eyes	 in	 the	 current	 study,	 in	
contrast	 to	 the	results	of	Lehmann	et	al	 (73).	 In	 the	current	study,	 the	DC	
subset	 is	 defined	 by	 gating	 on	 cells	 with	 a	 CD45hi	 CD11chi	 MHCIIhi	
expression	 (Figure	 5.7),	 while	 Lehman	 et	 al	 (2010)	 looked	 at	 CD45int/low	
CD11bhi	 CD11cint	 expression.	 The	 CD45low	 population	 of	 Lehman	 et	 al	
(2010),	which	we	define	as	microglia,	had	a	similarly	slightly	higher	CD11c	
subpopulation	(~8	cells/eye)	that	they	suggest	is	a	possible	DC	population,	
however	 we	 are	 not	 convinced	 that	 these	 cells	 are	 DCs,	 because	 of	 the	
relatively	 low	 level	 of	 CD11c	 expression	 and	 the	 undefined	 MHC‐II	
expression	level	in	their	flow	cytometric	analysis.		
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DC	defined	by	our	gating	strategy	(Figure	5.7)	are	present	 in	PBS‐injected	
murine	 retinas	 and	 at	 higher	 levels	 in	 both	 intravitreally	 WNV‐infected	
young	 and	 older	 naïve	mice	 (Figure	 5.9V	 and	 5.11V),	 but	 not	 in	 immune	
mice	at	either	day	1	or	3	post‐injection	(Figure	5.11V).	Given	that	immune	
day	3	mice	 had	 the	 highest	 CD45	 counts	 out	 of	 all	 the	older	mice	 (Figure	
5.11A),	 this	 indicates	 a	 significant	 difference	 in	 the	 leukocyte	maturation	
signals	present	for	recruited	monocytes	between	immune	and	naïve	WNV‐
infected	murine	retinas,	as	well	as	between	younger	and	older	naïve	mice.	
While	proportionally	there	are	more	Ly6Chi	monocytes	in	older	naïve	WNV	
mice	than	younger	counterparts,	the	inverse	is	true	for	Ly6Cint,	and	this	may	
explain	 the	 higher	 DC	 population	 in	 the	 older	 WNV‐infected	 naïve	 mice.	
Unlike	monocytes,	CD86+	expression	on	DCs	was	higher	in	all	WNV‐infected	
eyes,	whether	naïve	or	immune,	younger	or	older,	compared	with	their	age‐
matched	PBS	control	(Tables	5.1	and	5.2).		
	
	
Despite	 the	 significant	 age	 difference	 between	 these	 two	 groups,	 19‐21	
week	old	mice	are	not	considered	to	be	“aged	mice”	(generally	defined	by	
various	 groups	 anywhere	 between	 8	 to	 30	 months	 or	 older	 (363‐365)).	
Therefore	 the	 differences	 in	 leukocyte	 profiles	 likely	 reflect	 a	 young	 vs.	
mature	immune	system,	rather	than	an	aged	one.		
	
  235
While	 a	 definitive	 comparison	 would	 require	 a	 more	 comprehensive	
experimental	 setup,	 using	 both	 age	 groups,	 there	 is	 nevertheless	 a	
differential	 result	between	 the	 immune	systems	of	young	and	older	day	6	
mice	 (Figure	 5.9	 compared	 with	 Figure	 5.11).	 Comparing	 the	 leukocyte	
profile	recruited	to	the	eyes	of	intravitreally	WNV‐infected	aged	(≥8	months	
old)	mice	may	further	highlight	specific	aged‐related	immune	dysregulation	
mechanisms.	
	
Although	 there	 is	 discussion	 of	 lymphatic‐like	 channels	 in	 the	 choroid	
currently	in	literature,	given	the	absence	of	lymphatics	in	the	retina	and	the	
observed	 expression	 of	WNV	 in	 the	 brain	 for	 intravitreally	 injected	 mice	
(Figure	 5.3),	 the	 leukocyte	 profile	 in	 the	 cervical	 DLNs	 may	 occur	 in	
response	 the	WNV	 infection	 of	 the	 brain	 rather	 than	 retinal	 infection.	 In	
support	of	this,	our	cervical	DLN	profile	is	essentially	the	same	as	that	found	
in	 the	 cervical	 DLNs	 of	 mice	 in	 the	 intranasal	 WNV	 model	 (personal	
correspondence,	C.	Van	Vreden).	
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Collectively,	 WNV	 infection	 in	 the	 retina	 produces	 a	 primarily	 myeloid‐
driven	response	that	results	in	significant	perturbations	of	the	retina,	which	
cannot	occur	without	a	breakdown	in	the	outer	blood‐retinal	barrier.	While	
most	 of	 the	 subsets	 defined	 in	 the	 leukocyte	 profiles	 have	been	 shown	 in	
other	 research	 to	 have	 anti‐WNV	 and	 WNV‐clearance	 abilities,	 there	 is	
likely	 to	 be	 an	 immunopathogenic	 effect	 of	 these	 subsets	 within	 our	
experimental	conditions	especially	considering	this	demonstrated	effect	 in	
the	WNV‐infected	brain	(201).	Additionally,	despite	the	uninterrupted	route	
between	 the	 neural	 retina	 and	 the	 brain	 (relative	 to	 a	 neurotropic	 virus)	
and	heightened	lymphocyte	response	of	day	3	immune	mice,	compared	with	
age‐matched	 naïve	mice,	 it	 is	 of	 considerable	 interest	 that	 day	 3	 immune	
mice	exhibit	a	similar	myeloid	profile	with	only	marginally	 lower	 levels	of	
the	corresponding	myeloid	leukocytes.		
This	may	 indicate	that	 intranasal	WNV‐induced	 immunity	does	not	extend	
to	the	retina,	and	may	indicate	that	local	immune	memory	responses	in	the	
olfactory	 bulb	 are	 responsible	 for	 the	 majority	 of	 this	 immune	 response,	
local	 immune	 responses	 that	 the	 retina	would	 not	 have,	 given	 that	 it	 is	 a	
novel	WNV	site	for	the	immune	mice	in	this	model.	Nevertheless,	the	similar	
myeloid	response	in	memory	mice	may	also	point	to	a	generic	response	to	
re‐infection	 with	 WNV	 that	 occurs	 even	 in	 the	 presence	 of	 established	
memory.	 If	 confirmed,	 this	may	have	 implications	 for	 reinfection	by	other	
flaviviruses	 such	 as	 dengue,	 in	 which	 immunopathology	 may	 be	
exacerbated,	 as	 in	 the	 case	of	 a	 secondary	 exposure	 to	 a	different	dengue	
strain	which	is	believed	to	be	the	sequence	of	events	responsible	for	dengue	
haemorrhagic	fever.		 	
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Chapter 6: Conclusions and Future Directions 
	
	
While	various	 lines	of	 research	provide	evidence	of	 the	critical	 role	of	 the	
immune	system	in	the	pathogenesis	of	AMD	(see	(366)	for	a	comprehensive	
review),	the	majority	of	current	research	into	the	causes	of	AMD	approach	
the	immunology	as	having	a	non‐microbial	aetiology.	
	
The	main	hypotheses	regarding	the	stimulus	for	the	immunological	cascade	
involved	 in	 the	 pathogenesis	 of	 AMD	 propose	 a	 metabolic	 by‐product	
agonist	 (such	 as	 lipofuscin)	 or	 an	 inflammatory	 response	 to	 an	
environmental	 injury,	 such	as	 in	 the	 case	of	 light‐induced	damage	models	
(367,	368).	
Several	 lines	 of	 evidence	 support	 these	 hypotheses,	 however	 the	
histological	 and	 immunological	 findings	 that	 these	 models	 attempt	 to	
explain	can	also	readily	be	 found	 in	 immunological	responses	 to	 infection.	
With	the	exception	of	epidemiological	studies	 looking	at	the	association	of	
AMD	with	chlamydia	pneumoniae	(see	section	1.6.3),	there	are	very	limited	
studies	looking	at	the	possible	effects	of	a	chronic	pathogen	infection	in	the	
retina/BRB	 as	 probable	 contributors	 to	 AMD	 pathogenesis.	 Consequently,	
we	have	continued	on	from	a	recently	established	cell	culture	model	using	
the	Sarafend	strain	of	WNV	and	primary	human	RPE	cells,	 including	initial	
investigations	 of	 a	 mouse	 model	 of	 WNV	 ocular	 infection	 (Chapter	 5)	 to	
expand	upon	the	findings	observed	in	the	cell	culture	models	developed	in	
Chapters	3	and	4	of	the	thesis.		
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The	 use	 of	 WNV	 in	 the	 current	 studies	 is	 not	 directed	 to	 investigating	 a	
specific	 link	 between	 this	 virus	 and	 AMD,	 but	 rather	 to	 explore	 possible	
pathogen‐induced	immune	responses	and	chronic	 inflammation	that	could	
be	involved	in	the	pathogenesis	of	AMD.	
	
That	being	said,	given	the	highly	pro‐inflammatory	properties	of	WNV	and	
the	relatively	recent	spread	of	this	virus	across	previously	WNV‐free	areas	
as	 a	 result	 of	 the	 New	 York	 1999	 outbreak,	 it	 is	 conceivable	 that	 in	 the	
future	there	may	be	a	spike	in	AMD	cases,	such	retinal	infection	contributes	
to	the	initiation/exacerbation	of	AMD.	 	 	 	
	
6.1.	Breakdown	of	the	blood	retinal	barrier	
Rewritten	as	"The	anti‐apoptotic	profile	indicated	by	the	transcriptome	of	
WNV‐infected	hRPE	(Figure	3.11)	and	a	relatively	low	level	of	RPE	cell	
death	(Figure	3.10),	indicate	that	apoptosis,	even	in	the	face	of	infection,	is	
unusual	in	RPE	cells	under	these	conditions.	In	a	chronic	low‐level	infection	
and	the	resulting	chronic	inflammation	situation	however,	a	pro‐apoptotic	
response	is	produced	instead	(369).	A	characteristic	feature	of	atrophic	or	
dry	AMD	is	the	progressive	and	chronic	loss	of	RPE	and	outer	BRB	
breakdown.		
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Efforts	 to	 repair	 breaches	 in	 the	 outer	 BRB	 via	 RPE	 proliferation	may	 be	
hampered	by	 the	 cytokines	 that	use	 cell	 cycle	 arrest	 (such	 as	 the	 S‐phase	
arrest	observed	in	WNV‐infected	hRPE,	Figure	3.9)	as	an	anti‐viral	strategy,	
such	as	 IFN‐β1,	and	as	well	as	 the	 likely	 impaired	proliferative	and	motile	
capabilities	of	aged	RPE	(370).	
The	lack	of	TNF	and	MMP‐9	produced	by	WNV‐infected	hRPE	suggests	that	
for	 WNV	 infection,	 breakdown	 of	 the	 BRB	 is	 not	 a	 direct	 result	 of	 TNF–
mediated	 activity,	 in	 contrast	 to	 the	 proposed	 changes	 BBB	 that	 precede	
WNV	 infection	of	 the	brain	 (200).	The	BRB	breakdown	observed	at	48‐72	
hours	 post‐infection	 in	 the	 current	 hRPE	model	 (measured	 by	 TEER	 and	
electrical	 impedance	 (Figure	 4.1)),	 appears	 to	 occur	 before	 the	 onset	 of	
pathological	weight	 loss	for	mice	with	intravitreal	WNV	infection	(~	day	4	
post‐infection,	Figure	5.5).	This	 suggests	 that	outer	BRB	breakdown	could	
occur	 independently	 of	 the	 peak	 influx	 of	 leukocytes.	 However,	 since	 we	
could	 not	 establish	 that	 murine	 RPE	 was	 directly	 infected	 (no	 detectable	
NS1	immunolabelling	observed	in	mouse	RPE),	outer	BRB	degradation	as	a	
result	 of	 inflammatory	 leukocyte‐mediated	 mechanisms	 cannot	 be	 ruled	
out.	To	definitively	rule	out	direct	murine	RPE	 infection	in	the	 intravitreal	
injection	 model,	 further	 experiments	 are	 required	 such	 as	
immunofluorescence	 of	 eyecup	 flatmounts	 or	 WNV	 quantification	 from	
isolated	murine	RPE	via	qPCR	or	flow	cytometry	or	western	blot.	
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6.2.	Immunomodulation	and	retinal	damage‐reduction	
mechanisms.	
	
Complement	 activation	 is	 an	 important	 component	 of	 antibody‐mediated	
WNV	 clearance	 (371),	 and	 its	 potency	 is	 shown	 by	 the	 evolutionary	
adaptation	 of	 WNV	 to	 combat	 this,	 via	 binding	 and	 activation	 of	 the	
complement	 regulatory	 protein	 CFH	 (372).	 The	 complement	 system	 also	
has	important	roles	in	retinal	homeostasis,	as	signalling	via	the	complement	
component	 3a	 receptor	 C3AR1	 is	 shown	 to	 be	 important	 in	 attenuating	
retinal	degeneration	in	a	light‐induced	damage	model	(261).	Based	on	these	
observations,	and	upregulation	of	C3AR1	to	high	levels	occurred	with	WNV	
infection	 (section	 3.2.4),	we	 can	 hypothesize	 that	 excessive	 dampening	 of	
complement	 activation	 may	 result	 in	 not	 only	 increased	 WNV	 titres,	 but	
further	retinal	damage	during	infection.		
The	 increase	 in	WNV	 replication,	 as	measured	 by	 qPCR	 in	 IFN‐λ1‐treated	
hRPE	 (at	 concentrations	 found	 in	WNV‐infected	 hRPE	 cell	 culture	media)	
was	surprising,	given	the	various	direct	anti‐viral	effects	reported	for	IFN‐
λ1	 in	 other	 cell	 types	 and	 viruses	 (373,	 374).	 For	 example,	 IFN‐λ1	 shows	
exclusive	anti‐viral	properties	in	controlling	rotavirus	infection	in	intestinal	
epithelial	 cells	 (375).	 However,	 these	 earlier	 studies	 did	 not	measure	 the	
levels	 of	 IFN‐λ1	 produced	 in	 their	 models	 or	 use	 IFN‐λ	 blocking	 studies,	
raising	the	possibility	the	anti‐viral	activity	noted	was	only	a	result	of	using	
non‐physiologically	 high	 levels	 of	 IFN‐	 λ1,	 in	 contrast	 to	 our	 experiments	
which	were	based	on	levels	measure	in	culture.		
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This	posits	an	interesting	conundrum:	why	is	IFN‐λ1	production	increased	
at	all	if	it	contributes	to	a	WNV‐permissive	situation?	The	answer	may	lie	in	
anti‐viral	immune	strategies	that	are	not	exclusively	intracellular.	Lazear	et	
al	 (376)	 found	 that	 IFN‐λ	 signalling	 during	 peripheral	 WNV	 infection	
resulted	in	a	tightening	of	the	BBB,	which	improved	the	survival	of	mice.		
While	 combinations	 of	 the	 various	 IFN‐λs	 did	 not	 produce	 a	 similar	 BRB	
tightening	 (as	 measured	 by	 electrical	 impedance,	 section	 4.2.1)	 hRPE	
production	of	 IFN‐λ1	during	WNV‐infection	may	be	 important	 for	 shaping	
adaptive	 immune	 responses,	 especially	 given	 that	 dendritic	 cells	 can	
express	IFNLR1	(108).	Interestingly,	IFN‐λs	did	contribute	to	IDO1	activity	
(Figure	 3.4),	 which	 in	 our	 model	 is	 most	 likely	 an	 immunoregulatory	
response.	 Alternatively,	 exploitation	 of	 IFN‐λ1‐induced	 signalling	 in	 hRPE	
cells	by	WNV	may	be	another	immune	survival	strategy	of	the	virus.		 	
Regardless	of	 the	scenario,	 it	appears	that	IFN‐λ2	attenuates	the	pro‐WNV	
replication	 effect,	 and	 does	 not	 contribute	 to	 intracellular	 WNV	 control,	
either	on	 its	own	or	 in	conjunction	with	 IFN‐λ1	(Figure	3.8).	The	 levels	of	
IFN‐λ2	and	IFN‐λ3	(the	mRNA	of	which	was	found	to	be	upregulated	in	our	
previous	microarray	 (220))	produced	 in	WNV‐infected	hRPE	could	not	be	
discerned	 due	 to	 the	 lack	 of	 commercially	 available	 ELISAs	 that	
discriminate	between	IFN‐λ2	and	IFN‐λ3.	As	a	result,	it	is	likely	that	IFN‐β1	
is	the	sole	 interferon	(in	the	context	of	WNV	infection	of	hRPE)	capable	of	
intracellular	 WNV	 control.	 As	 a	 result,	 the	 effects	 of	 interaction	 between	
IFN‐λ1,	IFN‐λ2	and	IFN‐λ3	could	not	be	determined,	in	respect	to	both	viral	
control	and	IDO1	activity	contribution.	
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The	 production	 of	 active	 IDO1	 in	 WNV‐infected	 hRPE	 cells	 (partly	 as	 a	
result	of	IFN‐λs)	is	likely	to	be	involved	in	the	modulation	of	the	leukocytes	
observed	in	the	mouse	model.		IDO	has	been	found	to	regulate	Th17	CD4+	T‐
cells	 (276),	 skew	 NKT	 cells	 towards	 a	 Th2	 profile	 (280),	 suppress	 CD8	
responses	in	transplant,	viral	and	tumour	models	(377),	and		induce	Foxp3+	
T‐regs	(378).	However,	this	would	have	to	be	tested	in	our	model,	perhaps	
with	 IDO	 knock‐out	 mice	 to	 see	 if	 higher	 levels	 of	 retinal	 damage	 occur	
during	WNV	infection	when	compared	with	wildtype	mice.	
	
While	no	increase	in	CCL2	production	occurred	with	WNV‐infection	of	hRPE	
cells	(Chapter	3),	the	Ly6Chi	monocytes	recruited	in	the	in	vivo	murine	WNV	
BRB	 model	 (Chapter	 5)	 may	 have	 been	 recruited	 by	 other	 cytokines.	
Furthermore,	given	that	the	GCL	and	INL	of	the	neural	retina	were	primarily	
infected	in	the	murine	model	(Figure	5.3),	these	cells	could	have	potentially	
produced	 high	 levels	 of	 CCL2	 that	 resulted	 in	 the	 recruitment	 of	 these	
inflammatory	 monocytes.	 Indeed,	 in	 the	 BBB	 WNV	 model,	 high	 levels	 of	
CCL2	 are	 produced	 by	 neuronal	 cells	 in	 the	 brain	 (201)	 with	 little	 to	 no	
increase	of	this	cytokine	by	human	brain	microvascular	endothelial	cells	or	
human	brain	cortical	astrocytes	(379),	i.e.	the	other	cellular	components	of	
the	human	BBB.	
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Nevertheless,	CCL5	appears	to	be	the	dominant	cytokine	produced	by	WNV‐
infected	 hRPE,	 as	 evidenced	 by	 our	 previous	microarray	 study	 (220)	 and	
subsequent	qPCR/ELISA	studies	of	CCL2	and	CCL5	(Chapter	3).	This	is	also	
reflected	 in	 another	 BBB	WNV	mouse	model	 	 (21).	While	 both	 CCL5	 and	
CCL2	are	capable	of	recruiting	monocytes	(249)	and	modulating	leukocyte	
responses	 (380),	 they	 clearly	 recruit	 and	 modulate	 different	 leukocyte	
profiles,	as	evidenced	by	CCL2	neutralisation	experiments	in	the	WNV	brain	
model	(201).	In	these	experiments,	CCL2	neutralisation	prolonged	the	life	of	
WNV‐infected	mice.	If	the	in	vitro	CCL2/CCL5	WNV	hRPE	results	in	chapter	
3	 approximate	 the	 in	 vivo	 situation,	 the	 initial	 infection	 of	 the	 outer	 BRB	
may	 recruit	 a	moderate	 leukocyte	 response	 that	 produces	 relatively	 little	
damage.	 However,	 once	 WNV	 infection	 spreads	 into	 the	 neural	 retina,	 a	
“panic	 button”	 situation	 may	 occur	 in	 which	 CCL2	 is	 released,	 thereby	
recruiting	 damaging	 inflammatory	 Ly6Chi	 monocytes	 into	 the	 eye.	 	 Early	
control	 of	 WNV	 infection	 by	 RPE	 would	 thus	 be	 critical	 for	 minimising	
damage	 to	 the	 neural	 retina,	 not	 just	 from	 the	 cytopathic	 effects	 of	WNV	
replication,	but	also	from	the	 immunopathogenic	responses.	This	situation	
is	 not	 reflective	 of	 our	mouse	model	 however,	 as	 our	 technique	 evidently	
infects	the	neural	retina	first	and	the	RPE	last.	
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6.3.	WNV	immune	evasion	strategies	
	
Canonical	 Wnt	 pathway‐activated	 β‐catenin	 is	 a	 co‐repressor	 of	 IFN‐β1	
signalling	 (381),	 and	 is	 found	 to	 translocate	 to	 the	 nucleus	 in	 both	 the	
adenocarcinoma	cell	line	A549	and	the	embryonic	kidney	cell	line	HEK293T	
during	 infection	with	Sendai	virus	 (381).	Hence,	 the	 initial	 increase	of	β‐
catenin	staining	at	 the	cell	 junctions	 (via	rearrangement)	 in	WNV‐infected	
hRPE	 may	 be	 an	 attempt	 by	 the	 virus	 to	 inhibit	 IFN‐β1	 signalling,	
considering	 the	 substantial	 production	 of	 this	 cytokine	 during	 WNV	
infection	 (Figure	 3.1)	 and	 its	 potent	 anti‐viral	 effect	 (Figure	 3.5).	
Sequestering	of	β‐catenin	from	the	Wnt	pathway	is	also	achieved	by	binding	
to	E‐cadherin/CDH1	(382),	and	hence	the	downregulation	of	CDH1	noted	in	
WNV‐infected	hRPE	may	be	pro‐Wnt	process,	either	as	part	of	 the	normal	
anti‐viral	 cellular	 processes	 or	 as	 a	 survival	 mechanism	 by	WNV	 to	 limit	
IFN‐β1	signalling.	
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WNV	 evasion	 or	 survival	 strategies	 do	 not	 appear	 to	 be	 limited	 to	 innate	
signalling	in	the	hRPE	model.	Increased	HLA‐E	(first	noted	in	our	previous	
microarray	 study	 (220))	 has	 been	 shown	 to	 inhibit	 NK	 via	 CD94	 binding	
(383)	 (and	 is	 also	 upregulated	 by	 HCMV	 (384)).	 Taken	 together	 with	
increased	 MHC‐I	 observed	 in	 WNV‐infected	 hRPE	 (Figure	 4.2),	 this	 is	 of	
particular	 interest	 given	 the	 NK‐inhibitory	 ability	 of	 MHC‐I	 (described	 in	
Chapter	 5	 discussion	 ‐	 NK	 and	 NKT	 cell	 section).	 These	 findings	 are	
indicative	 of	 an	 general	 anti‐NK	 strategy	 associated	 with	 WNV	 infection,	
and	 may	 explain	 why	 attempts	 to	 investigate	 the	 effects	 of	 recruited	 NK	
cells	during	WNV	are	unsuccessful;	 the	 immune	system	may	have	adapted	
to	using	non‐NK	mechanisms	to	combat	WNV	infection.	
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6.4.	Other	findings	
Certain	 alleles	 of	 the	HLA‐A	 subgroup	 are	 reported	 to	 be	 associated	with	
symptomatic	 WNV	 (HLA‐A68)	 (385)	 and	 spontaneous	 birdshot	
chorioretinopathy,	 a	 rare	 form	 of	 posterior	 uveitis	 	 (there	 is	 a	 200‐fold	
higher	risk	for	developing	this	in	people	with	HLA‐A29)	(353).	It	has	been	
established	 that	 HLA‐A	 is	 involved	 in	 cell	 antigen	 presentation	 of	 WNV‐
derived	 peptides	 (386).	 The	 exact	molecular	mechanism	behind	 the	HLA‐
A29	 allele	 association	 with	 birdshot	 retinopathy	 beyond	 general	 HLA‐
mediated	 autoimmunity	 is	 not	 currently	 known	 (387),	 however	 the	
involvement	 of	 this	 HLA	 subgroup	 in	 WNV	 infection	 and	 birdshot	
retinopathy	may	 indicate	 an	 involvement	of	HLA‐A	 in	 the	pathogenesis	of	
chorioretinopathy,	which	is	of	interest	given	that	we	see	an	upregulation	of	
HLAA	in	WNV	infected	hRPE	(Figure	3.3A).	
The	 LD50	 for	 the	 intravitreal	 WNV	 mouse	 model	 in	 Chapter	 5	 lies	
somewhere	 between	 144	 pfu/mouse	 to	 14.4	 pfu/mouse,	 similar	 to	 that	
reported	as	the	intracranial	LD50	for	the	NY99	WNV	strain	in	8‐10	week	old	
C57BL/6	mice	 (100pfu/mouse)	 (388).	 The	 earliest	mortality	 timepoint	 (6	
days‐post	 intravitreal	 WNV	 infection)	 also	 correlates	 with	 the	 earliest	
mortality	timepoint	reported	for	the	intracranially‐injected	WNV	(personal	
communication,	L	Vu	Dinh).	
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From	the	studies	described	above,	we	can	conclude	that	in	naïve	mice,	WNV	
infection	 of	 the	 retina	 is	 likely	 to	 be	 effectively	 equivalent	 to	 intracranial	
WNV	infection.	Whether	there	is	a	differential	leukocyte	profile	in	the	brain	
after	intravitreal	inoculation	of	WNV	remains	to	be	established	and	will	be	
of	 significant	 interest.	 Furthermore,	 whether	 intranasal	 WNV	 infection	
results	 in	 retinal	 infection	 is	 not	 clear	 although	 a	 preliminary	 set	 of	
experiments	suggests	that	intranasally	administered	WNV	does	not	result	in	
retinal	infection	(personal	communication,	Prof	NJ	King).		
	
The	flow	cytometry	results	(Chapter	5)	provide	a	snapshot	of	 the	 immune	
processes	involved	from	the	peak	of	infection	through	to	just	prior	to	death	
in	 the	WNV	 intravitreal	 infection	model.	 These	 initial	 experiments	 can	 be	
extended	to	establish	the	exact	LD50	for	this	model,	assessing	the	initiation,	
peak	 and	 resolution	 of	 leukocyte	 profiles.	 The	 potential	 to	 investigate	
recurrent	 low	 level	 infection	 and	 chronic	 inflammation	 could	 also	 be	
pursued,	as	this	may	mimic	the	situation	that	our	pathogen‐mediated	BRB	
breakdown	hypothesis	postulates.	
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Another	 interesting	 finding	 is	 related	 to	 the	 effects	 of	 ageing	 on	 immune	
responses	 in	 the	 context	 of	 WNV	 intravitreal	 infection.	 A	 differential	
immune	 response	 is	 seen	 between	 young	 and	 older/adult	 mice	 (age	
difference	 of	 ~3	months)	 mice	 (Chapter	 5.6),	 despite	 a	 similar	 course	 of	
mortality	for	a	given	viral	dose.	As	age	is	a	major	risk	factor	for	developing	
AMD,	 using	 the	 intravitreal	 WNV	 infection	 mouse	 model	 would	 be	
informative	 for	 investigations	of	 the	recruited	 leukocyte	profile	kinetics	 in	
aged	 (>8	 months	 old)	 retinas/choroids	 when	 intravitreally	 infected	 with	
WNV.	 	 Of	 particular	 interest	 would	 be	 whether	 the	 immunopathogenic	
effects	 of	WNV	 could	 be	 induced	with	much	 lower	 viral	 titres	 in	 older	 or	
younger	mice.	
	
As	previously	noted	 in	 the	Chapter	5	discussion,	 it	 is	very	 likely	 that	 local	
memory	responses	play	a	large	part	in	WNV	immune	responses.	Another	set	
of	 experiments	 that	 would	 yield	 valuable	 information	 would	 be	 a	
comparison	 of	 the	 recruited	 leukocytes	 in	 the	 retina	 of	 immune	 mice	
generated	 from	 intranasal	 WNV	 administration	 and	 immune	 mice	
generated	 from	 intravitreal	 WNV	 infection.	 Notwithstanding	 the	
immunoprivileged	status	of	the	eye	and	olfactory	bulb,	the	leucocyte	milieu	
is	 almost	 certain	 to	 be	 distinct	 between	 the	 two.	 Furthermore,	 the	
difference	between	the	two	leucocyte	profiles	may	highlight	the	leucocytes	
that	are	recruited	to	the	eye	in	a	chronic	localised	infection	compared	to	a	
chronic	 systemic	 infection,	 representative	 of	 the	 two	 possible	 routes	 of	
WNV	 into	 the	 retina	 in	 human	WNV	 cases	 (from	 the	 brain	 via	 the	 optic	
nerve	or	into	the	retina	via	the	BRB).	
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6.5.	Conclusion	
 
The	investigations	presented	in	this	thesis	provide	an	interesting	and	novel	
contribution	to	the	eye	cell	biology	and	ocular	immunological	responses	to	
viral	 infection.	 To	 our	 knowledge,	 the	 in	 vitro	 studies	 are	 the	 first	 to	
investigate	 the	production	 and	 contributions	 of	 the	 type	 III	 interferons	 in	
primary	human	RPE	cells,	especially	with	respect	to	the	 induction	of	 IDO1	
activity.	 These	 studies	 also	 show	 that	 the	 contribution	 of	 IFN‐λ	 to	 WNV	
resolution	 in	 RPE	 cells	 may	 be	 more	 immunomodulatory	 rather	 than	
directly	 anti‐viral.	 	 Future	 experiments	 investigating	 anti‐pathogen	
responses	by	RPE	cells	could	benefit	greatly	from	studying	the	role	of	type	
III	interferons.	
	
The	initial	increase	of	TEER	and	electrical	impedance	in	WNV	infected	RPE	
monolayers	is	also	a	unique	finding,	given	the	physiological	implications	of	
viral	 entry	 into	 RPE	 cells.	 Elucidation	 of	 the	 likely	 soluble	 factor/s	
responsible	 for	 this	 finding	 will	 certainly	 yield	 fascinating	 insights	 into	
whether	 it	 is	 an	 anti‐viral	 response,	 or	 an	 apparently	 paradoxical	 WNV	
survival	strategy,	similar	to	WNV‐mediated	MHC‐I	 increases,	as	previously	
noted.	
	
  250
The	 establishment	 of	 the	 intravitreal	WNV	 infection	mouse	model	 is	 also	
novel,	with	application	of	the	14‐colour	flow	cytometry	technique	to	assess	
the	leukocyte	populations	in	the	eye.	No	papers	published	to	date	using	flow	
cytometry	 to	 study	 ocular	 leukocytes	 have	 used	 this	 many	 parameters,	
which	expand	both	the	scope	of	leukocyte	subsets	measured	and	increases	
confidence	 in	the	evidence	for	particular	 leukocyte	subsets,	as	determined	
by	 cell	 surface	markers,	 particularly	 as	 there	 are	 so	 few	 leukocytes	 in	 the	
eye.	
	
Initial	 studies	 investigating	 the	 lymphocytic	 subset	 of	 recruited	 cells	 are	
also	 presented	 in	 Chapter	 5;	 this	 subset	 has	 been	 extensively	 studied	 in	
retinal	autoimmune	models	but	seldom	during	viral	infections	of	the	murine	
retina.	
	
Overall,	 the	current	studies	have	 investigated	 the	effects	of	WNV	infection	
on	 the	 outer	 BRB	 considering	 adaptive	 and	 innate	 immunity,	 as	 well	 as	
intracellular	 and	 intercellular	 immune	 responses.	 These	 findings	 provide	
the	basis	for	further	in	vitro	and	in	vivo	investigations	to	elucidate	possible	
immune	mechanisms	involved	in	the	pathogenesis	of	AMD	and	other	retinal	
inflammatory	diseases. 
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